

EAST Search History






Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1938	((544/114,239) or (514/236.5,247)). CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/06/12 11:53

NPL

Results

1.	TITLE-ABSTR-KEY(HIV infection) and TITLE-ABSTR-KEY(reverse transcriptase) <i>[All Sources(- All Sciences -)]</i>	5
----	---	---

Copyright © 2006 Elsevier B.V. All rights reserved.
ScienceDirect® is a registered trademark of Elsevier B.V.



chain nodes :
 13 14 16 24 31 37
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11 12 18 19 20 21 22 23 25 26 27 28 29 30
 chain bonds :
 5-14 11-13 14-37 22-24 29-31
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 18-19 18-23 19-20
 20-21 21-22 22-23 25-26 25-30 26-27 27-28 28-29 29-30
 exact/norm bonds :
 7-8 7-12 8-9 9-10 10-11 11-12 11-13 14-37 18-19 18-23 19-20 20-21 21-22 22-23
 22-24 25-26 25-30 26-27 27-28 28-29 29-30 29-31
 exact bonds :
 5-14
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 7 : 18 : 25 :








 G1:O,S,N,CH2,SO2

 G2:[*1],[*2],[*3]

 Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
 12:Atom 13:CLASS 14:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom
 22:Atom 23:Atom 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS
 37:CLASS

=>

Uploading C:\Program Files\Stnexp\Queries\10807993 (Gr I).str



```

chain nodes :
13 14 16 24 31 37
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 18 19 20 21 22 23 25 26 27 28 29
30
chain bonds :
5-14 11-13 14-37 22-24 29-31
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 18-19 18-23
19-20 20-21 21-22 22-23 25-26 25-30 26-27 27-28 28-29 29-30
exact/norm bonds :
7-8 7-12 8-9 9-10 10-11 11-12 11-13 14-37 18-19 18-23 19-20 20-21 21-22
22-23 22-24 25-26 25-30 26-27 27-28 28-29 29-30 29-31
exact bonds :
5-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 7 : 18 : 25 :

```

G1:O,S,N,CH2,SO2

G2:[*1],[*2],[*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:CLASS 14:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom
 21:Atom 22:Atom 23:Atom 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
 30:Atom 31:CLASS 37:CLASS

L1 STRUCTURE UPLOADED

=> d 11
 L1 HAS NO ANSWERS
 L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam
 SAMPLE SEARCH INITIATED 07:39:48 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 254 TO ITERATE

100.0% PROCESSED 254 ITERATIONS 30 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 4124 TO 6036
 PROJECTED ANSWERS: 272 TO 928

L2 30 SEA SSS SAM L1

=> => s 11 sss ful
 FULL SEARCH INITIATED 07:43:50 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 4830 TO ITERATE

100.0% PROCESSED 4830 ITERATIONS 543 ANSWERS
 SEARCH TIME: 00.00.01

L3 543 SEA SSS FUL L1

=> => s 13
 L4 88 L3

=> d 14 1-88 bib,ab,hitstr

L4 ANSWER 1 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:440390 CAPLUS

DN 144-460847

DN 144.10001
TI Pharmaceuticals containing 5-thio- β -D-glucopyranosides as SGLT2 inhibitors and their combinations with other drugs

IN Kakinuma, Hiroyuki; Sato, Masakazu; Amada, Hideaki; Asanuma, Hajime; Tsuchiya, Yuko; Kumeta, Shinichiro

PA Taisho Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 69 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

III. *Capa*

PATENT NO

PATENT NO.:

KIND DATE

FATE

APPLICATION NO.

DATE

PI JP 2006117651 A2 (20060511) JP 2005-275500 20050922
PRAI JP 2004-279657 A 20040927

AB The compds. I-[B]-(un)substituted heteroaryl, XIA, XEA, RSA, RAX - H, C2-10 acyl, C7-10 aralkyl, C1-6 alkoxy-C2-10 acyl, etc.; Qx = N C; XA = (CH₂)_n, CO(CH₂)_n, CONH(CH₂)_n, COCH:CH, S, NH, etc. (n = 0-3); if Qx = N, then XA = (CH₂)_n, CO(CH₂)_n, C(OH)(CH₂)_n, CONH(CH₂)_n, COCH:CH; R5-R9 = H, halo, OH, C1-6 alkyl optionally substituted with halo or OH, (CH₂)_mQ (m = 0-4; Q = formyl, amino, NO₂, cyano, carboxy, C1-6 alkoxy, C1-6 alkylthio, NHCHO, C2-10 acylamino, carbamoyl, etc.), (un)substituted C3-7 cycloacyl, aryl, heteroaryl, etc.], their pharmaceutically acceptable salts, or their hydrates inhibit SGLT2 (sodium-dependent glucose transporter 2) and are useful for prevention and treatment of diabetes, diabetes-related diseases, or diabetic complication. Also claimed are pharmaceutical combinations of I with PPAR α agonists, insulin sensitivity enhancers, glycosidase inhibitors, biguanides, HMG-CoA reductase inhibitors, fibrates, appetite depressants, etc. Thus, 4'-(4'-ethylbenzyl)-5'-methyl-1'H-pyrazol-3'-yl 5-thio- β -D-glucopyranoside (II, preparation given) inhibited glucose uptake by rat brush border membrane vesicle at IC₅₀ of 0.31 μ M. Oral administration of II to streptozotocin-induced diabetic rats lowered plasma glucose from 500 to 200 mg/dL after 2-4 h.


IT 776317-72-7P, 4-(4-Ethylbenzyl)-2H-pyridazin-3-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 5-thio- β -D-glucopyranosides as SGLT2 (sodium-dependent glucose transporter 2) inhibitors for treatment of diabetes optionally in combination with other antidiabetics)

RN 776317-72-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(4-ethylphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1132971 CAPLUS

DN 143:405914

TI Process for preparing pyridazinone compounds

IN Kertesz, Denis John; Martin, Michael; Palmer, Wylie Solang

PA Roche Palo Alto Llc, USA

SO U.S. Pat. Appl. Publ., 21 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005234236	A1	20051020	US 2005-105990	20050414
	WO 2005100323	A1	20051027	WO 2005-EP3653	20050407
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		

PRAI US 2004-562650P P 20040415

OS CASREACT 143:405914; MARPAT 143:405914


AB The present invention provides a process for the preparation 6-[3-(hetero)aryloxy-2-fluoro-benzyl]-2H-pyridazin-3-one compds. I [R2 = (un)substituted aryl or heteroaryl; R6 = NO₂, NH₂, alkyl, halo, or a function group readily derived therefrom and R4c = H or alkyl]. There also is provided a process for the preparation of phenylacetic acid compds. II [R2 and R6 are as defined previously and R5a = H or alkyl], which are useful for the preparation of pyridazinone compds. Disclosed method improves over prior methods by avoiding a regioisomer problem.

IT 866959-45-7P 866959-46-8P 866959-48-0P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparing pyridazinone compds.)

RN 866959-45-7 CAPLUS


CN 1,3-Benzeneddicarbonitrile, 5-[3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-nitrophenoxy]- (9CI) (CA INDEX NAME)



RN 866959-46-8 CAPLUS

CN 1,3-Benzeneddicarbonitrile, 5-[6-amino-3-[(1,6-dihydro-5-methyl-6-oxo-3-

pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 866959-48-0 CAPLUS

CN Benzenediazonium, 2-(3,5-dicyanophenoxy)-4-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-3-fluoro-, tetrafluoroborate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 866959-47-9

CMF C20 H12 F N6 O2




CM 2

CRN 14874-70-5

CMF B F4

CCI CCS




IT 770717-15-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for preparing pyridazinone compds.)

RN 770717-15-2 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[6-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




IT 770717-97-0P 770718-81-5P 770718-83-7P
 770719-18-1P 770719-19-2P 770719-20-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(process for preparing pyridazinone compds.)


RN 770717-97-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[(5-bromo-3-pyridinyl)oxy]-4-chloro-2-fluorophenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770718-81-5 CAPLUS

CN 1H-Indole, 7-[(3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-nitrophenoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 770718-83-7 CAPLUS

CN 1H-Indole, 7-[(6-amino-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 770719-18-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[(5-bromo-3-pyridinyl)oxy]-2-fluoro-4-nitrophenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770719-19-2 CAPLUS

CN 1(6H)-Pyridazinecarboxylic acid, 3-[[3-[(5-bromo-3-pyridinyl)oxy]-2-fluoro-4-nitrophenyl]methyl]-5-methyl-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 770719-20-5 CAPLUS

CN 1(6H)-Pyridazinecarboxylic acid, 3-[[4-amino-3-[(5-bromo-3-pyridinyl)oxy]-2-fluorophenyl]methyl]-5-methyl-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 770717-77-6P 770717-98-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(process for preparing pyridazinone compds.)


RN 770717-77-6 CAPLUS

CN 3 (2H)-Pyridazinone, 6-[[4-chloro-2-fluoro-3-(1H-indol-7-yloxy)phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 770717-98-1 CAPLUS


CN 3 (2H)-Pyridazinone, 6-[[3-[(5-bromo-1-oxido-3-pyridinyl)oxy]-4-chloro-2-fluorophenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1042225 CAPLUS
 DN 143:347191
 TI Preparation of benzyl pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
 IN Dunn, James Patrick; Elworthy, Todd Richard; Hogg, Joan Heather;
 Stefanidis, Dimitrios
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


not find *Common JN*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005090317	A1	20050929	WO 2005-EP2779	20050316
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005215554	A1	20050929	US 2005-85869	X 20050322
PRAI	US 2004-555798P	P	20040323		no ODP
OS	MARPAT 143:347191				
AB	Title compds. I [R1, R2, R3 and R4 independently = H, alkyl, haloalkyl, etc.; R5 = (un)substituted aryl or heteroaryl; R6 = (CH2)pOH, CH2CO2R9, CH2OP(O)(OH)2, etc.; R7 and R8 independently = H, amino, alkylamino, etc.; R9 = H or alkyl; p = 1-3] and their pharmaceutically acceptable salts, are prepared and disclosed as non-nucleoside reverse transcriptase (nnRT) inhibitors. Thus, e.g., II was prepared by alkylation of III with formaldehyde. The pharmacokinetic activity was evaluated by orally administering various doses of I to Hanover-Wistar rats and subsequent determination of test compound concentration using HPLC and it was revealed that selected compds. of the invention possessed Cmax values in the range of 2.2 up to 15.5 µg/mL. I as non-nucleoside reverse transcriptase inhibitors should prove useful in the treatment of HIV mediated diseases. Pharmaceutical compns. comprising I are disclosed.				
IT	865795-58-0P 865795-84-2P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of benzyl pyridazinone derivs. as non-nucleoside reverse transcriptase inhibitors)				
RN	865795-58-0 CAPLUS				
CN	1,3-Benzenedicarbonitrile, 5-[6-chloro-3-[[1,6-dihydro-1-(hydroxymethyl)-5-methyl-6-oxo-3-pyridazinyl]methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)				



RN 865795-84-2 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[3-[(1-[2-(benzoyloxy)ethyl]-1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-6-chloro-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



IT 770717-55-0P 865795-59-1P 865795-60-4P

865795-61-5P 865795-62-6P 865795-63-7P

865795-64-8P 865795-65-9P 865795-66-0P

865795-67-1P 865795-68-2P 865795-69-3P

865795-70-6P 865795-71-7P 865795-72-8P

865795-73-9P 865795-74-0P 865795-75-1P

865795-76-2P 865795-77-3P 865795-78-4P

865795-79-5P 865795-80-8P 865795-81-9P

865795-82-0P 865795-83-1P 865795-85-3P

865795-86-4P 865795-87-5P 865795-88-6P

865795-89-7P 865795-90-0P 865795-91-1P

865795-92-2P 865795-93-3P 865795-94-4P

865795-95-5P 865795-96-6P 865795-97-7P

865795-98-8P 865796-05-0P 865796-08-3P

865796-10-7P 865796-12-9P 865796-14-1P


865796-16-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzyl pyridazinone derivs. as non-nucleoside reverse transcriptase inhibitors)

RN 770717-55-0 CAPLUS


CN Benzonitrile, 3-chloro-5-[6-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 865795-59-1 CAPLUS

CN D-Valine, [3-[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 865795-60-4 CAPLUS

CN Butanedioic acid, mono[3-[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinylmethyl ester (9CI) (CA INDEX NAME)



RN 865795-61-5 CAPLUS


CN Carbonic acid, [3-[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinylmethyl 2-(dimethylamino)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 865795-62-6 CAPLUS


CN 1,3-Benzeneddicarbonitrile, 5-[6-chloro-3-[[1,6-dihydro-5-methyl-6-oxo-1-[(phosphonoxy)methyl]-3-pyrimidinyl]methyl]-2-fluorophenoxy]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na


RN 865795-63-7 CAPLUS

CN 1,3-Benzeneddicarbonitrile, 5-[6-chloro-3-[[1,6-dihydro-1-(2-hydroxyethyl)-5-methyl-6-oxo-3-pyridazinyl]methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 865795-64-8 CAPLUS


CN 1(6H)-Pyridazineacetic acid, 3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo- (9CI) (CA INDEX NAME)



RN 865795-65-9 CAPLUS

CN L-Proline, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 865795-66-0 CAPLUS


CN Glycine, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 865795-67-1 CAPLUS


CN Propanoic acid, 2-methyl-, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester (9CI) (CA INDEX NAME)



RN 865795-68-2 CAPLUS
 CN 1,3-Benzenedicarbonitrile, 5-[3-[(1-[(acetyloxy)methyl]-1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-6-chloro-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 865795-69-3 CAPLUS
 CN 2H-Pyran-4-carboxylic acid, tetrahydro-, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester (9CI) (CA INDEX NAME)



RN 865795-70-6 CAPLUS
 CN 2-Butenedioic acid (2Z)-, mono[[3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865795-71-7 CAPLUS

CN D-Isoleucine, [3-[(4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl)methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 865795-72-8 CAPLUS


CN 3(2H)-Pyridazinone, 2-[(2R)-aminophenylacetyl]-6-[(4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl)methyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 865795-73-9 CAPLUS
 CN Carbonic acid, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinylmethyl 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 865795-74-0 CAPLUS
 CN Carbonic acid, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinylmethyl phenylmethyl ester (9CI) (CA INDEX NAME)




RN 865795-75-1 CAPLUS
 CN 3-Pyridinecarboxylic acid, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 865795-76-2 CAPLUS


CN 1-Piperidinepropanoic acid, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 865795-77-3 CAPLUS

CN 4-Morpholinepropanoic acid, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 865795-78-4 CAPLUS


CN Carbonic acid, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl 2-(4-morpholinyl)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl


PAGE 1-B



RN 865795-79-5 CAPLUS

CN D-Valine, [3-[[4-chloro-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 865795-80-8 CAPLUS

CN L-Asparagine, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 865795-81-9 CAPLUS

CN Butanedioic acid, mono[[3-[[4-chloro-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)




RN 865795-82-0 CAPLUS

CN Benzonitrile, 3-chloro-5-[6-chloro-3-[[1,6-dihydro-1-(hydroxymethyl)-5-methyl-6-oxo-3-pyridazinyl]methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 865795-83-1 CAPLUS


CN Benzonitrile, 3-chloro-5-[6-chloro-3-[[1,6-dihydro-5-methyl-6-oxo-1-[(phosphonooxy)methyl]-3-pyrimidinyl]methyl]-2-fluorophenoxy]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na


RN 865795-85-3 CAPLUS

CN Benzonitrile, 3-[6-chloro-3-[[1,6-dihydro-1-(hydroxymethyl)-5-methyl-6-oxo-3-pyridazinyl]methyl]-2-fluorophenoxy]-5-(difluoromethyl)- (9CI) (CA INDEX NAME)




RN 865795-86-4 CAPLUS

CN Butanedioic acid, mono[[3-[[4-chloro-3-[3-cyano-5-(difluoromethyl)phenoxy]-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)




RN 865795-87-5 CAPLUS

CN Benzonitrile, 3-[6-chloro-3-[[1,6-dihydro-1-(hydroxymethyl)-6-oxo-3-pyridazinyl]methyl]-2-fluorophenoxy]-5-fluoro- (9CI) (CA INDEX NAME)




RN 865795-88-6 CAPLUS

CN Butanedioic acid, mono[[3-[[4-chloro-3-(3-cyano-5-fluorophenoxy)-2-fluorophenyl]methyl]-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)




RN 865795-89-7 CAPLUS

CN Butanedioic acid, mono[[3-[[4-chloro-3-(3-cyano-5-(difluoromethyl)phenoxy)-2-fluorophenyl]methyl]-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)




RN 865795-90-0 CAPLUS


CN 1,3-Benzenedicarbonitrile, 5-[3-[[1,6-dihydro-1-(hydroxymethyl)-5-methyl-6-oxo-3-pyridazinyl]methyl]-6-ethyl-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 865795-91-1 CAPLUS
 CN 1,3-Benzenedicarbonitrile, 5-[3-[[1,6-dihydro-1-(hydroxymethyl)-5-methyl-6-oxo-3-pyridazinyl]methyl]-2-fluoro-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 865795-92-2 CAPLUS
 CN Butanedioic acid, mono[[3-[[4-bromo-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)




RN 865795-93-3 CAPLUS
 CN Butanedioic acid, mono[[3-[[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)




RN 865795-94-4 CAPLUS

CN Butanedioic acid, mono[[3-[[3-(3-chloro-5-cyanophenoxy)-4-ethyl-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)




RN 865795-95-5 CAPLUS

CN Butanedioic acid, mono[[3-[[3-(3,5-dicyanophenoxy)-4-ethyl-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)




RN 865795-96-6 CAPLUS

CN Butanedioic acid, mono[[3-[[3-(3-chloro-5-cyanophenoxy)-2-fluoro-4-methylphenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)




RN 865795-97-7 CAPLUS

CN Butanedioic acid, mono[[3-[[3,5-dicyanophenoxy]-2-fluoro-4-methylphenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester (9CI) (CA INDEX NAME)



RN 865795-98-8 CAPLUS


CN Butanedioic acid, mono[[3-[[4-chloro-3-[(4-cyano-6-methyl-2-pyridinyl)oxy]phenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester (9CI) (CA INDEX NAME)



RN 865796-05-0 CAPLUS

CN L-Proline, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865796-08-3 CAPLUS


CN 3(2H)-Pyridazinone, 2-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-6-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865796-10-7 CAPLUS

CN Benzeneacetic acid, α -amino-, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester (9CI) (CA INDEX NAME)



RN 865796-12-9 CAPLUS


CN Carbonic acid, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 865796-14-1 CAPLUS


CN L-Asparagine, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865796-16-3 CAPLUS

CN Butanedioic acid, mono[[3-[[4-chloro-3-(3-cyano-5-methylphenoxy)phenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl] ester (9CI) (CA INDEX NAME)




IT 770717-15-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzyl pyridazinone derivs. as non-nucleoside reverse transcriptase inhibitors)

RN 770717-15-2 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[6-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




IT **865795-99-9P 865796-00-5P 865796-01-6P
865796-02-7P 865796-03-8P 865796-04-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzyl pyridazinone derivs. as non-nucleoside reverse transcriptase inhibitors)

RN 865795-99-9 CAPLUS


CN D-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865796-00-5 CAPLUS


CN Carbonic acid, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 865796-01-6 CAPLUS


CN Phosphorous acid, [3-[[4-chloro-3-(3,5-dicyanophenoxy)-2-

fluorophenyl]methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl]methyl
bis(2-cyanoethyl) ester (9CI) (CA INDEX NAME)




RN 865796-02-7 CAPLUS

CN Phosphoric acid, [3-[(4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl)methyl]-5-methyl-6-oxo-1(6H)-pyridazinyl)methyl bis(2-cyanoethyl) ester (9CI) (CA INDEX NAME)



RN 865796-03-8 CAPLUS


CN 1,3-Benzenedicarbonitrile, 5-[6-chloro-3-[[1,6-dihydro-5-methyl-6-oxo-1-[(phosphonooxy)methyl]-3-pyrimidinyl)methyl]-2-fluorophenoxy]-, diammonium salt (9CI) (CA INDEX NAME)



●2 NH₃

RN 865796-04-9 CAPLUS


CN 1(6H)-Pyridazineacetic acid, 3-[(4-chloro-3-(3,5-dicyanophenoxy)-2-fluorophenyl)methyl]-5-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3


THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:477770 CAPLUS
 DN 144:233014
 TI Synthesis and antibacterial activity of some novel heterocycles
 AU Mohamed, M. I.
 CS Chemistry Department, Faculty of Girls, Ain Shams University, Heliopolis
 Cairo, 11757, Egypt
 SO Bulgarian Chemical Communications (2004) 36(4), 241-248
 CODEN: BCHCE4; ISSN: 0324-1130
 PB Bulgarian Academy of Sciences
 DT Journal
 LA English
 AB 3-Hydrazino-4-(2-methoxymethylphenyl)-6-aryl pyridazine was synthesized and its reactivity towards some reagents such as aliphatic, aromatic and heterocyclic anhydrides and aldehydes is reported. This compound was treated with α -diketones such as indole-2,3-dione (isatin), N-morpholinomethylisatin and N-piperidylmethylisatin to give the resp. derivs. 3-[N'-(2-oxo-1,3-dihydroindol-3-ylidene)hydrazino]-4-(2-methoxymethylphenyl)-6-tolyl pyridazine was oxidized by selenium dioxide to give 3-[N'-(2-oxo-1,3-dihydroindol-3-ylidene)hydrazino]-4-arooyl-6-tolylpyridazine which was treated with sulphamethoxazole to yield the sulpha-drug. The novel synthesized compds. were evaluated in regard to their antibacterial activity by the agar plate diffusion method. They showed a significant antibacterial activity against *Staphylococcus aureus*, *Bacillus subtilis*, *E. coli*, *Pseudomonas aeruginosa* and *Yersinia enterocolitica* bacteria.
 IT 177489-98-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of hydrazinomethoxymethylphenylarylpolyridazine derivative as antibacterial agent)
 RN 177489-98-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-4-[(2-methoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)





RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:912494 CAPLUS
 DN 142:280149
 TI Novel synthesis and antibacterial activity of some pyridazine derivatives
 AU Mohamed, M. I.; Zaky, H. T.; Kandile, N. G.
 CS Department of Chemistry, Faculty of Girls, Ain Shams University, Cairo, Egypt
 SO Journal of the Chinese Chemical Society (Taipei, Taiwan) (2004), 51(5A), 963-968
 CODEN: JCCTAC; ISSN: 0009-4536
 PB Chinese Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:280149
 AB Various pyridazin-3(2H)-ones, 3-chloropyridazines, and pyridazin-3(2H)-thiones were synthesized and treated with sulfamethoxazole to yield compds. like I. All new compds. were evaluated for their antibacterial activity and showed significant antibacterial activity against *Staphylococcus aureus* and *Bacillus subtilis* (Gram + ve) and *E. coli*, *Pseudomonas aeruginosa* and *Yersinia enterocolitica* (Gram - ve) bacteria by agar plate diffusion method.
 IT 847025-42-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and antibacterial activity of pyridazinones, pyridazinthiones, and pyridazine sulfamethoxazoles)
 RN 847025-42-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-methyl-4-[(3,4,5-trimethoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:903634 CAPLUS
 DN 143:78144
 TI Synthesis and reactions of 4-(p-methoxybenzyl)-6-(5,6,7,8-tetrahydro-2-naphthyl)-3(2H)-pyridazinone
 AU El-Din Harb, Nagwan M. S.
 CS Chemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt
 SO Journal of Pure and Applied Sciences (2000), 19(1), 87-98
 CODEN: JPASEQ; ISSN: 0255-3643
 PB Islamia University, Faculty of Science
 DT Journal
 LA English
 OS CASREACT 143:78144
 AB The title compound (I), obtained by reaction of the nonbenzylated analog with p-anisaldehyde, reacted with di-Me sulfate, HCHO, and CH₂:CHCHO, and underwent a Mannich reaction, all at the NH group. Reactions with POCl₃ and with P₂S₅ occurred at the carbonyl group. Reactions of one product (II) with amines and with thiourea were also examined
 IT 260058-86-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reactions of)
 RN 260058-86-4 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




IT 260058-90-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reactions of 4-(4-methoxybenzyl)-6-(5,6,7,8-tetrahydro-2-naphthyl)-3(2H)-pyridazinone)
 RN 260058-90-0 CAPLUS
 CN 1(6H)-Pyridazinepropanenitrile, 5-[(4-methoxyphenyl)methyl]-6-oxo-3-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




IT 260058-87-5P 260058-88-6P 260058-89-7P
 260058-91-1P 260058-97-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reactions of 4-(4-methoxybenzyl)-6-(5,6,7,8-tetrahydro-2-


naphthyl)-3(2H)-pyridazinone)
 RN 260058-87-5 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-methyl-6-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 260058-88-6 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(hydroxymethyl)-4-[(4-methoxyphenyl)methyl]-6-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 260058-89-7 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-(1-piperidinylmethyl)-6-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 260058-91-1 CAPLUS
 CN 1(6H)-Pyridazinepropanoic acid, 5-[(4-methoxyphenyl)methyl]-6-oxo-3-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 260058-97-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-(4-morpholinylmethyl)-6-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:878405 CAPLUS
 DN 141:350361
 TI Preparation of heteroaryl 5-thio- β -D-glucopyranoside derivatives as SGLT-2 inhibitors
 IN Kakinuma, Hiroyuki; Sato, Masakazu; Amada, Hideaki; Asanuma, Hajime; Tsuchiya, Yuko
 PA Taisho Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 109 pp.
 CODEN: PIXXD2

DT Patent

LA Japanese

FAN CNT 2

PATENT NO.

	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089967	A1 20041021	WO 2004-JP1272	20040206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1609799	A1 20051228	EP 2004-708901	20040206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1761676	A 20060419	CN 2004-80007740	20040206
PRAI	JP 2003-97838	A 20030401		
	JP 2003-404959	A 20031203		
	WO 2004-JP1272	W 20040206		

OS MARPAT 141:350361


AB Title compds. I [B = (un)substituted heteroaryl; R1A, R2A, R3A, R4A = H, acyl, etc.; Q = N, C; XA = (CH₂)_n, etc.; n = 0-3; R5, R6, R7, R8, R9 = H, halo, etc.] were prepared. For example, glycosidation of 2,3,4,6-tetra-O-acetyl-5-thio-D-glucopyranose with 4-(4-ethylbenzyl)-3-hydroxypyridine in Mitsunobu condition followed by deacetylation afforded compound II. In SGLT-2 (sodium-glucose linked cotransporter-2) inhibition assays, the IC₅₀ value of compound II was 0.14 μ M. Compds. I are claimed useful as SGLT-2 inhibitors for the treatment of diabetes, diabetes-related diseases, etc.

IT 776317-72-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heteroaryl 5-thio- β -D-glucopyranoside derivs. as SGLT-2 inhibitors for treatment of diabetes and diabetes-related diseases)

RN 776317-72-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(4-ethylphenyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:872802 CAPLUS

DN 141:366420

TI Method for selective preparation of heteroaryl 5-thio- β -D-aldohexopyranoside by Mitsunobu reaction of heteroaryl alcohols with 5-thio- β -D-aldohexopyranose derivative

IN Kakinuma, Hiroyuki; Sato, Masakazu; Amada, Hideaki; Asanuma, Hajime; Tsuchiya, Yuko

PA Taisho Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN. CNT 2

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI	WO 2004089966	A1	20041021	WO 2004-JP1244	20040206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, PL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI CN 1761676 A 20060419 CN 2004-80007740 20040206

JP 2003-97838 A 20030401

JP 2003-404959 A 20031203

OS MARPAT 141:366420

AB Disclosed is a method for preparing a heteroaryl 5-thio- β -D-aldohexopyranoside compound of the formula (I) [wherein Y = O, NH; R1-R4 = H, C2-10 aryl, C1-6 alkyl, C7-10 aralkyl, C1-6 alkoxy-C7-10 aralkyl, allyl, tri(C1-6 alkyl)silyl, C1-6 alkoxy-C1-6 alkyl, C2-6 alkoxycarbonyl; or when Y = O, R1 and R2 or R2 and R3 are combined together to form (un)substituted CH2; A = (un)substituted heteroaryl], which comprises reacting 5-thio-D-aldohexopyranose compound of the formula (II) (wherein R1-R4 = same as above) with heteroaryl alc. of formula A-OH (A = same as above) in the presence of a phosphine represented by PRXRYRZ [wherein RX, RY, RZ = C1-6 alkyl, (un)substituted Ph, pyridyl, C1-6 alkyl] and an azo reagent represented by R21-N:N-R22 [wherein R21, R22 = C2-5 alkoxycarbonyl, N,N-di(C1-4 alkyl)aminocarbonyl, piperidinocarbonyl]. Heteroaryl 5-thio- β -D-aldohexopyranosides are useful as inhibitors of sodium dependent glucose transporter 2 (SGLT2) (no data). Thus, 5.1 mmol di-Et azodicarboxylate (40% toluene solution) was added dropwise to a solution of 2,3,4,6-tetra-O-acetyl-5-thio-D-glucopyranose (937 mg, 2.6 mmol) and 1,2-dihydro-4-(4-ethylbenzyl)-5-methyl-3H-pyrazol-3-one (2.78 g, 12.9 mmol) and PPh3 (1.35 g, 5.1 mmol) in 14 mL THF at room temperature, stirred for at room temperature for 4 h, and concentrated to give, after silica gel chromatog.,

20% β -D-thioglucopyranoside compound (III).


IT 776317-72-7P, 4-(4-Ethylbenzyl)-2H-pyridazin-3-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(selective preparation of heteroaryl 5-thio- β -D-aldohexopyranosides by Mitsunobu reaction of heteroaryl alcs. with 5-thio- β -D-aldohexopyranose derivative)

RN 776317-72-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(4-ethylphenyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 4


THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:817869 CAPLUS
 DN 141:332204
 TI Preparation of benzyl-pyridazinones as reverse transcriptase inhibitors
 IN Dunn, James Patrick; Dymock, Brian William; Mirzahegan, Taraneh; Sjogren, Eric Brian; Swallow, Steven; Sweeney, Zachary Kevin
 PA F.Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 154 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


*App
PCT*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004085406	A1	20041007	WO 2004-EP2736	20040317
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004224191	A1	20041007	AU 2004-224191	20040317
	CA 2518823	AA	20041007	CA 2004-2518823	20040317
	EP 1608629	A1	20051228	EP 2004-721167	20040317
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008704	A	20060307	BR 2004-8704	20040317
	CN 1764649	A	20060426	CN 2004-80008121	20040317
	US 2004198736	A1	20041007	US 2004-807993	20040323
PRAI	US 2003-457144P	P	20030324		
	WO 2004-EP2736	A	20040317		
OS	MARPAT 141:332204				
AB	Title compds. represented by the formula I [wherein X1 = R5O, R5SO _n , R5CH ₂ ; etc.; R1, R2 = independently H, (halo)alkyl, alkoxy, alkylthio, etc.; R3 = H, (halo)alkyl, (halo)alkylthio, etc.; R4 = H, (cyclo)alkyl, (halo)alkoxy, etc.; R5 = (un)substituted (halo)alkyl, Ph, naphthyl, etc.; R7, R8 = independently H, (un)substituted (alkyl)amino, aminoalkylamino, etc.; n = 0-2; and pharmaceutically acceptable hydrates, solvates, clathrates and acid addition salts thereof] were prepared as reverse transcriptase (RT) inhibitors. For example, II was given in a multi-step synthesis starting from 4-hydroxy-3-methoxyphenylacetate. The prepared compds. were tested for inhibition of HIV-1 RT with IC ₅₀ values of 0.008-0.059 μM, and their formulations were also presented. Thus, I and their pharmaceutical compns. are useful as reverse transcriptase inhibitors for the treatment of disorders in which HIV and genetically related viruses.				
IT	770716-07-9P 770717-34-5P 770717-82-3P 770717-97-0P 770718-27-9P 770718-29-1P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of benzyl pyridazinones as reverse transcriptase inhibitors)				
RN	770716-07-9 CAPLUS				


CN 3(2H)-Pyridazinone, 6-[(3-(3-bromophenoxy)-4-fluorophenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 770717-34-5 CAPLUS
CN Benzonitrile, 3-[6-bromo-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-82-3 CAPLUS
CN Benzonitrile, 3-[6-chloro-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-ethenyl- (9CI) (CA INDEX NAME)




RN 770717-97-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[(3-[(5-bromo-3-pyridinyl)oxy]-4-chloro-2-fluorophenyl)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 770718-27-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[(3-bromophenyl)thio]-4-chlorophenyl]methyl]-(9CI) (CA INDEX NAME)



RN 770718-29-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[(3-bromophenyl)sulfinyl]-4-chlorophenyl]methyl]-(9CI) (CA INDEX NAME)



IT 770715-46-3P 770715-47-4P 770715-48-5P
 770715-49-6P 770715-50-9P 770715-51-0P
 770715-52-1P 770715-53-2P 770715-54-3P
 770715-55-4P 770715-56-5P 770715-57-6P
 770715-58-7P 770715-59-8P 770715-60-1P
 770715-61-2P 770715-62-3P 770715-63-4P
 770715-64-5P 770715-65-6P 770715-66-7P
 770715-67-8P 770715-68-9P 770715-69-0P
 770715-70-3P 770715-71-4P 770715-72-5P
 770715-73-6P 770715-74-7P 770715-75-8P
 770715-76-9P 770715-77-0P 770715-78-1P
 770715-79-2P 770715-80-5P 770715-81-6P
 770715-82-7P 770715-83-8P 770715-84-9P
 770715-85-0P 770715-86-1P 770715-87-2P
 770715-88-3P 770715-89-4P 770715-90-7P
 770715-91-8P 770715-92-9P 770715-93-0P
 770715-94-1P 770715-95-2P 770715-96-3P
 770715-97-4P 770715-98-5P 770715-99-6P
 770716-00-2P 770716-01-3P 770716-02-4P
 770716-03-5P 770716-04-6P 770716-05-7P
 770716-06-8P 770716-08-0P 770716-09-1P
 770716-10-4P 770716-11-5P 770716-12-6P
 770716-14-8P 770716-15-9P 770716-16-0P
 770716-17-1P 770716-20-6P 770716-21-7P
 770716-22-8P 770716-23-9P 770716-24-0P
 770716-25-1P 770716-26-2P 770716-27-3P
 770716-28-4P 770716-31-9P 770716-34-2P
 770716-37-5P 770716-38-6P 770716-39-7P
 770716-40-0P 770716-41-1P 770716-42-2P
 770716-43-3P 770716-44-4P 770716-48-8P


770716-55-7P 770716-56-8P 770716-61-5P
 770716-62-6P 770716-63-7P 770716-64-8P
 770716-65-9P 770716-66-0P 770716-67-1P
 770716-68-2P 770716-69-3P 770716-70-6P
 770716-71-7P 770716-72-8P 770716-73-9P
 770716-74-0P 770716-75-1P 770716-76-2P
 770716-77-3P 770716-78-4P 770716-79-5P
 770716-80-8P 770716-81-9P 770716-82-0P
 770716-83-1P 770716-84-2P 770716-85-3P
 770716-87-5P 770716-88-6P 770716-89-7P
 770716-90-0P 770716-92-2P 770716-93-3P
 770716-94-4P 770716-95-5P 770716-96-6P
 770716-97-7P 770716-98-8P 770716-99-9P
 770717-00-5P 770717-01-6P 770717-02-7P
 770717-03-8P 770717-04-9P 770717-05-0P
 770717-06-1P 770717-07-2P 770717-08-3P
 770717-09-4P 770717-10-7P 770717-11-8P
 770717-12-9P 770717-13-0P 770717-14-1P
 770717-15-2P 770717-16-3P 770717-17-4P
 770717-18-5P 770717-19-6P 770717-20-9P
 770717-21-0P 770717-22-1P 770717-23-2P
 770717-24-3P 770717-26-5P 770717-28-7P
 770717-29-8P 770717-30-1P 770717-31-2P
 770717-32-3P 770717-33-4P 770717-35-6P
 770717-36-7P 770717-37-8P 770717-38-9P
 770717-42-5P 770717-45-8P 770717-46-9P
 770717-47-0P 770717-48-1P 770717-49-2P
 770717-50-5P 770717-51-6P 770717-52-7P
 770717-53-8P 770717-54-9P 770717-55-0P
 770717-56-1P 770717-57-2P 770717-58-3P
 770717-59-4P 770717-60-7P 770717-61-8P
 770717-62-9P 770717-63-0P 770717-64-1P
 770717-65-2P 770717-66-3P 770717-67-4P
 770717-68-5P 770717-69-6P 770717-70-9P
 770717-71-0P 770717-72-1P 770717-73-2P
 770717-74-3P 770717-75-4P 770717-76-5P
 770717-77-6P 770717-78-7P 770717-79-8P
 770717-81-2P 770717-83-4P 770717-87-8P
 770717-89-0P 770717-90-3P 770717-91-4P
 770717-92-5P 770717-93-6P 770717-94-7P
 770717-95-8P 770717-96-9P 770717-98-1P
 770717-99-2P 770718-00-8P 770718-01-9P
 770718-02-0P 770718-03-1P 770718-04-2P
 770718-05-3P 770718-06-4P 770718-07-5P
 770718-08-6P 770718-09-7P 770718-10-0P
 770718-11-1P 770718-12-2P 770718-13-3P
 770718-14-4P 770718-15-5P 770718-16-6P
 770718-17-7P 770718-18-8P 770718-19-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzyl pyridazinones as reverse transcriptase inhibitors)

RN 770715-46-3 CAPLUS


CN 3(2H)-Pyridazinone, 6-[(3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-47-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(4-methylphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770715-48-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(4-chlorophenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770715-49-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-chlorophenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770715-50-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-methylphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770715-51-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(2-chlorophenoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-52-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3,4-dichlorophenoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-53-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3,5-dichlorophenoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-54-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3,5-dimethylphenoxy)-5-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-55-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3,5-dichlorophenoxy)-5-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 770715-56-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3,5-dichlorophenoxy)-5-ethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-57-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3,5-dichlorophenoxy)-4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-58-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(4-methoxy-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-59-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-(4-chlorophenoxy)-4-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770715-60-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(3-methoxy-5-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-61-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-(4-chlorophenoxy)-5-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770715-62-3 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[3-(3,5-dichlorophenoxy)-5-ethylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770715-63-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(4-chlorophenoxy)-4-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770715-64-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-methyl-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-65-6 CAPLUS
 CN Benzoic acid, 3-cyano-5-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 770715-66-7 CAPLUS
 CN 1,3-Benzene dicarbonitrile, 5-[[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770715-67-8 CAPLUS
 CN Benzonitrile, 4-[5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)




RN 770715-68-9 CAPLUS
 CN Benzonitrile, 3-[5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)




RN 770715-69-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(4-chlorophenoxy)-4-ethylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-70-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-chlorophenoxy)-5-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-71-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(4-chlorophenoxy)-5-methylphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-72-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3,5-dichlorophenoxy)-5-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-73-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-ethyl-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-74-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-chlorophenoxy)-4-ethylphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-75-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-chlorophenoxy)-4-methylphenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-76-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(3-chlorophenoxy)phenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-77-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-chlorophenoxy)-5-ethylphenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-78-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(4-chlorophenoxy)-5-ethylphenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-79-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(2-chlorophenoxy)-4-methylphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-80-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(2-chlorophenoxy)-4-ethylphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-81-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-3-(2-chlorophenoxy)phenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-82-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-methoxyphenoxy)-4-methylphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-83-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-84-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-methyl-3-[3-(trifluoromethyl)phenoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-85-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-chlorophenoxy)-4,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-86-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-methyl-3-(3-methylphenoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-87-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-bromophenoxy)-4-methylphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-88-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-chlorophenoxy)-4-(1-methylethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-89-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-fluorophenoxy)-4-methylphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-90-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-bromophenoxy)-4-chlorophenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-91-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-3-(4-chlorophenoxy)phenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-92-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-3-(3-methoxyphenoxy)phenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770715-93-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-3-(3,5-difluorophenoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770715-94-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-3-phenoxyphenyl)methyl]-4-methyl- (9CI)
 (CA INDEX NAME)




RN 770715-95-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-3-phenoxyphenyl)methyl]-5-methyl- (9CI)
 (CA INDEX NAME)




RN 770715-96-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(3,5-dichlorophenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770715-97-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-bromo-5-fluorophenoxy)-4-chlorophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770715-98-5 CAPLUS
 CN Benzonitrile, 3-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770715-99-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(3-hydroxyphenoxy)phenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 770716-00-2 CAPLUS
 CN Benzonitrile, 3-[5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770716-01-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(4-bromophenoxy)-4-chlorophenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 770716-02-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(3-fluorophenoxy)phenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 770716-03-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-04-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-bromophenoxy)-4-chlorophenyl]methyl]-4,5-dimethyl- (9CI) (CA INDEX NAME)




RN 770716-05-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-chlorophenoxy)-4-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-06-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-fluoro-3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-08-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(2-chlorophenoxy)phenyl]methyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 770716-09-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(2-chlorophenoxy)phenyl]methyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 770716-10-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(2-chlorophenoxy)phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770716-11-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-bromophenoxy)-4-chlorophenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770716-12-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-bromophenoxy)-4-chlorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 770716-14-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-fluoro-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770716-15-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-3-(2,4-dichlorophenoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770716-16-0 CAPLUS
 CN Benzonitrile, 3-[5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770716-17-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(2-chlorophenoxy)-4-fluorophenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 770716-20-6 CAPLUS
 CN Benzonitrile, 3-[2-chloro-5-[(1,6-dihydro-4,5-dimethyl-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-21-7 CAPLUS
 CN Benzonitrile, 3-[2-chloro-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-22-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(2-bromo-5-chlorophenoxy)-4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770716-23-9 CAPLUS
 CN Benzonitrile, 4-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-24-0 CAPLUS
 CN Benzonitrile, 3-chloro-4-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-25-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3,5-dichlorophenoxy)-4-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-26-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-bromo-5-methylphenoxy)-4-chlorophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-27-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-bromophenoxy)-4-chlorophenyl]methyl]-4-(chloromethyl)- (9CI) (CA INDEX NAME)




RN 770716-28-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-bromophenoxy)-4-chlorophenyl]methyl]-4-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 770716-31-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-2-methyl-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770716-34-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-bromophenoxy)-4-chloro-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-37-5 CAPLUS
 CN Benzonitrile, 4-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]-3-methyl- (9CI) (CA INDEX NAME)




RN 770716-38-6 CAPLUS
 CN Benzonitrile, 3-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 770716-39-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-bromophenoxy)-4-chlorophenyl)methyl]-5-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 770716-40-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-bromophenoxy)-4-chlorophenyl)methyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 770716-41-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(2,5-dichlorophenoxy)phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770716-42-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-bromo-5-methylphenoxy)-4-chlorophenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 770716-43-3 CAPLUS
 CN Benzonitrile, 3-[2-chloro-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 770716-44-4 CAPLUS


CN 3(2H)-Pyridazinone, 6-[(4-chloro-2-fluoro-3-phenoxyphenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 770716-48-8 CAPLUS


CN 3(2H)-Pyridazinone, 6-[(4-bromo-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 770716-55-7 CAPLUS


CN 3(2H)-Pyridazinone, 6-[(4-bromo-3-(3-chlorophenoxy)phenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 770716-56-8 CAPLUS


CN 3(2H)-Pyridazinone, 6-[(4-bromo-3-phenoxyphenyl)methyl]-4-methyl- (9CI)
(CA INDEX NAME)

RN 770716-61-5 CAPLUS


CN 3(2H)-Pyridazinone, 6-[(4-chloro-3-(3-chlorophenoxy)phenyl)methyl]-5-(methylamino)- (9CI) (CA INDEX NAME)




RN 770716-62-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(3-chlorophenoxy)phenyl]methyl]-4-(methylamino)- (9CI) (CA INDEX NAME)




RN 770716-63-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(3-chlorophenoxy)phenyl]methyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 770716-64-8 CAPLUS
 CN Benzonitrile, 2-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]-3-fluoro- (9CI) (CA INDEX NAME)




RN 770716-65-9 CAPLUS
 CN Benzonitrile, 3-bromo-4-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-66-0 CAPLUS
 CN Benzonitrile, 3-chloro-2-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-67-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(2,6-dichlorophenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-68-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(2-chloro-6-fluorophenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-69-3 CAPLUS
 CN 1,3-Benzenedicarbonitrile, 4-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-70-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(5-chloro-2-methylphenoxy)phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 770716-71-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(3-chlorophenoxy)phenyl]methyl]-4-[(2-hydroxyethyl)methylamino]- (9CI) (CA INDEX NAME)




RN 770716-72-8 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[[2-(aminocarbonyloxy)ethyl]methylamino]-6-[[4-chloro-3-(3-chlorophenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-73-9 CAPLUS

CN Benzamide, 3-bromo-4-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-74-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(3,5-dibromophenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-75-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(3,5-dibromophenoxy)phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770716-76-2 CAPLUS

CN 1,3-Benzeneddicarbonitrile, 5-[2-chloro-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-77-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-(2-bromo-5-chlorophenoxy)-4-chloro-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-78-4 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-79-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[7-(4-chlorophenoxy)-5-benzofuranyl]methyl]- (9CI) (CA INDEX NAME)




RN 770716-80-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[7-(3,5-dichlorophenoxy)-5-benzofuranyl]methyl]-(9CI) (CA INDEX NAME)




RN 770716-81-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[7-(3-chlorophenoxy)-5-benzofuranyl]methyl]-(9CI) (CA INDEX NAME)




RN 770716-82-0 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[7-(3,5-difluorophenoxy)-5-benzofuranyl]methyl]-(9CI) (CA INDEX NAME)




RN 770716-83-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[7-(3,5-dibromophenoxy)-5-benzofuranyl]methyl]-(9CI) (CA INDEX NAME)



RN 770716-84-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[7-(3,5-dichlorophenoxy)-2,3-dihydro-5-benzofuranyl]methyl]-(9CI) (CA INDEX NAME)




RN 770716-85-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(2,3-dihydro-7-phenoxy-5-benzofuranyl)methyl]-(9CI) (CA INDEX NAME)




RN 770716-87-5 CAPLUS

CN Benzonitrile, 4-[(5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-7-benzofuranyl]oxy)- (9CI) (CA INDEX NAME)




RN 770716-88-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(7-(3,5-dimethylphenoxy)-5-benzofuranyl)methyl]- (9CI) (CA INDEX NAME)




RN 770716-89-7 CAPLUS


CN Benzonitrile, 3-[(5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-7-benzofuranyl]oxy)- (9CI) (CA INDEX NAME)




RN 770716-90-0 CAPLUS
 CN 2-Pyridinecarbonitrile, 6-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 770716-92-2 CAPLUS
 CN Benzonitrile, 4-chloro-2-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-93-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-(3-bromophenoxy)-4-chloro-2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770716-94-4 CAPLUS
 CN Benzonitrile, 4-chloro-2-[6-chloro-3-[(1,6-dihydro-6-oxo-3-

pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770716-95-5 CAPLUS

CN 1,4-Benzenedicarbonitrile, 2-[6-chloro-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770716-96-6 CAPLUS

CN Benzonitrile, 3-[6-chloro-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-fluoro- (9CI) (CA INDEX NAME)




RN 770716-97-7 CAPLUS


CN Benzonitrile, 4-chloro-2-[2-chloro-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770716-98-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-2-fluoro-3-phenoxyphenyl)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 770716-99-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(3,5-dichlorophenoxy)-2-fluorophenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-00-5 CAPLUS
 CN Benzonitrile, 3-[6-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-fluoro- (9CI) (CA INDEX NAME)




RN 770717-01-6 CAPLUS

CN Benzonitrile, 3-[2-chloro-5-[(5-(dimethylamino)-1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770717-02-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(3-(5-bromo-2-chlorophenoxy)-4-chloro-2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770717-03-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(4-bromo-2-fluoro-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770717-04-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(4-bromo-3-(3-bromophenoxy)-2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770717-05-0 CAPLUS

CN Benzonitrile, 4-chloro-3-[6-chloro-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-06-1 CAPLUS

CN Benzonitrile, 4-bromo-2-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770717-07-2 CAPLUS

CN Benzonitrile, 3-[6-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-08-3 CAPLUS

CN Benzonitrile, 4-bromo-2-[2-chloro-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770717-09-4 CAPLUS

CN 1,4-Benzeneddicarbonitrile, 2-[2-chloro-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770717-10-7 CAPLUS

CN Benzonitrile, 3-[2-bromo-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770717-11-8 CAPLUS

CN 1,4-Benzeneddicarbonitrile, 2-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770717-12-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-bromo-3-(2-chlorophenoxy)phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-13-0 CAPLUS

CN Benzonitrile, 3-[6-bromo-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-fluoro- (9CI) (CA INDEX NAME)




RN 770717-14-1 CAPLUS

CN Benzonitrile, 2-chloro-4-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-methylphenoxy- (9CI) (CA INDEX NAME)



RN 770717-15-2 CAPLUS


CN 1,3-Benzenedicarbonitrile, 5-[6-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 770717-16-3 CAPLUS


CN 1,3-Benzenedicarbonitrile, 5-[6-chloro-3-[(1,6-dihydro-6-oxo-3-

pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-17-4 CAPLUS

CN Benzonitrile, 2-chloro-6-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770717-18-5 CAPLUS

CN Benzonitrile, 2-chloro-6-[2-chloro-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 770717-19-6 CAPLUS


CN Benzonitrile, 4-chloro-2-[5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770717-20-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-[2-(methylsulfonyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770717-21-0 CAPLUS
 CN Acetamide, N-[2-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 770717-22-1 CAPLUS
 CN Methanesulfonamide, N-[2-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 770717-23-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(2-nitrophenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770717-24-3 CAPLUS
 CN Benzonitrile, 2-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 770717-26-5 CAPLUS
 CN Benzonitrile, 4-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy- (9CI) (CA INDEX NAME)




RN 770717-28-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(2-aminophenoxy)-4-chlorophenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 770717-29-8 CAPLUS

CN Benzonitrile, 4-chloro-2-[5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770717-30-1 CAPLUS

CN Benzonitrile, 3-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-methylphenoxy]-5-fluoro- (9CI) (CA INDEX NAME)




RN 770717-31-2 CAPLUS

CN Benzonitrile, 4-[6-chloro-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-32-3 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770717-33-4 CAPLUS

CN Benzonitrile, 3-[5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770717-35-6 CAPLUS

CN Benzonitrile, 3-[2,3-dibromo-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-6-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-36-7 CAPLUS

CN Benzonitrile, 3-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 770717-37-8 CAPLUS

CN Benzonitrile, 3-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770717-38-9 CAPLUS

CN Benzonitrile, 3-[3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770717-42-5 CAPLUS

CN Benzonitrile, 3-[6-bromo-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-45-8 CAPLUS

CN Benzonitrile, 3-[2-bromo-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]-4-chloro- (9CI) (CA INDEX NAME)




RN 770717-46-9 CAPLUS

CN Benzonitrile, 4-chloro-3-[5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770717-47-0 CAPLUS

CN Benzonitrile, 3-[2-bromo-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]-4-chloro- (9CI) (CA INDEX NAME)




RN 770717-48-1 CAPLUS

CN Benzonitrile, 4-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-methylphenoxy- (9CI) (CA INDEX NAME)



RN 770717-49-2 CAPLUS


CN 1,2-Benzenedicarbonitrile, 3-[2-chloro-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 770717-50-5 CAPLUS


CN Benzonitrile, 2-[5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-

(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 770717-51-6 CAPLUS

CN Benzonitrile, 3-[6-bromo-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-4-chloro- (9CI) (CA INDEX NAME)




RN 770717-52-7 CAPLUS

CN Benzonitrile, 3-[6-bromo-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-4-chloro- (9CI) (CA INDEX NAME)




RN 770717-53-8 CAPLUS

CN Benzonitrile, 4-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-6-ethyl-2-fluorophenoxy- (9CI) (CA INDEX NAME)




RN 770717-54-9 CAPLUS

CN Benzonitrile, 4-chloro-3-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-6-ethyl-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-55-0 CAPLUS

CN Benzonitrile, 3-chloro-5-[6-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-56-1 CAPLUS

CN Benzonitrile, 3-[6-chloro-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 770717-57-2 CAPLUS

CN Benzonitrile, 3-[6-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 770717-58-3 CAPLUS

CN Benzonitrile, 4-chloro-3-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770717-59-4 CAPLUS

CN Benzonitrile, 3-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-methylphenoxy]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-60-7 CAPLUS

CN Benzonitrile, 3-[3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-methylphenoxy]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-61-8 CAPLUS

CN Benzonitrile, 4-chloro-3-[3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770717-62-9 CAPLUS

CN Benzonitrile, 3-[5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 770717-63-0 CAPLUS

CN Benzonitrile, 3-[6-bromo-3-[[5-(dimethylamino)-1,6-dihydro-6-oxo-3-pyridazinyl]methyl]-2-fluorophenoxy]-4-chloro- (9CI) (CA INDEX NAME)




RN 770717-64-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-chloro-2-fluoro-3-(1H-indol-4-yloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770717-65-2 CAPLUS


CN 3(2H)-Pyridazinone, 6-[(4-chloro-2-fluoro-3-(5-quinolinyloxy)phenyl)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-66-3 CAPLUS
 CN Benzonitrile, 3-chloro-5-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-6-ethyl-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-67-4 CAPLUS
 CN Benzonitrile, 3-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-methylphenoxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 770717-68-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(4-chloro-2-fluoro-3-(8-quinolinyloxy)phenyl)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-69-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-2-fluoro-3-[(1-oxido-8-quinolinyl)oxy]phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 770717-70-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[5-bromo-2-(methylsulfonyl)phenoxy]-4-chlorophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770717-71-0 CAPLUS
 CN Benzonitrile, 3-[2-chloro-5-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 770717-72-1 CAPLUS

CN Benzonitrile, 3-[6-bromo-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-chloro- (9CI) (CA INDEX NAME)




RN 770717-73-2 CAPLUS

CN Benzonitrile, 3-[6-bromo-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-chloro- (9CI) (CA INDEX NAME)




RN 770717-74-3 CAPLUS


CN Benzonitrile, 3-chloro-5-[3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 770717-75-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(7-phenoxy-5-benzofuranyl)methyl]- (9CI) (CA INDEX NAME)




RN 770717-76-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-2-fluoro-3-(1H-indol-4-yloxy)phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 770717-77-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-2-fluoro-3-(1H-indol-7-yloxy)phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-78-7 CAPLUS
 CN Benzonitrile, 3-chloro-5-[6-chloro-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-79-8 CAPLUS

CN Benzonitrile, 3-[6-chloro-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-(difluoromethyl)- (9CI) (CA INDEX NAME)




RN 770717-81-2 CAPLUS

CN Benzonitrile, 3-[6-chloro-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-ethyl- (9CI) (CA INDEX NAME)




RN 770717-83-4 CAPLUS

CN Benzonitrile, 2-(3-cyanophenoxy)-4-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 770717-87-8 CAPLUS

CN 1,3-Benzeneddicarbonitrile, 5-[3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-6-ethyl-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 770717-89-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[(6-chloro-2-pyridinyl)oxy]-4-methylphenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-90-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-[(4-methyl-2-pyridinyl)oxy]phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-91-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-[(4-methyl-1-oxido-2-pyridinyl)oxy]phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-92-5 CAPLUS

CN 2-Pyridinecarbonitrile, 6-[2-chloro-5-[(1,6-dihydro-4-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-93-6 CAPLUS

CN 2-Pyridinecarbonitrile, 6-[2-chloro-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-94-7 CAPLUS

CN 4-Pyridinecarbonitrile, 2-[2-chloro-5-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]phenoxy]-6-methyl- (9CI) (CA INDEX NAME)



RN 770717-95-8 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[2-fluoro-4-methyl-3-(3-pyridinyl)phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 770717-96-9 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[2-fluoro-4-methyl-3-[(1-oxido-3-

pyridinyl)oxy]phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-98-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[(5-bromo-1-oxido-3-pyridinyl)oxy]-4-chloro-2-fluorophenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 770717-99-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-(3-bromo-5-cyclopropylphenoxy)-4-chloro-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-00-8 CAPLUS

CN Benzonitrile, 3-[6-chloro-3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-5-cyclopropyl- (9CI) (CA INDEX NAME)




RN 770718-01-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-chloro-2-fluoro-3-(2,3,5-trichlorophenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-02-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[(3-chlorophenyl)thio]-4-nitrophenyl]methyl]- (9CI) (CA INDEX NAME)



RN 770718-03-1 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[4-amino-3-[(2-chlorophenyl)thio]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 770718-04-2 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[4-amino-3-[(3-chlorophenyl)thio]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 770718-05-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[7-(phenylmethyl)-5-benzofuranyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-06-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[7-[(2-fluorophenyl)methyl]-5-benzofuranyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-07-5 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[7-[(2,6-difluorophenyl)methyl]-5-benzofuranyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-08-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[7-[(2-methoxyphenyl)methyl]-5-benzofuranyl]methyl]- (9CI) (CA INDEX NAME)



RN 770718-09-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-methyl-3-(phenylmethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-10-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[(4-chlorophenyl)methyl]-4-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-11-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[7-[(3,5-dichlorophenyl)methyl]-5-benzofuranyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-12-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[(2-chlorophenyl)methyl]-4-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-13-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(phenylmethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-14-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[(3-chlorophenyl)methyl]-4-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-15-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[(3,5-dichlorophenyl)methyl]-4-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-16-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[7-[(4-bromophenyl)methyl]-5-benzofuranyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-17-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-[(4-chlorophenyl)methyl]-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-18-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[(3-chlorophenyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 770718-19-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(3-[(2-chlorophenyl)methoxy]phenyl)methyl]- (9CI)
(CA INDEX NAME)

IT 770718-20-2P 770718-21-3P 770718-22-4P

770718-23-5P 770718-24-6P 770718-25-7P


770718-26-8P 770718-28-0P 770718-44-0P

770718-45-1P 770718-46-2P 770718-49-5P


770719-18-1P 770722-01-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzyl pyridazinones as reverse transcriptase inhibitors)

RN 770718-20-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(3-[(4-chlorophenyl)methoxy]phenyl)methyl]- (9CI)
(CA INDEX NAME)


RN 770718-21-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(7-(2-methylpropoxy)-5-benzofuranyl)methyl]- (9CI)
(CA INDEX NAME)


RN 770718-22-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(7-butoxy-5-benzofuranyl)methyl]- (9CI) (CA INDEX)


NAME)




RN 770718-23-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[7-(1-ethylpropoxy)-5-benzofuranyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 770718-24-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-butoxy-4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770718-25-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-chloro-3-(1-ethylpropoxy)phenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 770718-26-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(cyclopropylmethoxy)-4-ethyl-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-28-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[(3-bromophenyl)sulfonyl]-4-chlorophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-44-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(3-benzoyl-4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 770718-45-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(4-chlorobenzoyl)-4-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-46-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3,5-dichlorobenzoyl)-4-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 770718-49-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(3-chlorobenzoyl)-4-methylphenyl]methyl]- (9CI)
 (CA INDEX NAME)



RN 770719-18-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[(5-bromo-3-pyridinyl)oxy]-2-fluoro-4-nitrophenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 770722-01-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[(6-chloro-2-pyridinyl)oxy]-4-methylphenyl]methyl]-5-methyl- (9CI) (CA INDEX NAME)




IT 770718-81-5P 770718-83-7P 770719-19-2P
 770719-20-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzyl pyridazinones as reverse transcriptase inhibitors)


RN 770718-81-5 CAPLUS

CN 1H-Indole, 7-[3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluoro-6-nitrophenoxy]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 770718-83-7 CAPLUS

CN 1H-Indole, 7-[6-amino-3-[(1,6-dihydro-5-methyl-6-oxo-3-pyridazinyl)methyl]-2-fluorophenoxy]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 770719-19-2 CAPLUS

CN 1(6H)-Pyridazinecarboxylic acid, 3-[[3-[(5-bromo-3-pyridinyl)oxy]-2-fluoro-4-nitrophenyl]methyl]-5-methyl-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 770719-20-5 CAPLUS


CN 1(6H)-Pyridazinecarboxylic acid, 3-[[4-amino-3-[(5-bromo-3-pyridinyl)oxy]-2-fluorophenyl]methyl]-5-methyl-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:616812 CAPLUS
 DN 142:176785
 TI Synthesis of nitrogenous heterocycles derived from pyridazinones
 AU Mohamed, M. I.; Zaky, H. T.; Kandile, N. G.
 CS Department of Chemistry, Faculty of Girl, Ain Shams University, Cairo, 11757, Egypt
 SO Bulgarian Chemical Communications (2003), 35(4), 252-258
 CODEN: BCHCE4; ISSN: 0324-1130
 PB Bulgarian Academy of Sciences
 DT Journal
 LA English
 OS CASREACT 142:176785
 AB 6-(Me or aryl)-4-(o-methoxybenzyl)pyridazin-3(2H)-ones were oxidized by a simple method using sodium dichromate and acetic acid to give the corresponding 6-(Me or aryl)-4-(o-methoxybenzoyl)pyridazin-3(2H)-ones. The latter reacted in the lactim form with phosphorus oxychloride to give the corresponding 6-(Me or aryl)-4-(o-methoxybenzoyl)-3-chloropyridazines. The behavior of 6-(Me or aryl)-4-(o-methoxybenzoyl)pyridazin-3(2H)-ones and the chloro derivs. towards different nucleophilic species was studied. The reaction of 6-(Me or aryl)-4-(o-methoxybenzoyl)pyridazin-3(2H)-ones in the lactam form with dimethylsulfate, formaldehyde and formaldehyde in the presence of morpholine are also reported.
 IT 121137-72-2 121137-73-3 126775-18-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis of nitrogenous heterocycles derived from pyridazinones)
 RN 121137-72-2 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 121137-73-3 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 126775-18-6 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)



X
5

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:610403 CAPLUS
 DN 139:164630
 TI Preparation of indan derivatives as thyroid hormone receptor ligands
 IN Shiohara, Hiroaki; Nakamura, Tetsuya; Kikuchi, Norihiko; Ozawa, Tomonaga;
 Kitazawa, Makio
 PA Kissei Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 197 pp.
 CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003064369	A1	20030807	WO 2003-JP772	20030128
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2473162	AA	20030807	CA 2003-2473162	20030128
	EP 1471049	A1	20041027	EP 2003-703059	20030128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005085541	A1	20050421	US 2003-502737	20030128
PRAI	JP 2002-20893	A	20020130		
	WO 2003-JP772	W	20030128		

OS MARPAT 139:164630

AB The title compds. I [W represents O, CH₂, etc.; R₁ represents halogeno, lower alkyl, halo(lower alkyl), CN, etc.; R₂ represents hydrogen, halogeno, lower alkyl, etc.; R₃ represents hydroxy, etc.; R₄ represents hydrogen, halogeno, alkyl, halo(lower alkyl), substituted alkyl, aryl, aralkyl, alkoxy, substituted alkoxy, alkanoyl, aroyl, etc.; R₅ represents hydrogen, halogeno, alkyl, substituted alkyl, etc.; and A represents XA₂COR₁₀, etc.; X represents O, etc.; A₂ represents alkylene; R₁₀ represents OH, alkoxy, etc.] are prepared In an in vitro test for thyroid hormone receptor β binding, compds. of this invention showed Ki values of 1.2 nM to 57.6 nM. In an in vitro test for thyroid hormone receptor α binding, compds. of this invention showed Ki values of 69.3 nM to 10000 nM.


IT 575503-17-2P 575503-36-5P 575503-75-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indan derivs. as thyroid hormone receptor ligands)


RN 575503-17-2 CAPLUS

CN Propanoic acid, 3-[[7-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenoxy]-2,3-dihydro-6-methyl-1H-inden-1-yl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 575503-36-5 CAPLUS

CN Acetic acid, [[7-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenoxy]-2,3-dihydro-6-methyl-1H-inden-4-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 575503-75-2 CAPLUS

CN Propanoic acid, 3-[[7-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenoxy]-2,3-dihydro-6-methyl-1H-inden-4-yl]amino]-3-oxo- (9CI) (CA INDEX NAME)




IT 575504-70-0P 575504-71-1P 575504-92-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indan derivs. as thyroid hormone receptor ligands)


RN 575504-70-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-[(2,3-dihydro-5-methyl-7-nitro-1H-inden-4-yl)oxy]-2-hydroxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 575504-71-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-[(2,3-dihydro-5-methyl-7-nitro-1H-inden-4-yl)oxy]-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)



RN 575504-92-6 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[5-[(7-amino-2,3-dihydro-5-methyl-1H-inden-4-yl)oxy]-2-hydroxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RE.CNT 12


THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:437803 CAPLUS
 DN 139:292214
 TI Reactivity of pyridazine-3(2H)-thiones
 AU Kandile, N. G.; Zaky, H. T.; Mohamed, M. I.; Hamad Elgazwy, Abdel-Sattar S.
 CS Department of Chemistry, Faculty of Girls, Ain Shams University, Cairo, 11757, Egypt
 SO Heteroatom Chemistry (2003), 14(4), 334-341
 CODEN: HETCE8; ISSN: 1042-7163
 PB John Wiley & Sons, Inc.
 DT Journal
 LA English
 OS CASREACT 139:292214
 AB 4,6-Disubstituted pyridazine-3(2H)-thiones were prepared by thiation of 4,6-disubstituted pyridazin-3(2H)-one either with thiourea or phosphorus pentasulfide. The reactivity of 4,6-disubstituted pyridazine-3(2H)-thiones towards nucleophilic and electrophilic species under different conditions was studied successively. The structure of the products was confirmed by NMR and mass spectral data. Mechanisms for their formation are also proposed. Compds. thus prepared and derivatized included 4-(2-methoxybenzyl)-6-methyl-3(2H)-pyridazinethione, 6-methyl-4-[(1-naphthalenyl)methyl]-3(2H)-pyridazinethione, 6-methyl-4-[(2-naphthalenyl)methyl]-3(2H)-pyridazinethione, 4-(2-methoxybenzyl)-6-phenyl-3(2H)-pyridazinethione, 4-(2-methoxybenzyl)-6-(4-methylphenyl)-3(2H)-pyridazinethione and 4-(2-methoxybenzyl)-6-(4-chlorophenyl)-3(2H)-pyridazinethione.
 IT 121137-72-2, 4-(2-Methoxybenzyl)-6-phenyl-3(2H)-Pyridazinone
 121137-73-3, 4-(2-Methoxybenzyl)-6-(4-methylphenyl)-3(2H)-Pyridazinone 126775-18-6, 4-(2-Methoxybenzyl)-6-methyl-3(2H)-Pyridazinone 177489-97-3, 6-(4-Chlorophenyl)-4-(2-methoxybenzyl)-3(2H)-Pyridazinone
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and reactions of pyridazinethiones)
 RN 121137-72-2 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)






RN 126775-18-6 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 177489-97-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-chlorophenyl)-4-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:905927 CAPLUS

DN 138:305

TI Preventive or recurrence-suppressive agents for liver cancer

IN Ohnota, Hideki; Hayashi, Morimichi; Kuroda, Junji; Komatsu, Yoshimitsu; Nishimura, Toshihiro

PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 142 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002094319	A1	20021128	WO 2002-JP4601	20020513
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2001-149775	A	20010518		
OS	MARPAT	138:305			
AB	Preventive or recurrence-suppressive agents for liver cancer containing as the active ingredient thyroid hormone receptor agonists having an effect of inhibiting the expression of liver estrogen sulfotransferase; and usage of the agents. The thyroid hormone receptor agonists are preferably compds. represented by the general formula I (R1 and R2 = alkyl, halogeno, or the like; R3 = hydrogen, alkyl, halogeno, or the like; X = hydroxyl or the like; W = O, S, CH2, or the like; Y = alkyl, -Q-T (wherein Q = O, CH2, CH(OH), or the like; and T = optionally substituted aryl or the like), or the like; Z = hydrogen, alkoxy, or the like; and A = -NHCO-Y1-CO2R8, -CH2CH(R9)NR10R11, or the like) or pharmaceutically acceptable salts thereof.				
IT	373641-15-7P 373641-64-6P				
	RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preventive or recurrence-suppressive agents for liver cancer containing thyroid hormone receptor agonists)				
RN	373641-15-7	CAPLUS			
CN	Propanoic acid, 3-[(4-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino)-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)				

*Saul**an**#16*



RN 373641-64-6 CAPLUS

CN Propanoic acid, 3-[4-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)




IT 373642-49-0P 373642-51-4P 373642-98-9P,

6-[5-(4-Amino-2,6-dimethylphenoxy)-2-hydroxybenzyl]-2H-pyridazin-3-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preventive or recurrence-suppressive agents for liver cancer containing thyroid hormone receptor agonists)


RN 373642-49-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(5-(2,6-dimethyl-4-nitrophenoxy)-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 373642-51-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(5-(2,6-dimethyl-4-nitrophenoxy)-2-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 373642-98-9 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[5-(4-amino-2,6-dimethylphenoxy)-2-hydroxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:287762 CAPLUS
 DN 138:73219
 TI 3-O-Substituted benzyl pyridazinone derivatives as COX inhibitors
 AU Chintakunta, Vamsee Krishna; Akella, Venkateswarlu; Vedula, Manohar
 Sharma; Mamnoor, Prem Kumar; Mishra, Parimal; Casturi, Seshagiri Rao;
 Vangoori, Akhila; Rajagopalan, Ramanujam
 CS Discovery Chemistry, Dr. Reddy's Research Foundation, Hyderabad, 500050,
 India
 SO European Journal of Medicinal Chemistry (2002), 37(4), 339-347
 CODEN: EJMCA5; ISSN: 0223-5234
 PB Editions Scientifiques et Medicales Elsevier
 DT Journal
 LA English
 OS CASREACT 138:73219
 AB New 3-O-substituted benzyl pyridazinone compds. have been synthesized and
 evaluated for their cyclooxygenase inhibitory activity and COX-2
 selectivity. Among the compds. synthesized, three compds., e.g. I, have
 shown in vitro COX-2 selectivity. These compds. have been evaluated for
 their in vivo potential using carrageenan-induced rat paw edema assay.
 One compound (I) showed 32% anti-inflammatory activity at 30 mg kg⁻¹ dose.
 IT 479690-30-7P 479690-31-8P 479690-32-9P
 479690-33-0P 479690-34-1P 479690-35-2P
 479690-36-3P 479690-37-4P 479690-38-5P
 479690-39-6P 479690-40-9P 479690-41-0P
 479690-42-1P 479690-43-2P 479690-44-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of benzyl pyridazinone derivs. as COX inhibitors)
 RN 479690-30-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[2-(4-bromophenyl)-2-oxoethoxy]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 479690-31-8 CAPLUS
 CN Acetamide, 2-[[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]-N-(4-
 methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 479690-32-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[2-(4-chlorophenyl)-2-oxoethoxy]phenyl]methyl]-
(9CI) (CA INDEX NAME)




RN 479690-33-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[2-(4-methylphenyl)-2-oxoethoxy]phenyl]methyl]-
(9CI) (CA INDEX NAME)




RN 479690-34-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[2-[4-(1,1-dimethylethyl)phenyl]-2-oxoethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 479690-35-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-[2-(4-fluorophenyl)-2-oxoethoxy]phenyl]methyl]-
(9CI) (CA INDEX NAME)




RN 479690-36-3 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[3-[2-(3,4-dimethoxyphenyl)-2-oxoethoxy]phenyl]methyl]-
(9CI) (CA INDEX NAME)




RN 479690-37-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[2-(4-chloro-3-methylphenyl)-2-oxoethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 479690-38-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[2-(4-fluoro-3-methylphenyl)-2-oxoethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 479690-39-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[2-(4-fluoro-3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 479690-40-9 CAPLUS
 CN Acetamide, N-(3,4-difluorophenyl)-2-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 479690-41-0 CAPLUS
 CN Acetamide, 2-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 479690-42-1 CAPLUS
 CN Acetamide, 2-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]-N-(4-ethylphenyl)- (9CI) (CA INDEX NAME)



RN 479690-43-2 CAPLUS
 CN Acetamide, N-1,3-benzodioxol-5-yl-2-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 479690-44-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-[2-(2,4-dichlorophenyl)-2-oxoethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




IT 479690-28-3P 479690-29-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzyl pyridazinone derivs. as COX inhibitors)


RN 479690-28-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 479690-29-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:220564 CAPLUS
 DN 136:263177
 TI Preparation of pyridazinones and triazinones exhibiting excellent inhibitory activities against AMPA receptor and/or kainate receptor
 IN Nagato, Satoshi; Kawano, Koki; Ito, Koichi; Norimine, Yoshihiko; Ueno, Kohshi; Hanada, Takahisa; Amino, Hiroyuki; Ogo, Makoto; Hatakeyama, Shinji; Ueno, Masataka; Groom, Anthony John; Rivers, Leanne; Smith, Terence
 PA Eisai Co., Ltd., Japan
 SO PCT Int. Appl., 174 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022587	A1	20020321	WO 2001-JP8058	20010917
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001090229	A5	20020326	AU 2001-90229	20010917
	CA 2422589	AA	20030317	CA 2001-2422589	20010917
	EP 1319659	A1	20030618	EP 2001-970120	20010917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 524745	A	20060127	NZ 2001-524745	20010917
	ZA 2003001537	A	20040225	ZA 2003-1537	20030225
	NO 2003001232	A	20030519	NO 2003-1232	20030317
	US 2003225081	A1	20031204	US 2003-380783	20030318
PRAI	JP 2000-282636	A	20000918		
	JP 2000-289412	A	20000922		
	JP 2000-342614	A	20001109		
	GB 2001-2822	A	20010205		
	GB 2001-2824	A	20010205		
	WO 2001-JP8058	W	20010917		

OS MARPAT 136:263177
 AB The title compds. [I; wherein A1, A2 and A3 are each independently C3-8 cycloalkyl, C3-8 cycloalkenyl, a 5- to 14-membered nonarom. heterocyclic group, a C6-14 aromatic carbocyclic group, or a 5- to 14-membered aromatic heterocyclic group, any of which may be substituted; Q is O, S, or NH; Z is C or N; X1, X2 and X3 are each independently a single bond, optionally substituted C1-6 alkylene, optionally substituted C2-6 alkenylene, optionally substituted C2-6 alkynylene, NH, O, NHCO, CONH, SOO-2, or the like; R1 and R2 are each independently hydrogen or optionally substituted C1-6 alkyl, or alternatively R1 and R2 may be united in such a way that CR2-ZR1 forms C:C; and R3 is hydrogen, optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, or alternatively R3 may unite with any atom on the ring A1 or A3 to form together with the atom an optionally substituted C5-8 carbocycle or an optionally substituted 5- to 8-membered heterocycle] or salts thereof, or hydrates of both are prepared. These compds. do not inhibit N-methyl-D-aspartic acid (NMDA) receptor but they

are excellent inhibitors of α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and/or kainic acid receptor. They are useful for the prevention or treatment of acute neurodegenerative diseases, acute cerebral vascular disorders, head injury, spinal cord injury, nerve disorders caused by low oxygen or sugar level, chronic neurodegenerative diseases, Alzheimer's disease, Parkinson's diseases, Huntington's chorea, amyotrophic lateral sclerosis, spinocerebellar degeneration, epilepsy, hepatic encephalopathy, peripheral nerve disorder, Parkinson's syndrome, spastic hemiplegia (paralysis), pain, neuralgia, schizophrenia, anxiety, drug dependence, nausea, vomiting, urination disorder, eye sight disorder caused by glaucoma, hearing disorders caused by antibiotics, food poisoning, infectious encephalomyelitis (including HIV encephalomyelitis), cerebral vascular dementia, dementia caused by meningitis, and nerve diseases. They are also used for treatment or prevention of demyelinating diseases including encephalitis, acute disseminated encephalomyelitis, multiple sclerosis, acute multiple neuritis, Guillain-Barre syndrome, chronic inflammatory demyelinating multiple nerve disorders, Marchiava-Bignami disease, central bulbopontine breakdown, optic nerve myelitis, Devic's disease (neuromyelitis optica), Balo's disease, HIV myelopathy, HTLV myelopathy, progressive white substance encephalopathy or secondary demyelinating diseases (including central nervous system erythematodes, tuberous multiple polyarteritis, Sjögren syndrome, sarcoidosis, or cerebral angiitis). Thus, to a solution of 75 mg 2-(2-iodophenyl)-4-(3-pyridyl)-2,3-dihydro-5H-[1]benzopyrano[4,3-c]pyridazin-3-one in 2 mL 1-methyl-2-pyrrolidone were added 55 mg Zn(CN)2 and 5 mg tetrakis(triphenylphosphine)palladium and stirred at 100° for 1 h to give 34 mg 2-(2-cyanophenyl)-4-(3-pyridyl)-2,3-dihydro-5H-[1]benzopyrano[4,3-c]pyridazin-3-one (II). II inhibited the AMPA-induced influx of Ca into rat fetal cerebral cortex nerve cells with IC50 of 0.02 μ M.


IT **404931-29-9P**, 4-(4-Methoxybenzyl)-6-phenyl-2-(2-tolyl)-2H-pyridazin-3-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridazinones and triazinones exhibiting excellent inhibitory activities against AMPA receptor and/or kainate receptor for treatment or prevention of acute or chronic neurodegenerative diseases)

RN 404931-29-9 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-(2-methylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:833261 CAPLUS
 DN 135:371762
 TI Preparation of malonanilic acid derivatives as preventives or remedies for circulatory disease
 IN Shiohara, Hiroaki; Nakamura, Tetsuya; Kikuchi, Norihiko; Ohnota, Hideki;
 Koizumi, Takashi; Kitazawa, Makio
 PA Kissei Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 118 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

Search as #13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085670	A1	20011115	WO 2001-JP3499	20010424
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2000-140743 A 20000512

OS MARPAT 135:371762


AB Compds. represented by the general formula (I) or pharmacol. acceptable salts thereof [wherein W represents oxygen, sulfur, methylene, CO, SO, or SO₂; R represents hydrogen, C₁-6 alkyl or aryl-C₁-6 alkyl; R₁ and R₂ represent each C₁-3 alkyl, CF₃, or halogeno; R₃ represents hydrogen, C₁-3 alkyl, halogeno, or CF₃; Y represents C₁-6 alkyl, CF₃, 6-oxo-1,6-dihydropyridazin-3-ylmethyl, or -Q-T (wherein Q represents oxygen, methylene, hydroxymethylene, or CO; and T represents optionally substituted aryl or arylmethyl or cycloalkylmethyl optionally containing O in the ring); and Z represents hydrogen or C₁-3 alkoxy or Y and Z are linked together to form tetramethylene] are prepared. These compds. I have excellent effects of lowering neutral fat level and non-HDL cholesterol level in the blood, inhibiting or suppressing the accumulation of neutral fat in the liver and protecting or ameliorating the liver function and, therefore, are useful as preventives or remedies for circulatory diseases such as hyperlipemia, arteriosclerosis, fatty liver, and hepatitis. Thus, 4-[3-(4-fluorobenzoyl)-4-hydroxyphenoxy]-3,5-dimethylmalonanilic acid Et ester was reduced by NaBH₄ in THF at room temperature for 13 h to give 4-[3-(4-fluorophenyl)hydroxymethyl]-4-hydroxyphenoxy]-3,5-dimethylmalonanilic acid Et ester which was converted into 4-[3-(4-fluorophenyl)hydroxymethyl]-4-hydroxyphenoxy]-3,5-dimethylmalonanilic acid potassium salt (II). II at 30 nmol/kg twice a day for 2 wk lowered the triglyceride level in liver of male KK-Ay mice from 16.1 (control) to 2.8 mg/1 g liver.

IT 373641-15-7P 373641-64-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of malonanilic acid derivs. lowering neutral fat level and non-HDL cholesterol level in blood as preventives or remedies for circulatory diseases)


RN 373641-15-7 CAPLUS

CN Propanoic acid, 3-[[4-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 373641-64-6 CAPLUS

CN Propanoic acid, 3-[[4-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)




IT 373642-49-0P 373642-51-4P 373642-98-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of malonanilic acid derivs. lowering neutral fat level and non-HDL cholesterol level in blood as preventives or remedies for circulatory diseases)


RN 373642-49-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dimethyl-4-nitrophenoxy)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 373642-51-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dimethyl-4-nitrophenoxy)-2-hydroxyphenyl]methyl]- (9CI) (CA INDEX NAME)



RN 373642-98-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-(4-amino-2,6-dimethylphenoxy)-2-hydroxyphenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:861458 CAPLUS

DN 134:32761

TI Sulfonyl thyromimetic compounds for treating hair loss

IN Zhang, Lilly Li-Xin; Youngquist, Robert Scott

PA University of Texas Southwestern Medical Center, USA

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000072810	A1	20001207	WO 2000-US5199	20000301
	W: AU, BR, CA, CN, JP, KR, MX, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2374260	AA	20001207	CA 2000-2374260	20000301
	EP 1185232	A1	20020313	EP 2000-915939	20000301
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2003500430	T2	20030107	JP 2000-620922	20000301
	US 6646005	B1	20031111	US 2002-980351	20020221
PRAI	US 1999-137023P	P	19990601		
	WO 2000-US5199	W	20000301		

OS MARPAT 134:32761

AB A method of treating hair loss comprises a composition containing a cardiac-sparing

compound [I, R1 = e.g., -(CH₂)_n(CHNR₇R₈)_mC(O)R₉; n = 1-3; m = 0-1; R₂ and R₃ = Cl, Br, I, or Me, R₇ and R₈ = H, or C1-4 alkyl; R₉ = OH, C1-4 alkoxy, and NR₇R₈; R₄ = e.g., H, Cl, Br, I, C1-4 alkyl, C4-6 cycloalkyl, C1-4 haloalkyl, C4-6 halocycloalkyl, R₅ = OH and C1-4 alkoxy] and their salts, hydrates or derivs. A composition for topical administration contained 3,5-dibromo-4-(3-cyclohexyl-4-hydroxyphenylsulfonyl)phenylacetic acid 5, EtOH 57, propylene glycol 19, and dimethylisosorbide 19%. A human male subject suffering from male pattern baldness was treated by the above formulation.


IT 155780-58-8

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sulfonyl thyromimetic compds. for treating hair loss)

RN 155780-58-8 CAPLUS

CN Benzeneacetic acid, 3,5-dibromo-4-[[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:393357 CAPLUS
 DN 133:99878
 TI Mechanism of liver-selective thyromimetic activity of SKF L-94901: evidence for the presence of a cell-type-specific nuclear iodothyronine transport process
 AU Ichikawa, K.; Miyamoto, T.; Kakizawa, T.; Suzuki, S.; Kaneko, A.; Mori, J.; Hara, M.; Kumagai, M.; Takeda, T.; Hashizume, K.
 CS Department of Aging Medicine and Geriatrics, Shinshu University School of Medicine, Matsumoto-City, 390-8621, Japan
 SO Journal of Endocrinology (2000), 165(2), 391-397
 CODEN: JOENAK; ISSN: 0022-0795
 PB Society for Endocrinology
 DT Journal
 LA English
 AB The thyromimetic compound SKF L-94901 shows more potent thyromimetic activity in the liver than in the pituitary gland or heart when administered to rats. The mechanisms of liver-selectivity of SKF L-94901 were examined using cultured rat hepatoma cells (dRLH-84) and rat pituitary tumor cells (GH3), both of which showed saturable cellular uptake of triiodothyronine (T3). When isolated nuclei with partial disruption of the outer nuclear membrane were used, SKF L-94901 competed for [¹²⁵I]T3 binding to nuclear receptors almost equally in dRLH-84 and GH3 cells. SKF L-94901 also did not discriminate thyroid hormone receptors (TR) $\alpha 1$ and $\beta 1$ in terms of binding affinity and activation of the thyroid hormone responsive element. In intact cells, however, SKF L-94901 was a more potent inhibitor of nuclear [¹²⁵I]T3 binding in dRLH-84 cells than in GH3 cells at an early phase of the nuclear uptake process and after binding equilibrium. These data suggest that SKF L-94901 is more effectively transported to nuclear TRs in hepatic cells than in pituitary cells and therefore shows liver-selective thyromimetic activity. In conclusion, SKF L-94901 discriminates hepatic cells and pituitary cells at the nuclear transport process. The cellular transporters responsible for this discrimination were not evident.
 IT 105211-23-2, SKF L-94901
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (SKF L-94901 liver-selective thyromimetic activity from cell-type-specific nuclear iodothyronine transport process)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:55409 CAPLUS
 DN 132:194339
 TI Synthesis and reactions of 4-(p-methoxybenzyl)-6-(5,6,7,8-tetrahydro-2-naphthyl)pyridazin-3(2H)-one
 AU Harb, Nagwa M. S. El-Din
 CS Chemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt
 SO Journal of the Serbian Chemical Society (1999), 64(11), 663-672
 CODEN: JSCSEN; ISSN: 0352-5139
 PB Serbian Chemical Society
 DT Journal
 LA English
 AB Condensation of the title compound (I, X = O), prepared by reaction of 6-(5,6,7,8-tetrahydro-2-naphthyl)-4,5-dihydropyridazin-3(2H)-one and anisaldehyde, with di-Me sulfate, formaldehyde and acrylonitrile, and also the formation of the Mannich base, proceeded smoothly at the 2-position. 3-Chloro-4-(p-methoxybenzyl)-6-(5,6,7,8-tetrahydro-2-naphthyl)pyridazine (II) was prepared in low yield by reaction of I (X = O) with phosphorus oxychloride. Reaction of II with benzylamine, aniline and piperidine were also carried out. I (X = S) was prepared either by reaction of II with thiourea or by reaction of I (X = O) with phosphorus pentasulfide. The reactions of this thione with acrylonitrile, morpholine and piperidine were also investigated.

IT 260058-86-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reactions of)
 RN 260058-86-4 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




IT 260058-88-6P 260058-90-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reactions of 4-(p-methoxybenzyl)-6-(5,6,7,8-tetrahydro-2-naphthyl)pyridazin-3(2H)-one)
 RN 260058-88-6 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(hydroxymethyl)-4-[(4-methoxyphenyl)methyl]-6-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 260058-90-0 CAPLUS

CN 1(6H)-Pyridazinepropanenitrile, 5-[(4-methoxyphenyl)methyl]-6-oxo-3-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)

IT 260058-87-5P 260058-89-7P 260058-91-1P
260058-97-7PRL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and reactions of 4-(p-methoxybenzyl)-6-(5,6,7,8-tetrahydro-2-naphthyl)pyridazin-3(2H)-one)


RN 260058-87-5 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-methyl-6-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 260058-89-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-(1-piperidinylmethyl)-6-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 260058-91-1 CAPLUS

CN 1(6H)-Pyridazinepropanoic acid, 5-[(4-methoxyphenyl)methyl]-6-oxo-3-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 260058-97-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-(4-morpholinylmethyl)-6-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:205355 CAPLUS
 DN 130:223287
 TI 3-Aroylbenzylpyridazinone derivatives
 IN Allen, Darin A.; Dunn, James P.; Sjogren, Eric B.; Smith, David B.
 PA Syntex (U.S.A.) Inc., USA
 SO U.S., 16 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5886178	A	19990323	US 1997-864708	19970528
PRAI US 1997-864708			19970528	
OS MARPAT 130:223287				

AB The title compds. and their pharmaceutically acceptable salts are inhibitors of prostaglandin G/H synthase and are antiinflammatory and analgesic agents. Thus, 2-[3-(4-methoxybenzoyl)-2-chlorophenyl]acetonitrile, prepared in 98% yield from 3-(4-methoxybenzoyl)-2-chlorobenzyl bromide and KCN in DMSO, was treated with 3,6-dichloropyridazine to give 52% {2-[3-(4-methoxybenzoyl)-2-chlorophenyl]-2-(6-chloropyridazin-3-yl)}acetonitrile which was hydrolyzed to give 39% 6-[3-(4-methoxybenzoyl)-2-chlorophenyl]-2H-pyridazin-3-one. Extensive data was given for the analgesic and antiinflammatory activity of the title compds. E.g., by measuring the inhibition of carrageenan-induced paw edema in the rat it was determined that 6-[3-(4-methoxybenzoyl)-2-methylphenyl]-2H-pyridazin-3-one gave 44% inhibition at 10 mg/kg.

IT 200000-78-8P 200000-80-2P, 6-[3-(4-Methoxybenzoyl)-2-methylphenyl]-2H-pyridazin-3-one 200001-03-2P

200001-05-4P 200001-07-6P 200001-15-6P


200001-20-3P 200001-37-2P 200001-38-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and analgesic and anti-inflammatory activity of aroylbenzylpyridazinones)


RN 200000-78-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-methyl-3-[4-(methylthio)benzoyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200000-80-2 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[3-(4-methoxybenzoyl)-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-03-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-methoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-05-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichloro-4-methylbenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-07-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-methoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 200001-15-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dibromo-4-methylbenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-20-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-methoxy-5-(2,4,6-trimethylbenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 200001-37-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-38-3 CAPLUS
 CN 3(2H)-Pyridazinone, 2-methyl-6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 200001-55-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and analgesic and anti-inflammatory activity of


aroylbenzylpyridazinones)
 RN 200001-55-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-hydroxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-
 (9CI) (CA INDEX NAME)




IT 200000-75-5P 200000-76-6P 200000-77-7P
 200000-83-5P 200000-85-7P 200000-98-2P
 200001-00-9P 200001-01-0P 200001-04-3P
 200001-09-8P 200001-11-2P 200001-12-3P
 200001-13-4P 200001-14-5P 200001-17-8P
 200001-19-0P 200001-21-4P 200001-22-5P
 200001-23-6P 200001-24-7P 200001-25-8P
 200001-26-9P 200001-27-0P 200001-28-1P
 200001-29-2P 200001-30-5P 200001-31-6P
 200001-32-7P 200001-33-8P 200001-34-9P
 200001-35-0P 200001-36-1P 200001-39-4P
 200001-40-7P 200001-41-8P 200001-43-0P
 200001-44-1P 200001-45-2P 200001-46-3P
 200001-47-4P 200001-57-6P 200002-17-1P
221168-76-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and analgesic and anti-inflammatory activity of
 aroylbenzylpyridazinones)


RN 200000-75-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-methoxy-3-(4-methoxybenzoyl)phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 200000-76-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(4-chlorobenzoyl)-2,6-dimethylphenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 200000-77-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[3-(4-chlorobenzoyl)-2-methylphenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 200000-83-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-methoxy-3-(4-methylbenzoyl)phenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 200000-85-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[4-hydroxy-3-(4-methylbenzoyl)phenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 200000-98-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-amino-3-(4-chlorobenzoyl)phenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 200001-00-9 CAPLUS
 CN Acetamide, N-[2-(4-chlorobenzoyl)-6-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 200001-01-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2-chloro-4-fluorobenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-04-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2-chlorobenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-09-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichloro-4-methoxybenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-11-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichloro-4-ethoxybenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-12-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichloro-4-propoxybenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-13-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-difluorobenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-14-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2-bromobenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-17-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(5-benzoyl-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 200001-19-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-methoxy-5-(4-methylbenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 200001-21-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dimethylbenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-22-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-methoxy-5-(4-methoxy-2,6-dimethylbenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-23-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(5-(4-ethoxy-2,6-dimethylbenzoyl)-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 200001-24-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(5-(2,6-dimethoxybenzoyl)-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 200001-25-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(2-(2-propenyl)-5-(2,4,6-trichlorobenzoyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 200001-26-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(2-ethoxy-5-(2,4,6-trichlorobenzoyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 200001-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-(cyclopropylmethoxy)-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-28-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-(cyclopropylmethoxy)-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 200001-29-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-propoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-
(9CI) (CA INDEX NAME)


RN 200001-30-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-(1-methylethoxy)-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-31-6 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2-propenyl)-6-[[2-(2-propenyl)oxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-32-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-propoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 200001-33-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-butoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-butyl- (9CI) (CA INDEX NAME)




RN 200001-34-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-ethoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 200001-35-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-butoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-36-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-(2-methylpropoxy)-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-39-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-40-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-butyl-6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-41-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 200001-43-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2-fluoroethyl)-6-[(2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 200001-44-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-[2,6-dichloro-4-(methylthio)benzoyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)



RN 200001-45-2 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[5-[2-chloro-4,6-bis(methylthio)benzoyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)



RN 200001-46-3 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[2-(methylthio)-5-(2,4,6-

trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-47-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-[2,6-dichloro-4-(methylthio)benzoyl]-2-(methylthio)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-57-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichlorobenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)



RN 200002-17-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 221168-76-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichloro-4-methylbenzoyl)-2-

10/807,993


methoxyphenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:108525 CAPLUS
 DN 130:223229
 TI Synthesis and some reactions of 4-aryl and 4-aryl-6-(p-acetamidophenyl)pyridazin-3(2H)-ones
 AU Ismail, M. Fekry; Derbala, H. A. Y.; Abu-El-Yazeed, H. S. E.
 CS Chemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1998), 37B(10), 1007-1015
 CODEN: IJSBDB; ISSN: 0376-4699
 PB National Institute of Science Communication, CSIR
 DT Journal
 LA English
 AB Base catalyzed condensation of 6-aryl-4,5-dihydropyridazin-3-(2H)-ones with benzaldehyde and p-methoxybenzaldehyde affords the corresponding 6-aryl-4-arylmethylpyridazin-3(2H)-ones. Oxidation of the latter pyridazinones using sodium dichromate in acetic acid, followed by condensation with hydrazine hydrate or 2,4-dinitrophenyl hydrazine furnishes hydrazones.
 IT **221048-78-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reactions of aroyl- and aryl(acetamidophenyl)pyridazinones)
 RN 221048-78-8 CAPLUS
 CN Acetamide, N-[4-[1,6-dihydro-5-[(4-methoxyphenyl)methyl]-6-oxo-3-pyridazinyl]phenyl]- (9CI) (CA INDEX NAME)




IT **221048-84-6P 221048-86-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reactions of aroyl- and aryl(acetamidophenyl)pyridazinones)
 RN 221048-84-6 CAPLUS
 CN Acetamide, N-[4-[1,6-dihydro-5-[(4-methoxyphenyl)methyl]-1-methyl-6-oxo-3-pyridazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 221048-86-8 CAPLUS


CN Acetamide, N-[4-[1-(2-cyanoethyl)-1,6-dihydro-5-[(4-methoxyphenyl)methyl]-6-oxo-3-pyridazinyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 22 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:452486 CAPLUS
 DN 129:170801
 TI Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression
 AU Ness, Gene C.; Lopez, Dayami; Chambers, Christopher M.; Newsome, William P.; Cornelius, Peter; Long, Catherine A.; Harwood, H. James, Jr.
 CS Department of Biochemistry and Molecular Biology, College of Medicine and the Institute for Biomolecular Science, University of South Florida, Tampa, FL, 33612, USA
 SO Biochemical Pharmacology (1998), 56(1), 121-129
 CODEN: BCPCA6; ISSN: 0006-2952
 PB Elsevier Science Inc.
 DT Journal
 LA English
 AB The mechanisms by which thyroid hormone (triiodothyronine (T3)) and a thyromimetic, 2-amino-3-(3,5-dibromo-4-[4-hydroxy-3-(6-oxo-1,6-dihydro-pyridazin-3-ylmethyl)-phenoxy]-phenyl)-propionic acid (L-94901), lower plasma low d. lipoprotein (LDL) cholesterol and raise plasma high d. lipoprotein (HDL) cholesterol levels was investigated in thyroidectomized and sham-operated rats. Thyroidectomy resulted in a 77% increase in plasma LDL cholesterol, a 60% decrease in plasma triglycerides, and a modest reduction in HDL cholesterol. Daily oral dosing with T3 (10-170 nmol/kg) or L94901 (100-1000 nmol/kg) for 7 days decreased plasma LDL cholesterol in thyroidectomized rats by 60-80%, resp. This reduction in LDL cholesterol was accompanied by a dose-dependent increase in HDL cholesterol levels of up to 60%. Thus, the ratio of LDL to HDL was decreased from 1.01 to 0.12 after treatment with L-94901 and to 0.25 after dosing with T3. In sham-operated animals, T3 and L-94901 lowered LDL cholesterol by 61 and 46%, resp., and increased HDL cholesterol by 25 and 53%, resp. Immunoblotting anal. of liver membranes prepared from thyroidectomized or sham-operated rats demonstrated that LDL receptor protein levels were increased by up to eight-fold. Northern blotting anal. revealed similar large increases in hepatic LDL receptor mRNA levels that accounted for the increases in LDL receptor protein levels. Hepatic 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase mRNA, protein, and activity were increased 2- to 3-fold. The T3- and L-94901-mediated increases in serum HDL levels were associated with 2- to 3-fold increases in apo A-I mRNA levels. In contrast with most other hypcholesterolemic agents, T3 and L-94901 significantly increase HDL cholesterol levels in addition to decreasing LDL cholesterol levels due to induction of hepatic apo A-I and LDL receptor gene expression.
 IT 105211-23-2, L-94901
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (triiodothyronine and thyromimetic L-94901 effect on serum lipoprotein levels and hepatic LDL receptor, hydroxymethylglutaryl CoA reductase, and apo A-I gene expression)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:789228 CAPLUS
DN 128:61475
TI Some reactions of barbituric acid-containing 6-(4-biphenylyl)-4,5-dihydro-3(2H)-pyridazinone
AU Radwan, A. M.; Kissab, R. R.; Sayed, G. H.
CS Chemistry Department, Faculty of Science, Al-Azhar (for Girls) University, Egypt
SO Al-Azhar Bulletin of Science (1996), 7(1, Pt. 1), 205-209
CODEN: ABSCE7; ISSN: 1110-2535
PB Al-Azhar University, Faculty of Science
DT Journal
LA English
AB Some new pyridazinone derivs. containing the barbiturate moiety were synthesized via addition of barbituric acid to 4-PhC₆H₄COCH:CHCOOH, followed by cyclization of the adduct with hydrazine, phenylhydrazine, and semicarbazide. Reactions of pyridazinone I with p-anisaldehyde, bromine-acetic acid, POCl₃, and P₂S₅ were examined
IT 200112-21-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(reactions of barbituric acid-containing 6-(4-biphenylyl)-4,5-dihydro-3(2H)-pyridazinone)
RN 200112-21-6 CAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[6-[1,1'-biphenyl]-4-yl-2,3-dihydro-5-[(4-methoxyphenyl)methyl]-3-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:783659 CAPLUS
 DN 128:48233
 TI Preparation of 6-benzyl-2H-pyridazin-3-ones as cyclooxygenase inhibitors
 IN Allen, Darin Arthur; Dunn, James Patrick; Sjogren, Eric Brian; Smith, David Bernard
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 810218	A1	19971203	EP 1997-108260	19970522
	EP 810218	B1	20021204		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CA 2205757	AA	19971130	CA 1997-2205757	19970521
	CA 2205757	C	20060124		
	CN 1169426	A	19980107	CN 1997-111479	19970521
	CN 1136196	B	20040128		
	AT 229007	E	20021215	AT 1997-108260	19970522
	ES 2186821	T3	20030516	ES 1997-108260	19970522
	JP 10045723	A2	19980217	JP 1997-134941	19970526
	JP 2790450	B2	19980827		
	BR 9703332	A	19980922	BR 1997-3332	19970530
PRAI	US 1996-18672P	P	19960530		

OS MARPAT 128:48233

AB Title compds. [I; R1 = H, halo, alkyl, alkoxy, etc.; R3,R4 = H, halo, OH, alkyl, alkoxy, etc.; R5 = H, halo, alk(en)yloxy, alkylthio, alkynyl; R7 = H, alkyl, cyano, etc.; R10 = (un)substituted Ph, -pyridyl, -thienyl, -furyl; R20 = H, (halo)alkyl, hydroxyalkyl, alkenyl; dashed line = optional bond] were prepared Thus, 4-(MeO)C6H4COC6H3ClMe-2,3 (preparation given)

was converted in 2 steps 3-(4-methoxybenzoyl)-2-chlorophenylacetonitrile which was condensed with 3,6-dichloropyridazine and the product hydrolyzed to give I [R1 = Cl, R3-R5 = R7 = R20 = H, R10 = C6H4(OMe)-4, dashed line = bond]. Data for biol. activity of I were given.


IT 200000-75-5P 200000-76-6P 200000-77-7P
 200000-78-8P 200000-80-2P 200000-83-5P
 200000-85-7P 200000-98-2P 200001-00-9P
 200001-01-0P 200001-03-2P 200001-04-3P
 200001-05-4P 200001-07-6P 200001-09-8P
 200001-11-2P 200001-12-3P 200001-13-4P
 200001-14-5P 200001-15-6P 200001-17-8P
 200001-19-0P 200001-20-3P 200001-21-4P
 200001-22-5P 200001-23-6P 200001-24-7P
 200001-25-8P 200001-26-9P 200001-27-0P
 200001-28-1P 200001-29-2P 200001-30-5P
 200001-31-6P 200001-32-7P 200001-33-8P
 200001-34-9P 200001-35-0P 200001-36-1P
 200001-37-2P 200001-38-3P 200001-39-4P
 200001-40-7P 200001-41-8P 200001-43-0P
 200001-44-1P 200001-45-2P 200001-46-3P
 200001-47-4P 200001-55-4P 200001-57-6P
 200002-17-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 6-benzyl-2H-pyridazin-3-ones as cyclooxygenase inhibitors)


RN 200000-75-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-methoxy-3-(4-methoxybenzoyl)phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 200000-76-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-(4-chlorobenzoyl)-2,6-dimethylphenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 200000-77-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[3-(4-chlorobenzoyl)-2-methylphenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 200000-78-8 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[2-methyl-3-[4-(methylthio)benzoyl]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 200000-80-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(3-(4-methoxybenzoyl)-2-methylphenyl)methyl]- (9CI)
(CA INDEX NAME)


RN 200000-83-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(4-methoxy-3-(4-methylbenzoyl)phenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 200000-85-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(4-hydroxy-3-(4-methylbenzoyl)phenyl)methyl]- (9CI)
(CA INDEX NAME)


RN 200000-98-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(2-amino-3-(4-chlorobenzoyl)phenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 200001-00-9 CAPLUS


CN Acetamide, N-[2-(4-chlorobenzoyl)-6-[(1,6-dihydro-6-oxo-3-

pyridazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 200001-01-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-(2-chloro-4-fluorobenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-03-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-methoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-04-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-(2-chlorobenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-05-4 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichloro-4-methylbenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-07-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-methoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 200001-09-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichloro-4-methoxybenzoyl)-2-methoxyphenyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 200001-11-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichloro-4-ethoxybenzoyl)-2-methoxyphenyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 200001-12-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichloro-4-propoxybenzoyl)-2-methoxyphenyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 200001-13-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-difluorobenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-14-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2-bromobenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-15-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dibromo-4-methylbenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-17-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(5-benzoyl-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 200001-19-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[[2-methoxy-5-(4-methylbenzoyl)phenyl]methyl]- (9CI)
(CA INDEX NAME)




RN 200001-20-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[[2-methoxy-5-(2,4,6-trimethylbenzoyl)phenyl]methyl]-
(9CI) (CA INDEX NAME)




RN 200001-21-4 CAPLUS
CN 3 (2H)-Pyridazinone, 6-[[5-(2,6-dimethylbenzoyl)-2-methoxyphenyl]methyl]-
(9CI) (CA INDEX NAME)




RN 200001-22-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[[2-methoxy-5-(4-methoxy-2,6-dimethylbenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-23-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(5-(4-ethoxy-2,6-dimethylbenzoyl)-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 200001-24-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(5-(2,6-dimethoxybenzoyl)-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 200001-25-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(2-(2-propenyl)-5-(2,4,6-trichlorobenzoyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 200001-26-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(2-ethoxy-5-(2,4,6-trichlorobenzoyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 200001-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-(cyclopropylmethoxy)-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-28-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-(cyclopropylmethoxy)-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 200001-29-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-propoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-
(9CI) (CA INDEX NAME)


RN 200001-30-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-(1-methylethoxy)-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-31-6 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2-propenyl)-6-[[2-(2-propenyl)oxy]-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-32-7 CAPLUS


CN 3(2H)-Pyridazinone, 6-[[2-propoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 200001-33-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-butoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-butyl- (9CI) (CA INDEX NAME)



RN 200001-34-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-ethoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 200001-35-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[2-butoxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-36-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-(2-methylpropoxy)-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-37-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-38-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-methyl-6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-39-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-40-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-butyl-6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-41-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 200001-43-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2-fluoroethyl)-6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-44-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-[2,6-dichloro-4-(methylthio)benzoyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-45-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-[2-chloro-4,6-bis(methylthio)benzoyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-46-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-(methylthio)-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-47-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-[2,6-dichloro-4-(methylthio)benzoyl]-2-(methylthio)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-55-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-hydroxy-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200001-57-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[5-(2,6-dichlorobenzoyl)-2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 200002-17-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-methyl-5-(2,4,6-trichlorobenzoyl)phenyl]methyl]-2-(2-propenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:644180 CAPLUS
 DN 127:326319
 TI Beneficial effects of a novel thyromimetic on lipoprotein metabolism
 AU Taylor, Anthony H.; Stephan, Zouhair F.; Steele, Ronald E.; Wong, Norman
 C. W.
 CS Endocrine Res. Group, Deps. Med. and Medical Biochem., Fac. Med., Health
 Sci. Cent., Univ. Calgary, Calgary, AB, T2N 4N1, Can.
 SO Molecular Pharmacology (1997), 52(3), 542-547
 CODEN: MOPMA3; ISSN: 0026-895X
 PB Williams & Wilkins
 DT Journal
 LA English
 AB Although L-triiodothyronine (L-T3) lowers cholesterol, this hormone is not used to treat hypercholesterolemia because of its cardiotoxic effects. Thyromimetics, such as the novel compound CGS 23425, that mimic the beneficial but lack the detrimental effects of T3, may be useful in the treatment of hypercholesterolemia. To show that CGS 23425 has no cardiotoxicity, atrial contractility and force were both measured and found to be unchanged in rats treated with up to 10 mg/kg drug. The lipid lowering actions of this drug resulted in a 44% decrease in low-d. lipoprotein (LDL) cholesterol in hypercholesterolemic rats treated with 10 μ g/kg of the compound. Normal rats required a higher dose of 1000 μ g/kg to elicit a similar 50% reduction in LDL cholesterol. Both CGS 23425 or T3 (10 nM) increased the specific binding of 125I-labeled LDL to Hep G2 cells and increased LDL receptor number by 44 and 49%, resp. These data indicate that CGS 23425 enhances hepatic clearance of serum LDL cholesterol. Normal and fat-fed animals treated with the drug showed a dose-dependent increase in apolipoprotein A1, a protein that promotes the efflux of cholesterol from peripheral tissues. Transient transfection of a rat apolipoprotein A1 promoter - chloramphenicol acetyltransferase construct, in human hepatoma cells, showed a dose-dependent increase in chloramphenicol acetyltransferase activity with EC50 values of 2 + 10-12 M and 10-10 M for thyroid hormone receptors β 1 and α 1, resp., with maximal responses at 10-7 M. These data indicate that CGS 23425 is a thyromimetic that increases apolipoprotein A1 expression via thyroid hormone receptor. In summary, CGS 23425 ameliorates hypercholesterolemia by increasing apolipoprotein A1 and the clearance of LDL cholesterol. Therefore, a compound like CGS 23425 may be useful for the prevention and reversal of atherosclerosis.
 IT 105211-23-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (comparison with; beneficial effects of thyromimetic CGS23425 on
 lipoprotein metabolism)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:220542 CAPLUS
 DN 126:207522
 TI Stat 5 SH2 domain-specific compounds for enhancement of erythropoiesis
 IN Dunnington, Damien John
 PA Smithkline Beecham Corporation, USA; Dunnington, Damien John
 SO PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9702024	A1	19970123	WO 1996-US11158	19960628
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9649237	A1	19960827	AU 1996-49237	19960209
	EP 809490	A1	19971203	EP 1996-905494	19960209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
	BR 9607614	A	19980609	BR 1996-7614	19960209
	JP 10513474	T2	19981222	JP 1996-524486	19960209
	EP 811159	A1	19971210	EP 1996-906615	19960212
	R: BE, CH, DE, DK, FR, GB, IT, LI, NL				
	JP 10513564	T2	19981222	JP 1996-524493	19960212
	CA 2225666	AA	19970123	CA 1996-2225666	19960628
	AU 9664055	A1	19970205	AU 1996-64055	19960628
	ZA 9605499	A	19980330	ZA 1996-5499	19960628
	ZA 9605500	A	19980330	ZA 1996-5500	19960628
	EP 835104	A1	19980415	EP 1996-923579	19960628
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 10512585	T2	19981202	JP 1996-505268	19960628
	FI 9703259	A	19971008	FI 1997-3259	19970807
	NO 9703659	A	19971008	NO 1997-3659	19970808
PRAI	US 1995-497357	A	19950630		
	US 1996-598715	A2	19960208		
	US 1995-386381	A	19950210		
	US 1995-400220	A	19950307		
	WO 1996-US1964	W	19960209		
	WO 1996-US2490	W	19960212		
	WO 1996-US11158	W	19960628		

AB Invented is a method of enhancing erythropoiesis in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human Stat 5 SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human Stat 6 SH2 domain, binds to a human hcp SH2 domain, a human Grb2 SH2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such Stat 5 SH2 domain, and binds to a human src SH2 domain, a human lck SH2 domain and a human fyn SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such Stat 5 SH2 domain.


IT 105190-08-7P 105190-13-4P 187664-30-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Stat 5 SH2 domain-specific compds. to enhance erythropoiesis)

RN 105190-08-7 CAPLUS


CN 3(2H)-Pyridazinone, 6-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 105190-13-4 CAPLUS

CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187664-30-8 CAPLUS

CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 27 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:192125 CAPLUS
 DN 126:181352
 TI Use of Stat 6 SH2 domain-specific compounds to treat allergic reactions
 IN Dunnington, Damien John
 PA Smithkline Beecham Corporation, USA; Dunnington, Damien John
 SO PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9702023	A1	19970123	WO 1996-US11074	19960628
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9649237	A1	19960827	AU 1996-49237	19960209
	EP 809490	A1	19971203	EP 1996-905494	19960209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
	BR 9607614	A	19980609	BR 1996-7614	19960209
	JP 10513474	T2	19981222	JP 1996-524486	19960209
	EP 811159	A1	19971210	EP 1996-906615	19960212
	R: BE, CH, DE, DK, FR, GB, IT, LI, NL				
	JP 10513564	T2	19981222	JP 1996-524493	19960212
	CA 2225668	AA	19970123	CA 1996-2225668	19960628
	AU 9664807	A1	19970205	AU 1996-64807	19960628
	ZA 9605499	A	19980330	ZA 1996-5499	19960628
	ZA 9605500	A	19980330	ZA 1996-5500	19960628
	EP 871436	A1	19981021	EP 1996-924322	19960628
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2000514036	T2	20001024	JP 1997-505234	19960628
	FI 9703259	A	19971008	FI 1997-3259	19970807
	NO 9703659	A	19971008	NO 1997-3659	19970808
PRAI	US 1995-497357	A	19950630		
	US 1996-598716	A	19960208		
	US 1995-386381	A	19950210		
	US 1995-400220	A	19950307		
	WO 1996-US1964	W	19960209		
	WO 1996-US2490	W	19960212		
	WO 1996-US11074	W	19960628		

AB Invented is a method of treating allergic reactions in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human Stat 6 SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human Stat 5 SH2 domain, binds to a human hcp SH2 domain, a human Grb2 SH2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such Stat 6 SH2 domain, and binds to a human src SH2 domain, a human lck SH2 domain and a human fyn SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such Stat 6 SH2 domain.


IT 105211-23-2P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (Stat 6 SH2 domain-specific compds. to treat allergic reactions)

RN 105211-23-2 CAPLUS

CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 105190-08-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Stat 6 SH2 domain-specific compds. to treat allergic reactions)

RN 105190-08-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:634955 CAPLUS
 DN 125:266017
 TI Use of hcp specific compounds to enhance erythropoiesis
 IN Dunnington, Damien John
 PA Smithkline Beecham Corporation, USA
 SO Eur. Pat. Appl., 46 pp.
 CODEN: EPXXDW

DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 728482	A2	19960828	EP 1996-200269	19960207	
	EP 728482	A3	19991020			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
	AU 9644405	A1	19960822	AU 1996-44405	19960207	
	ZA 9601000	A	19960807	ZA 1996-1000	19960208	
	CA 2169132	AA	19960811	CA 1996-2169132	19960208	
	ZA 9601001	A	19960813	ZA 1996-1001	19960208	
	CN 1135333	A	19961113	CN 1996-104364	19960208	
	CN 1137378	A	19961211	CN 1996-105740	19960208	
	JP 09002974	A2	19970107	JP 1996-59922	19960208	
CA 2212645	AA	19960815	CA 1996-2212645	19960209		
WO 9624343	A1	19960815	WO 1996-US1964	19960209		
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN						
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG						
AU 9649237	A1	19960827	AU 1996-49237	19960209		
EP 809490	A1	19971203	EP 1996-905494	19960209		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI						
BR 9607614	A	19980609	BR 1996-7614	19960209		
JP 10513474	T2	19981222	JP 1996-524486	19960209		
WO 9624847	A1	19960815	WO 1996-US2490	19960212		
W: JP, US						
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
EP 811159	A1	19971210	EP 1996-906615	19960212		
R: BE, CH, DE, DK, FR, GB, IT, LI, NL						
JP 10513564	T2	19981222	JP 1996-524493	19960212		
ZA 9601318	A	19970127	ZA 1996-1318	19960220		
ZA 9605499	A	19980330	ZA 1996-5499	19960628		
ZA 9605500	A	19980330	ZA 1996-5500	19960628		
FI 9703259	A	19971008	FI 1997-3259	19970807		
NO 9703659	A	19971008	NO 1997-3659	19970808		
PRAI	US 1995-386381	A	19950210			
	US 1995-400220	A	19950307			
	US 1995-497357	A	19950630			
	US 1995-540680	A	19951011			
	US 1995-581089	A	19951229			
	WO 1996-US1964	W	19960209			
	WO 1996-US2490	W	19960212			

AB Invented is a method of enhancing erythropoiesis in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to the human hcp SH2 domain with a binding affinity

greater than fifty-fold higher than the binding affinity with which the compound binds to a human SH-PTP2 SH2 domain, and, binds to a human src SH2 domain, a human lck SH2 domain, a human fyn SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such hcp SH2 domain. Thus, Et 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate and Et 3-ethoxycrotonate in toluene were treated with camphorsulfonic acid and heated at reflux for 3 h. The mixt was cooled, concentrated, and the residue dissolved in Et acetate. Acetic acid was added, solvent evaporated, and the resulting solid triturated with MeOH to yield Et 4-hydroxy-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-2-carboxylate. This is refluxed in phosphorus oxychloride for 3.5 h. The phosphorus oxychloride was removed and the residual oil dissolved in Et acetate, washed and dried to produce Et 4-chloro-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-2-carboxylate. In MeOH this was treated with hydrazine monohydrate and heated at reflux for 16 h, poured over diluted aqueous HCl to precipitate

2,3,7,8,9,10-hexahydro-4-methyl-1H-benzo[b]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one. Compds. of the invention were tested for binding affinity with peptides representing the protein domains listed above. In mice, L-3,5-dibromo-3'-(6-oxo-3(1H)-pyridazinylmethyl)thyronine increased reticulocyte counts at dosages from 200-800 mg/kg/day.

IT 105211-23-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(use of hcp domain-specific compds. to enhance erythropoiesis)

RN 105211-23-2 CAPLUS

CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 105190-08-7P 105190-13-4P 105190-17-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(use of hcp domain-specific compds. to enhance erythropoiesis)

RN 105190-08-7 CAPLUS


CN 3(2H)-Pyridazinone, 6-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 105190-13-4 CAPLUS

CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105190-17-8 CAPLUS

CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-5-(1,1-dimethylethyl)-4-hydroxyphenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 29 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:623003 CAPLUS
 DN 125:238690
 TI Ligands for the SH2 domain of the src protein for treatment of bone resorption diseases
 IN Dunnington, Damien John
 PA Smithkline Beecham Corporation, USA
 SO Eur. Pat. Appl., 46 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 727211	A1	19960821	EP 1996-200270	19960207
	R: AT, BE, CH, AU 9644404	DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE	19960822	AU 1996-44404	19960207
	ZA 9601000	A	19960807	ZA 1996-1000	19960208
	CA 2169136	AA	19960811	CA 1996-2169136	19960208
	ZA 9601001	A	19960813	ZA 1996-1001	19960208
	CN 1135333	A	19961113	CN 1996-104364	19960208
	CN 1137378	A	19961211	CN 1996-105740	19960208
	JP 09087200	A2	19970331	JP 1996-59921	19960208
	CA 2212645	AA	19960815	CA 1996-2212645	19960209
	WO 9624343	A1	19960815	WO 1996-US1964	19960209
	W: AM, AU, BB, BG, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9649237	A1	19960827	AU 1996-49237	19960209
	EP 809490	A1	19971203	EP 1996-905494	19960209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
	BR 9607614	A	19980609	BR 1996-7614	19960209
	JP 10513474	T2	19981222	JP 1996-524486	19960209
	WO 9624847	A1	19960815	WO 1996-US2490	19960212
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 811159	A1	19971210	EP 1996-906615	19960212
	R: BE, CH, DE, DK, FR, GB, IT, LI, NL				
	JP 10513564	T2	19981222	JP 1996-524493	19960212
	ZA 9601318	A	19970127	ZA 1996-1318	19960220
	ZA 9605499	A	19980330	ZA 1996-5499	19960628
	ZA 9605500	A	19980330	ZA 1996-5500	19960628
	FI 9703259	A	19971008	FI 1997-3259	19970807
	NO 9703659	A	19971008	NO 1997-3659	19970808
PRAI	US 1995-386381	A	19950210		
	US 1995-400220	A	19950307		
	US 1995-497357	A	19950630		
	US 1995-541080	A	19951011		
	US 1995-580868		19951229		
	WO 1996-US1964	W	19960209		
	WO 1996-US2490	W	19960212		

AB A method of treating a bone resorption disease by administering a compound that binds to the SH2 domain of the human src, e.g. I, protein with a binding affinity greater than 50-fold higher than for the SH2 domains of

the human lck, fyn, hcp, Grb2, SH-PTP2, and p85 is described. The preparation of a number of compds. is described. An assay system for binding of these ligands to SH2 domains using SH2 domains manufactured as fusion proteins in *Escherichia coli* is described. I inhibited inhibited 45Ca in a mouse embryonic ulna model with an IC50 of 19 μ M.


IT **105190-08-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reactions of; ligands for SH2 domain of src protein for treatment of bone resorption diseases)

RN 105190-08-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



IT **182198-18-1P**


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as ligand for SH2 domain of src protein; ligands for SH2 domain of src protein for treatment of bone resorption diseases)


RN 182198-18-1 CAPLUS

CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-4-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 30 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:420087 CAPLUS
 DN 125:114557
 TI Synthesis and reactions of β -(4-chlorobenzoyl)- α -[4-(1-phenyl-3,5-pyrazolidinedione)] propionic acid
 AU Radwan, Azza Mohamed
 CS Faculty Science, Al-Azhar University, Cairo, Egypt
 SO Al-Azhar Bulletin of Science (1995), 6(1), 89-94
 CODEN: ABSCE7; ISSN: 1110-2535
 PB Al-Azhar University, Faculty of Science
 DT Journal
 LA English
 AB Pyrazolidinedione derivative I was prepared by nucleophilic addition of 1-phenyl-3,5-pyrazolidinedione to β -(p-chlorophenyl)acrylic acid. Reactions of I with hydrazine, phenylhydrazine and hydroxylamine hydrochloride afforded the corresponding pyridazinones II (X = NH, NPh) and oxazinone I (X = O). The behavior of pyridazinone derivative I (X = NH) towards anisaldehyde, benzoyl chloride and phosphorus pentasulfide was also investigated.
 IT 178999-56-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reactions of chlorobenzoyl(phenyldioxopyrazolyl)propionic acid)
 RN 178999-56-9 CAPLUS
 CN 3,5-Pyrazolidinedione, 4-[6-(4-chlorophenyl)-2,3-dihydro-5-[(4-methoxyphenyl)methyl]-3-oxo-4-pyridazinyl]-1-phenyl- (9CI) (CA INDEX NAME)





L4 ANSWER 31 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:338854 CAPLUS
 DN 125:26674
 TI Effects of the novel thyroid hormone analogs, SKF L-94901, Dibit, and 3'-AC-T2 on mitochondrial function
 AU Horrum, Mark A.; Tobin, Richard B.; Ecklund, Robert E.
 CS College Medicine, University Nebraska Medical Center, Omaha, NE, 68105, USA
 SO Biochemistry and Molecular Biology International (1996), 38(1), 61-72
 CODEN: BMBIES; ISSN: 1039-9712
 PB Academic
 DT Journal
 LA English
 AB The effects of L-T3 and three novel analogs, SKF L-94901 (3,5-dibromo-3'-pyridazinone-L-thyronine), Dibit (3,5-dibromo-3'-isopropyl-L-thyronine), and 3'-Ac-T2 (3'-acetyl-3,5-diiodo-L-thyronine), on mitochondrial parameters were determined in hypothyroid rats. The parameters include the 24 h hormone-induced changes in the bcl complex and in the proton permeability of the mitochondrial inner membrane. The cardiac sparing analog, SKF L-94901, had no effect on mitochondrial respiration or proton permeability, but the analog did increase α -glycerophosphate dehydrogenase activity, mitochondrial ubiquinone content, and altered the bypass respiration in the bcl complex. Dibit also did not increase respiration significantly but did change the other parameters. 3'-Ac-T2 increased respiration, mitochondrial ubiquinone content, proton permeability, enzyme activity and altered the bypass of the antimycin A blockage in the bcl complex.
 IT 105211-23-2, SKF L-94901
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (thyroid hormone analogs effect on mitochondrial function)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 32 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:253160 CAPLUS
 DN 125:10729
 TI New pyridazine derivatives. Effects on a biological system
 AU Kandi, N. G.; Mohamed, M. I.; Zaky, H. T.; Mohamed, M. S.
 CS Coll. Women, Ain Shams Univ., Cairo, Egypt
 SO *Tinctoria* (1996), 93(3), 40-9
 CODEN: TINCAW; ISSN: 0040-7984
 PB Edizioni Ariminum
 DT Journal
 LA Italian
 AB The pyridazinones I [R = Cl, OMe, Me, H; R2 - 2-MeOC6H4, 2,4,6-(MeO)3C6H2] were pred. by reductive alkylation with RCHO and were converted to some N-substituted derivs., thiones, ene chlorides, ene amines, and ene hydrazines. I were devoid of bactericidal and fungicidal activity.
 IT 177489-97-3P 177489-98-4P 177489-99-5P
 177490-00-5P 177490-01-6P 177490-02-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, reactions, and bactericidal and fungicidal activity of aryl(methoxybenzyl)pyridazinones)
 RN 177489-97-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-chlorophenyl)-4-[(2-methoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 177489-98-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-4-[(2-methoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 177489-99-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-(4-chlorophenyl)-4-[(2,4,6-trimethoxyphenyl)methyl]-(9CI) (CA INDEX NAME)



RN 177490-00-5 CAPLUS


CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-4-[(2,4,6-trimethoxyphenyl)methyl]-(9CI) (CA INDEX NAME)




RN 177490-01-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-(4-methylphenyl)-4-[(2,4,6-trimethoxyphenyl)methyl]-(9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)



RN 177490-02-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-4-[(2,4,6-trimethoxyphenyl)methyl]- (9CI)
(CA INDEX NAME)


IT 121137-73-3P 177490-03-8P 177490-04-9P

177490-05-0P 177490-06-1P 177490-07-2P

177490-08-3P 177490-09-4P 177490-10-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, reactions, and bactericidal and fungicidal activity of
aryl(methoxybenzyl)pyridazinones)

RN 121137-73-3 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-(4-methylphenyl)- (9CI)
(CA INDEX NAME)


RN 177490-03-8 CAPLUS

CN 1(6H)-Pyridazineacetic acid, 3-(4-chlorophenyl)-5-[(2-methoxyphenyl)methyl]-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 177490-04-9 CAPLUS

CN 3(2H)-Pyridazinone, 2-acetyl-6-(4-chlorophenyl)-4-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 177490-05-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-acetyl-6-(4-methoxyphenyl)-4-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 177490-06-1 CAPLUS

CN 3(2H)-Pyridazinone, 2-acetyl-6-(4-chlorophenyl)-4-[(2,4,6-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 177490-07-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-acetyl-6-(4-methoxyphenyl)-4-[(2,4,6-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 177490-08-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-acetyl-6-(4-methylphenyl)-4-[(2,4,6-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 177490-09-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-acetyl-6-phenyl-4-[(2,4,6-trimethoxyphenyl)methyl]-
(9CI) (CA INDEX NAME)





RN 177490-10-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-acetyl-4-[(2-methoxyphenyl)methyl]-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 33 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:167653 CAPLUS
 DN 124:196496
 TI Composite insecticide
 IN Xu, Jianjun
 PA Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 6 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1108885	A	19950927	CN 1995-111205	19950106
PRAI	CN 1995-111205		19950106		
AB	The title composite insecticide consists of isocarbophos (4-34%, weight%), isothioate (2-34%), Damantong (0.6-10.5), dimethoate (and/or Folimat, 4-34%). It is active as contact and stomach poison against coccids and acarids.				
IT	174494-07-6 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses) (composite insecticide)				
RN	174494-07-6 CAPLUS				
CN	3(2H)-Pyridazinone, 4-chloro-2-(1,1-dimethylethyl)-5-[[4-[(1,1-dimethylethyl)thio]phenyl]methyl]- (9CI) (CA INDEX NAME)				




L4 ANSWER 34 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:871851 CAPLUS
 DN 124:86262
 TI Heterocyclic tautomerism. IX. Structural revision of a series of pharmacologically active pyridazines
 AU Guard, James A. M.; Steel, Peter J.
 CS Chemistry Dep., Univ. Canterbury, Christchurch, N. Z.
 SO Australian Journal of Chemistry (1995), 48(9), 1601-7
 CODEN: AJCHAS; ISSN: 0004-9425
 PB Commonwealth Scientific and Industrial Research Organization
 DT Journal
 LA English
 AB On the basis of ¹H NMR n.O.e. measurements and an x-ray crystal structure determination, it is shown that a large series of pharmacol. active pyridazine derivs. should be represented as aromatic pyridazine tautomers [e.g. (1b)-(3b)], rather than the previously reported arylidene-4,5-dihydropyridazines [e.g. (1a)-(3a)]. Crystals of (7b) are monoclinic, P21/c, a 13.312(3), b 7.269(1), c 11.753(2) Å, β 101.38(3)°, Z = 4; the structure was refined to a conventional R[I > 2σ(I)] 0.037.
 IT 172606-32-5P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (structural revision of pharmacol. active pyridazines as tautomers)
 RN 172606-32-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-methyl-5-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:539859 CAPLUS
DN 123:83307
TI Synthesis and reactions of some 6-(3-methyl-4-chlorophenyl)-4-(5-barbiturate)-2,3,4,5-tetrahydropyridazin-3-ones
AU Sayed, G. H.; Radwan, A.; Abd Elhalim, M. S.; Khalil, M.
CS Fac. Sci., Ain-Shams Univ., Cairo, Egypt
SO Journal of the Chemical Society of Pakistan (1994), 16(4), 265-9
CODEN: JCSPDF; ISSN: 0253-5106
PB Chemical Society of Pakistan
DT Journal
LA English
AB Some new pyridazinone derivs. (3) were synthesized through the addition of barbituric acid to β -aroylerylic acid (1) followed by cyclization of the adducts. Reactions of (3) with anisaldehyde, bromine-acetic acid mixture and POCl_3 gave the 4,5,6-trisubstituted pyridazinone (4), the 5-bromopyridazinone (5) and the tetrachloro derivative (6), resp. The latter reacts with hydrazine hydrate to give tetrahydrazino derivative (7). Reaction of (3) with phosphorus pentasulfide in one instance namely at short time and less amount of P_2S_5 gave the monothio derivative (8), in the second instance at long times and excess P_2S_5 gave the tetrathioderivative (9). Compound (2,3a) and (6) posses moderate activity against Gram-pos. Compound (2) possesses also moderate activity against Gram-neg. and slight activity against fungi. Some new pyridazinone derivs. were synthesized through the addition of barbituric acid to β -aroylerylic acid followed by cyclization of the adducts. Reactions of pyridazinones with anisaldehyde, bromine-acetic acid mixture and POCl_3 gave a 4,5,6-trisubstituted pyridazinone, a 5-bromopyridazinone and a tetrachloro derivative. Reaction of pyridazinones with phosphorus pentasulfide in one instance namely at short time and less amount of P_2S_5 gave a monothio derivative, in the second instance at long times and excess P_2S_5 gave a tetrathioderivative.
IT 165559-46-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (oxopyridazinyl)pyrimidinetriones)
RN 165559-46-6 CAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[6-(4-chloro-3-methylphenyl)-2,3-dihydro-5-[(4-methoxyphenyl)methyl]-3-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 36 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:655743 CAPLUS
 DN 121:255743
 TI Synthesis and chemistry of 4-aryloyl-3-oxo- and 3-chloropyridazine derivatives
 AU Shalaby, Alyaa A.; Youssef, Ali M.; Youssef, Wael A.; Shams, Nabil A.
 CS Faculty Science, Ain Shams University, Cairo, Egypt
 SO Journal of the Chinese Chemical Society (Taipei, Taiwan) (1994), 41(4), 477-80
 CODEN: JCCTAC; ISSN: 0009-4536
 DT Journal
 LA English
 AB 4H,5H-6-Phenyl- and 6-p-phenoxyphenylpyridazin-3(2H)-ones were reacted with aromatic aldehydes to give 4-arylmethylpyridazin-3-(2H)-ones (2). Oxidation of (2) with various oxidizing agents (selenium dioxide in ethanol or chromium trioxide in acetic acid) gave 4-aryloyl-6-arylpypyridazin-3(2H)-ones (3). Chlorination of (3) with phosphorous oxychloride afforded 4-aryloyl-6-aryl-3-chloropyridazine (4). 1H-3-Aryl-5-phenylpyrazolo[3,4-c]pyridazines were obtained by heating (4) with excess hydrazine hydrate.
 IT 158502-65-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 158502-65-9 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[[4-(dimethylamino)phenyl]methyl]-6-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 37 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:504602 CAPLUS
 DN 121:104602
 TI Fatty acid turnover rates in the adipose tissues of the growing chicken
(Gallus domesticus)
 AU Foglia, T. A.; Cartwright, A. L.; Gyurik, R. J.; Philips, J. G.
 CS USDA, Philadelphia, PA, 19118, USA
 SO Lipids (1994), 29(7), 497-502
 CODEN: LPDSAP; ISSN: 0024-4201
 DT Journal
 LA English
 AB The purpose of this study was to investigate the mobility of fatty acids in adipose tissue of the chicken and to determine whether adipose tissue dynamics are altered by dietary repartitioning agents. The turnover rates of fatty acids and triglycerides were estimated in adipose tissue of growing chicks by using isopentadecanoic acid (IPDA) and elaidic acid (EA) as marker dietary fatty acids. The half-life of IPDA in abdominal and sartorial adipose tissues of birds over 6-10 wk of age were 20 and 23 days, resp. The half-life for the remaining total carcass lipids was 23 days. The corresponding half-life for EA in abdominal fat tissue of birds over 2-7 wk of age was 18 days, a half-life not significantly different from the IPDA half-lives. A thyromimetic repartitioning agent (L-94901) fed to birds at the 2 ppm level at 2-7 wk of age significantly decreased the half-life of EA in abdominal fat tissue to 6 days. The data suggest that fatty acids were released from a more labile adipose site and subsequently reincorporated into abdominal and sartorial tissues and that fat mobilization occurred at the same time as did adipose tissue deposition in the growing chicken.
 IT 105211-23-2, L-94901
 RL: BIOL (Biological study)
 (fatty acid turnover rates in adipose tissue of chicken in development response to)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 38 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:450249 CAPLUS
 DN 121:50249
 TI Computer-assisted molecular modeling of benzodiazepine and thyromimetic
 inhibitors of the HepG2 iodothyronine membrane transporter
 AU Kragie, Laura; Forrester, Maureen L.; Cody, Vivian; McCourt, Mary
 CS Fac. Nat. Sci. Math., State Univ. New York, Buffalo, Amherst, NY, 14260,
 USA
 SO Molecular Endocrinology (1994), 8(3), 382-91
 CODEN: MOENEN; ISSN: 0888-8809
 DT Journal
 LA English
 AB T3 cellular uptake is inhibited in the presence of benzodiazepines (BZs).
 The structure-activity relationship of BZ inhibition correlates strongly
 with halogen substitution of the nonfused Ph ring and indicates that this
 ring is required for activity. A structure-activity series of
 thyromimetic (TH) inhibitors of the HepG2 iodothyronine transporter
 further point out the critical importance of the amino group of the alanine
 side chain, its L-stereo configuration, and the size of the substituents
 of the inner and outer Ph rings. A third series of compds., reported to
 interact at related sites, were inactive as HepG2 iodothyronine transport
 inhibitors, and therefore the potent inhibitors were restricted to the BZ
 and TH compds. Using both of these BZ and TH structure-activity series
 along with computer-assisted mol. modeling techniques, the authors determined
 which chemical structural components were important at the transporter
 interaction site. By superimposing structures from active chems.,
 excluding residues from poor inhibitors, and incorporating mol.
 electropotential data, the authors developed a five-point model of BZ
 conformational similarity to the endogenous transporter ligand, L-T3: the
 alkyl substitution at the N1 of the BZ ring seems to stimulate the alanine
 side chain of T3, and the electroneg. halogen and oxygen atoms of
 substituents at R3/R7/R2'/R4' of BZ form a pyrimidyl pharmacophore that
 seems to correspond with the 3-1/5-1/3'-1/4'-OH substituents of T3, resp.
 These points, suggesting a tilted cross-bow formation, may be sites for
 ligand interaction with the iodothyronine transporter.
 IT 105170-16-9, SKF-L 94690 105170-24-9, SKF-L 94918
 105211-23-2
 RL: BIOL (Biological study)
 (triiodothyronine binding by iodothyronine transporter inhibition by,
 structure in relation to)
 RN 105170-16-9 CAPLUS
 CN L-Tyrosine, O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-
 hydroxyphenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105170-24-9 CAPLUS
 CN L-Tyrosine, 3,5-dichloro-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-

hydroxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105211-23-2 CAPLUS

CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 39 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:435024 CAPLUS
 DN 121:35024
 TI Preparation of 4-(3-cyclohexyl-4-hydroxy or-methoxyphenylsulfonyl)-3,5-dibromophenylacetic thyromimetic cholesterol-lowering agents
 IN Walker, Keith A.; Labadie, Sharada S.; Kertesz, Denis J.; Laughton, Craig W.
 PA Syntex (U.S.A.), Inc., USA
 SO U.S., 15 pp.
 CODEN: USXXAM


DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5284971	A	19940208	US 1992-914837	19920716
PRAI US 1992-914837				
OS MARPAT 121:35024				


AB Title compds. I (R1 = R9CO(CHNR7R8)m(CH2)n wherein n = 1-3, m = 0,1, R7, R8 = H, Cl-4 alkyl, R9 = HO, Cl-4 alkoxy, R8R7N; R3, R5 = Br, Cl, iodo, Me; R31 = H, Cl, Br, iodo, Cl-4 alkyl, C4-6 cycloalkyl, Cl-4 haloalkyl, C4-6 halocycloalkyl, Ar(R10)CH wherein Ar = 5-hydroxypyrid-2-yl, 6-hydroxypyrid-3-yl, 6-hydroxypyridazin-3-yl, 6-methoxypyridazin-3-yl, 6-hydroxypyridazin-3-yl N-oxide, 6-methoxypyridazin-3-yl N-oxide, R10 = H, Cl-4 alkyl; R41 = HO, bioprecursor) and pharmaceutically acceptable salts thereof, useful as anticholesteremic agents (no data), are prepared SO2C12 in CH2C12 was added to Me 3,5-dibromo-4-mercaptophenylacetate (preparation given) followed by 2-(Me2CH)C6H4OMe to give Me 3,5-dibromo-4-[(3-isopropyl-4-methoxyphenyl)thio]phenylacetate which with m-ClC6H4CO2OH in CH2C12 was reacted for 20 h to give I (R1 = MeO2CCH2, R3 = R5 = Br, R31 = Me2CH, R41 = MeO). Pharmaceutical formulations comprising I are given.

IT 155780-47-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation are reaction of, in preparation of anticholesteremics)

RN 155780-47-5 CAPLUS
 CN Benzeneacetic acid, 3,5-dibromo-4-[[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 155780-58-8P
 RL: SPN (Synthetic preparation); PREP-(Preparation)
 (preparation of, as anticholesteremic)
 RN 155780-58-8 CAPLUS
 CN Benzeneacetic acid, 3,5-dibromo-4-[[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




IT 105190-08-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of anticholesteremics)

RN 105190-08-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:290501 CAPLUS

DN 120:290501

TI Thyroid hormones increase insulin-like growth factor I content in the medium of rat bone tissue

AU Lakatos, Peter; Caplice, Matthew D.; Khanna, Vikram; Stern, Paula H.

CS Med. Sch., Northwestern Univ., Chicago, IL, USA

SO Journal of Bone and Mineral Research (1993), 8(12), 1475-81

CODEN: JBMREJ; ISSN: 0884-0431

DT Journal

LA English

AB The mechanism of action of thyroid hormones on bone is still not clear. At low concns., they stimulate bone formation; at high concns. they elicit bone resorption in vitro and in vivo. In the present study the authors investigated the effect of T3 and T4 as well as their active and inactive analogs (TRIAC, SKF L-94901, rT3 and DIT) on the IGF-I and TNF- α content in the medium of UMR-106 rat osteoblastic cells and fetal rat limb bones. In the dose-response studies, a biphasic increase in medium IGF-I was observed in both cells and limb bones, with peak stimulatory concns. of 10-8 M for T3 and 10-7 M for T4 in both systems. At higher concns., at which thyroid hormones elicit bone resorption, the stimulatory effect diminished and finally was no longer detectable. The active analogs TRIAC and SKF L-94901 also enhanced IGF-I release in UMR-106 cells. The inactive compds. rT3 and DIT failed to increase IGF-I in these cultures. The protein content of the cell culture wells exposed to high concns. of thyroid hormones was similar to those containing low concns., indicating that the decrease in IGF-I content at high doses was not due to toxic effects. This was also confirmed by trypan blue exclusion. Time course studies with UMR-106 cells revealed a significant increase in medium IGF-I after 2 days of incubation. No significant further increase was observed after this up to 5 days of culture. In contrast, the medium of limb bone cultures showed a linear increase in IGF-I content up to 7 days of culture. No TNF- α production was observed in either UMR-106 cells or fetal limb bones. Also, no increase in medium TNF- α levels was seen in response to thyroid hormones. Based on the authors' results, the authors conclude that IGF-I may be responsible for some of the anabolic effects of thyroid hormones in bone tissue, but TNF- α , at least in the models the authors used, does not play a role in the mediation of thyroid hormone action.

IT 105211-23-2, SKF L-94901


RL: BIOL (Biological study)

(insulin-like growth factor and tumor necrosis factor in bone in response to)

RN 105211-23-2 CAPLUS

CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 41 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:270285 CAPLUS

DN 120:270285

TI Some reactions with β -(3,4-dimethylbenzoyl)- α -(indol-3-yl)propionic acid and screening of their antibacterial activities
 AU Abdel Halim, M. S.; Radwan, A.; Saad, M. A.; Sayed, G. H.; Khalil, M.
 CS Fac. Sci., Ain-Shams Univ., Egypt
 SO Journal of the Chemical Society of Pakistan (1993), 15(3), 202-6
 CODEN: JCSPDF; ISSN: 0253-5106

DT Journal

LA English


AB β -(3,4-Dimethylbenzoyl)acrylic acid reacts with indole to give β -(3,4-dimethylbenzoyl)- α -(indol-3-yl)propionid acid. The condensation of this compound with hydrazines affords pyridazinones I [R = H, Ph]. Reactions of I [R = H] gave I [R = Ac, SO₂Ph, Me, CH₂CO₂H, CO₂Et]. Reactions of I [R = H] with POCl₃ and P₂S₅ gave the chloro derivative and the thiopyridazine derivative II, which are subjected to further substitution with anthranilic acid, p-anisidine, sodium azide, hydrazine hydrate and benzylamine. The in-vitro antibacterial screening revealed that some of the new compds. possess activity against Gram-pos., Gram-neg. bacteria and fungi.

IT 154535-34-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 154535-34-9 CAPLUS


CN 3(2H)-Pyridazinone, 5-[[4-(dimethylamino)phenyl]methyl]-6-(3,4-dimethylphenyl)-4-(1H-indol-3-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 42 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1993:560209 CAPLUS
 DN 119:160209
 TI The effect of solvent on the synthesis of pyridazinones and some reactions
 of the new compounds
 AU Sayed, Galal Hosni; Radwan, Azza; Hamed, Ashraf Ahmed; Boraie, Waleed El
 Sayed
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Bulletin of the Chemical Society of Japan (1993), 66(2), 477-82
 CODEN: BCSJA8; ISSN: 0009-2673
 DT Journal
 LA English
 AB The reaction of 4-aryl-4-oxo-2-(5-oxo-1,3-diphenyl-2-pyrazolin-4-yl)butanoic acids with hydrazine hydrate in ethanol afforded (oxopyrazolinyl)pyridazinones I (R = p-ClC₆H₄, p-tolyl); in 1-butanol pyrazolo[3,4-c]pyridazine derivative II was obtained, while in acetic acid the 6-aryl-3(2H)-pyridazinone was the product. A probable mechanism has been proposed. The behavior of I toward di-Me sulfate, di-Et sulfate, Et bromoacetate, p-anisaldehyde, phosphoryl chloride and phosphorus pentasulfide has been studied.
 IT **147674-90-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 147674-90-6 CAPLUS
 CN 3(2H)-Pyridazinone, 4-(4,5-dihydro-5-oxo-1,3-diphenyl-1H-pyrazol-4-yl)-5-[(4-methoxyphenyl)methyl]-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)





L4 ANSWER 43 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1993:38862 CAPLUS
 DN 118:38862
 TI Novel synthesis of 4-aryl-6-phenylpyridazin-3(2H)-ones. [Erratum to
 document cited in CA116(13):128838k]
 AU Ismail, M. F.; Sayed, F. S.; Emara, S. A.; Shindy, A. A.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Zeitschrift fuer Naturforschung, B: Chemical Sciences (1992), 47(9), 1346
 CODEN: ZNBSEN; ISSN: 0932-0776
 DT Journal
 LA English
 AB A tech. error in the text (the Exptl. section) has been corrected. The error
 was not reflected in the abstract or the index entries.
 IT **57999-76-5**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (oxidation of, with sodium dichromate (Erratum))
 RN 57999-76-5 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX
 NAME)




IT **64657-96-1P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and oxidation of, with sodium dichromate (Erratum))
 RN 64657-96-1 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-methyl-6-phenyl- (9CI)
 (CA INDEX NAME)



L4 ANSWER 44 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1992:128838 CAPLUS
 DN 116:128838
 TI Novel synthesis of 4-aryl-6-phenylpyridazin-3(2H)-ones
 AU Ismail, M. F.; Sayed, F. S.; Emara, S. A.; Shindy, A. A.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Zeitschrift fuer Naturforschung, B: Chemical Sciences (1991), 46(12), 1720-2
 CODEN: ZNBSEN; ISSN: 0932-0776
 DT Journal
 LA English
 OS CASREACT 116:128838
 AB Title compds. I (R = H, OMe, Cl) were prepared by the oxidation of the corresponding 4-arylmethyl derivs. II with Na₂Cr₂O₇ in HOAc. I (R = H, Cl) reacted with NH₂NH₂ to give the corresponding hydrazones, whereas I (R = OMe) was treated with H₂NOH.HCl to give the oxime. I (R = H, OMe, Cl) were methylated with Me₂SO₄ to give 2-Me derivs. III, whereas the chlorination of I (R = same) with POCl₃ gave 6-chloro derivs. IV.
 IT **57999-76-5**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (oxidation of, with sodium dichromate)
 RN 57999-76-5 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)




IT **64657-96-1P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and oxidation of, with sodium dichromate)
 RN 64657-96-1 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-methyl-6-phenyl- (9CI) (CA INDEX NAME)





L4 ANSWER 45 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1992:76846 CAPLUS
 DN 116:76846
 TI Differential effect of a new thyromimetic on triiodothyronine transport into myoblasts and hepatoma and neuroblastoma cells
 AU Lakshmanan, Mark; Goncalves, Edison; Pontecorvi, Alfredo; Robbins, Jacob
 CS Clin. Endocrinol. Branch, Natl. Inst. Diabetes Dig. Kidney Dis., Bethesda, MD, 20892, USA
 SO Biochimica et Biophysica Acta, Molecular Cell Research (1992), 1133(2), 213-17
 CODEN: BBAMCO; ISSN: 0167-4889
 DT Journal
 LA English
 AB 3,5-Dibromo-3'-pyridazinone-L-thyronine (L-94901), a member of a novel class of thyromimetics, reduces cholesterol plasma levels with little effect on cardiac function in rats. Because receptor binding of L-94901 in isolated heart and liver nuclei is similar but binding in liver nuclei in vivo was 50-fold higher than in cardiac nuclei, its effect on T3 transport across the plasma membrane of myoblasts, hepatoma cells, and neuroblasts was studied. Saturable, stereospecific, and energy dependent transport of T3 into the 3 cell lines was previously demonstrated. After equilibrium of intact cells with hormone, nuclear binding of T3 was decreased by L-94901 in all 3 cell lines. While whole cell uptake and whole cell binding of T3 was only slightly affected by L-94901, kinetic anal. of the initial rate of uptake showed uncompetitive or noncompetitive inhibition and a differential decrease in Vmax. Furthermore, the Ki for the liver and brain derived cells was 10-fold lower than for the muscle derived cells. This effect on the plasma membrane transport of T3 may explain the differential effect reported in the intact animal.
 IT 105211-23-2, L-94901
 RL: BIOL (Biological study)
 (triiodothyronine transport by brain and liver and muscle cell membrane response to)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 46 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1992:59299 CAPLUS
 DN 116:59299
 TI Synthesis and reactions of some new pyridazinones
 AU Ismail, A. A.; Radwan, R.; Abdel Hamid, H. A.; Sayed, G. H.; Mohamed, S. M.
 CS Fac. Sci., Al-Azhar Univ. Girls, Cairo, Egypt
 SO Journal of the Chemical Society of Pakistan (1991), 13(2), 111-15
 CODEN: JCSPDF; ISSN: 0253-5106
 DT Journal
 LA English
 AB β -(P-chlorobenzyl)acrylic acid $\text{RCOCH:CHCO}_2\text{H}$ ($\text{R=4-ClC}_6\text{H}_4$) reacts with 3-methyl-1-phenyl-2-pyrazolin-5-one to give the adduct I. Reactions of I with hydrazine hydrate and phenylhydrazine afford the corresponding 4-pyrazolinonylpyridazinones II (R1 = H, Ph). Reactions of 4-pyrazolinonylpyridazinone II (R1 = H) with dimethylsulfate, diethylsulfate, Et bromoacetate, benzenesulfonyl chloride, anisaldehyde, phenylmagnesium bromide and bromine-acetic acid mixture have been described. Reaction of II (R1 = H) with POCl_3 yield the chloro derivative III. The behavior of the III towards sodium methoxide, hydrazine hydrate, anthranilic acid and sodium azide has been investigated.
 IT 138581-47-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 138581-47-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-chlorophenyl)-4-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)-5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 47 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1991:647603 CAPLUS
 DN 115:247603
 TI Thyroid hormone analog SKF L-94901 accelerates regression of Moloney sarcoma and inhibits periosteal osteogenesis mediated by this tumor
 AU Włodarski, K. H.; Kowalski, M.; Underwood, A. H.
 CS Inst. Biostruct., Med. Acad., Warsaw, 02-004, Pol.
 SO Folia Biologica (Prague, Czech Republic) (1991), 37(2), 125-30
 CODEN: FOBLAN; ISSN: 0015-5500
 DT Journal
 LA English
 AB Prolonged administration of the synthetic thyroid hormone analog SKF L-94901 accelerates regression of the Moloney sarcoma virus-induced tumors and reduces the periosteal osteogenesis mediated by this tumor in mice.
 IT 105211-23-2, SKF L94901
 RL: BIOL (Biological study)
 (as thyroid hormone analog, Moloney sarcoma virus-induced tumor and periosteal osteogenesis inhibited by)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 48 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1991:527855 CAPLUS
 DN 115:127855
 TI The thyroid hormone analog SKF-94901 and iodothyronine binding sites in mammalian tissues: differences in cytoplasmic binding between liver and heart
 AU Barlow, John W.; Raggatt, Lorna E.; Lim, Chen Fee; Kolliniatis, Emily; Topliss, Duncan J.; Stockigt, Jan R.
 CS Ewen Downie Metab. Unit, Alfred Hosp., Melbourne, 3181, Australia
 SO Acta Endocrinologica (1991), 124(1), 37-44
 CODEN: ACENA7; ISSN: 0001-5598
 DT Journal
 LA English
 AB The thyroid hormone analog SKF-94901 exhibits greater thyromimetic activity in the liver than in the heart. This difference in activity may reflect heterogeneity in the affinity of SKF-94901 for different forms of the T3 receptor. A difference in extranuclear transport of the analog could also account for the different response of these two tissues. The binding of SKF-94901 was studied in membrane, cytosolic and nuclear preps. from the liver and heart of Macac fascicularis. Uptake of SKF-94901 into H4 liver cells was low. Binding of [¹²⁵I]T3 to cell membrane preps. (K_d ≈ 3 μM), and to nuclear exts. (K_d ≈ 0.2 nM) was displaceable by SKF-94901 with a potency 2-5% that of T3 in each case. No difference was observed between the liver and heart for SKF-94901 binding to membranes or nuclear extract. With cytosol, [¹²⁵I]T3 binding was identical in the heart (K_d = 22.7 nM) and liver tissue (K_d = 30.3 nM). In liver and in cardiac cytosol after preliminary washing to remove serum, iodothyronine potency was in the order T3 > T4 > rT3. The ratio of SKf-94901 to T3 concns. which gave 50% displacement was 15.9 in the liver and 152.3 in the heart. The selective tissue activity of SKF-94901 may be related to its reduced affinity for the cytosolic binding proteins in the heart, rather than a difference in affinity for various forms of the T3 receptor.
 IT 105211-23-2
 RL: BIOL (Biological study)
 (heart and liver iodothyronine receptors binding of)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 49 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1991:471546 CAPLUS
 DN 115:71546
 TI Synthesis and reactions of some new pyridazinones
 AU Abdel Ghani, Essam
 CS Fac. Sci., Zagazig Univ., Zagazig, Egypt
 SO Bulletin of the Chemical Society of Japan (1991), 64(6), 2032-4
 CODEN: BCSJA8; ISSN: 0009-2673
 DT Journal
 LA English
 AB The title compds., e.g., I (R = H, Me, Et, CH₂CO₂Et) were prepared in 2 steps from p-EtOC₆H₄COCH:CHCO₂H and pyrazolone II. Subsequent derivatizations of I, e.g., thionation, chlorination, amination, alkylation, gave addnl. derivs. thereof, 4 of which were tested for antibacterial activity. Various reactions of the above derivs. were also studied. Thus, e.g., the heterocyclization of a dichloro derivative obtained from I (R = H) with NaN₃ gave tetrazole III.
 IT 135128-65-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 135128-65-3 CAPLUS
 CN 3(2H)-Pyridazinone, 4-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)-6-(4-ethoxyphenyl)-5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 50 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1991:471513 CAPLUS
 DN 115:71513
 TI Synthesis of some new pyridazinones
 AU Kandile, Nadia G.; Ahmed, Effat A.
 CS Univ. Coll. Women, Ain Shams Univ., Heliopolis, Egypt
 SO Acta Chimica Hungarica (1990), 127(6), 829-35
 CODEN: ACHUDC; ISSN: 0231-3146
 DT Journal
 LA English
 OS CASREACT 115:71513


AB Reactions of methylpyridazinone I with RCHO (R = 1-, 2-naphthyl, 2-MeOC₆H₄) in 5% ethanolic KOH gave arylmethylpyridazinones II (R as above; R₁ = H). Various reactions of II (R₁ = H) are reported. Thus, the reaction of II (R₁ = H) with CH₂O, Me₂SO₄ and ClCH₂CO₂Et gave II (R₁ = CH₂OH, Me, CH₂CO₂Et) resp. Mannich reaction of II (R₁ = H) with CH₂O and piperidine or morpholine gave II (R₁ = CH₂R₂, R₂ = piperidino, morpholino). II (R₁ = H) reacted with POCl₃ to give chloropyridazines III. Reaction III with amines and NaN₃ is also reported.

IT **135066-36-3P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, with piperidine or morpholine)

RN 135066-36-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-(hydroxymethyl)-4-[(2-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




IT **126775-18-6P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and N-alkylation or Mannich reaction of)


RN 126775-18-6 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




IT **135066-41-0P 135066-42-1P 135066-44-3P**


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 135066-41-0 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-methyl-2-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)





RN 135066-42-1 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-methyl-2-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 135066-44-3 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)





L4 ANSWER 51 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1991:207174 CAPLUS
 DN 114:207174
 TI Studies of 6-anisyl-4-pyrazolinonyl-2,3,4,5-tetrahydropyridazin-3-one
 AU El-Mobayed, M.
 CS Fac. Sci., Zagazing Univ., Zagazig, Egypt
 SO Anales de Quimica (1990), 86(7), 808-11
 CODEN: ANQUEX; ISSN: 1130-2283
 DT Journal
 LA English
 OS CASREACT 114:207174
 AB β -(p-Methoxybenzoyl)acrylic acid reacts with 1,3-diphenyl-2-pyrazolin-5-one to give the adduct I (R = R1 = H) which condenses with p-chlorobenzaldehyde to give the arylidene derivative I (RR1 = CHC6H4Cl-4). Reaction of I (R = R1 = H) with hydrazine hydrate affords the pyridazinone II. The reaction of II with Et bromoacetate, anisaldehyde, phosphorus oxychloride and phosphorus pentasulfide are also described.
 IT 133706-17-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 133706-17-9 CAPLUS
 CN 3(2H)-Pyridazinone, 4-(4,5-dihydro-5-oxo-1,3-diphenyl-1H-pyrazol-4-yl)-6-(4-methoxyphenyl)-5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)





L4 ANSWER 52 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1991:59880 CAPLUS
 DN 114:59880
 TI Effects of hypothyroidism on the metabolism of lipid emulsion models of triacylglycerol-rich lipoproteins in rats
 AU Redgrave, Trevor G.; Elsegood, Caryn L.; Mamo, John C. L.; Callow, Matthew J.
 CS Dep. Physiol., Univ. West. Australia, Nedlands, 6009, Australia
 SO Biochemical Journal (1991), 273(2), 375-81
 CODEN: BIJOAK; ISSN: 0306-3275
 DT Journal
 LA English
 AB Methimazole-treated hypothyroid rats were injected i.v. with triacylglycerol/cholesteryl oleate/cholesterol/phospholipid emulsions designed to model the composition of chylomicrons. Hypothyroidism decreased the clearance rates of emulsion cholesteryl oleate. The clearance of emulsion triolein was affected much less and could be accounted for by residual triolein in remnants, suggesting that triacylglycerol lipolysis by lipoprotein lipase was unaffected by hypothyroidism but that the clearance of remnants from plasma was decreased. Assays in vitro showed increased activities of lipoprotein lipase and hepatic lipase in hypothyroid rats. Emulsions were incubated with postheparin plasma lipoprotein lipase to prepare remnants in vitro. The clearance from plasma of pre-formed remnants was slower after injection into hypothyroid rats than in control rats. Uptake of remnant cholesteryl oleate by the liver was decreased in the hypothyroid rats. Treatment of hypothyroid rats for 7 days with T3 reversed the inhibition of hepatic remnant uptake and normalized plasma cholesterol. A thyroid hormone analog with decreased hypermetabolic side-effects, L-94901, attenuated plasma cholesterol levels and improved but did not normalize the remnant clearance. Emulsions incubated with plasma from hypothyroid rats had a decreased ratio of apolipoprotein E/apolipoprotein C compared with control rats or hypothyroid rats treated with T3. The change in the apolipoprotein E/apolipoprotein C ratio probably accounts for the defect in remnant clearance in hypothyroidism.
 IT 105211-23-2, L-94901
 RL: BIOL (Biological study)
 (lipid and lipoprotein metabolism in hypothyroidism response to)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 53 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1990:565837 CAPLUS
 DN 113:165837
 TI Thyroid hormone analog SKF L-94901: effects on amino acid and carbohydrate metabolism in rat skeletal muscle in vitro
 AU Leighton, Brendan; Dimitriadis, George D.; Parry-Billings, Mark; Bond, Jane; Kemp, Paul; Newsholme, Eric A.
 CS Dep. Biochem., Univ. Oxford, Oxford, OX1 3QU, UK
 SO Biochemical Pharmacology (1990), 40(5), 1161-4
 CODEN: BCPCA6; ISSN: 0006-2952
 DT Journal
 LA English
 AB The effects of hyperthyroidism caused by T3 and the effects of the T3 analog SKF L-94901 (I) on glycogen synthesis, glutamine release, and lactate formation were studied in rat stripped soleus muscle in vitro. Plasma glucose and lactate levels and glutamine and glycogen in gastrochemius and soleus muscles, resp. were also determined. Hyperthyroidism increased glycolysis rate and decreased glycogen formation in soleus muscle. I also increased glycolysis, but it was 5-fold less effective than T3. T3 increased the rate of glutamine release; I had no effect on glutamine metabolism
 IT 105211-23-2, SKFL-94901
 RL: BIOL (Biological study)
 (amino acid and carbohydrate metabolism in muscle response to)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 54 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1990:526873 CAPLUS
 DN 113:126873
 TI Apolipoprotein B mRNA editing is modulated by thyroid hormone analogs but not growth hormone administration in the rat
 AU Davidson, Nicholas O.; Carlos, Ruth C.; Lukaszewicz, Annalise M.
 CS Dep. Med., Univ. Chicago, Chicago, IL, 60637, USA
 SO Molecular Endocrinology (1990), 4(5), 779-85
 CODEN: MOENEN; ISSN: 0888-8809
 DT Journal
 LA English
 AB Recent work has demonstrated that the unique post-transcriptional editing reaction which modifies mammalian apolipoprotein (apo) B100 mRNA, producing an in-frame stop codon in the modified (apo B48) transcript, is modulated in vivo in the rat liver by thyroid hormone (T3). The results of studies undertaken to examine the effects of 2 synthetic T3 analogs [L 94901 (I) and L 94690 (II)] and growth hormone on apo B gene expression are reported together with their effects on hepatic apo A-I, A-IV, C-III, and malic enzyme (ME) mRNAs. The T3 analogs were previously shown to exhibit similar binding to the hepatic nuclear T3 receptor (50% and 38% of native T3) but differing biopotency (18 and <3% of native T3). Apo B100 mRNA editing, determined by differential hybridization of polymerase chain reaction amplified apo B cDNA, demonstrated 50-56% unmodified (apo B100) mRNA in control and hypothyroid animals, and this proportion was unaltered by GH (61% B100 mRNA), despite a reduction in apo B100 synthesis. Both T3 analogs altered apo B mRNA editing (12-16% B100 mRNA), and no apo B100 synthesis was detectable in vivo. Addnl., both T3 analogs produced a 4-10-fold induction in hepatic apo A-I and A-IV mRNA abundance, similar to the effects of native T3. GH produced no alteration to apo A-I or A-IV mRNA abundance and neither T3 analog, GH, or native T3 produced a change in apo C III mRNA abundance. Finally, in contrast to the greater than 20-fold induction of both the 27s, and 21s Me transcript (average of 2-4-fold) with both T3 analogs. However, the more potent T3 analog induced the 27s ME transcript to a variable extent (range, 5-100% of native T3) while the less potent analog consistently produced less than 10% induction of the 27s ME transcript, compared to native T3. Taken together, the data indicate that these synthetic T3 analogs caputulate several actions of native T3 on hepatic apo gene expression in the rat but exhibit divergence in relation to another class to T3-responsive genes involved in hepatic lipogenesis.
 IT 105170-16-9, L 94690 105211-23-2, L 94901
 RL: BIOL (Biological study)
 (apolipoprotein B-100 mRNA editing modulation by, in liver)
 RN 105170-16-9 CAPLUS
 CN L-Tyrosine, O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]-3,5-diiodo (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105211-23-2 CAPLUS



CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 55 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1990:514754 CAPLUS
 DN 113:114754
 TI Synthesis of substituted diphenyl ethers using the Diels-Alder reaction
 AU Carter, Stephen D.; Thetford, Dean; Voyle, Martyn; Sammes, Peter G.
 CS Smith Kline and French Res. ltd., Frythe/Welwyn/Hertfordshire, AL6 9AR, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and
 Bio-Organic Chemistry (1972-1999) (1990), (4), 1231-3
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 113:114754
 AB The Diels-Alder reaction of phenoxyfurans with MeO2CC.tplbond.CCO#2Me gave
 cycloadducts which were converted into di-Ph ethers I (R1 = H, Br; R2, R3
 = H, Me). I are synthetically related to L-94901.
 IT 105211-23-2, L 94901
 RL: RCT (Reactant); RACT (Reactant or reagent)
 ((dibromomethylphenoxy)hydroxypthalate as synthetic precursor for)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-
 hydroxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L4 ANSWER 56 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1990:235463 CAPLUS
 DN 112:235463
 TI Action of mercuric acetate on pyridazine derivatives
 AU Kandile, N. G.; Soliman, A. A.; El Sawi, E. A.
 CS Chem. Dep., Univ. Coll. Women, Heliopolis, Egypt
 SO Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry (1989), 19(8), 779-86
 CODEN: SRIMCN; ISSN: 0094-5714
 DT Journal
 LA English
 OS CASREACT 112:235463
 AB 4,6-Disubstituted pyridazin-3(2H)-ones I (R = Ph, 4-MeC₆H₄, R₁ = 1-naphthyl, 2-MeOC₆H₄) react with Hg(OAc)₂ in AcOH to give mercurated products II. The mercuration reactions took place on the active methylene group. The reaction with 4,5-dihydro-6-(phenyl and p-tolyl)pyridazin-3(2H)-one gives the corresponding dimer via two steps: mercuration reaction on position 4 to form mercuri-bis-compds. followed by demercuration by treatment with Ag wire. Mercuration of 4,5-dihydro-6-methylpyridazin-3(2H)-one took place in position 4 to give monomercurated product.
 IT 121137-72-2 121137-73-3 126775-18-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (mercuration of, with mercuric acetate)
 RN 121137-72-2 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 121137-73-3 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)





RN 126775-18-6 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 57 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1990:230088 CAPLUS
 DN 112:230088
 TI Studies on the in vitro tropic effects of a novel thyromimetic
 AU Poole, A.; Angus, R.; Catto, L.; Jones, R. B.
 CS Dep. Toxicol., Smith Kline and French Res. Ltd., Welwyn/Herts., AL6 9AR,
 UK
 SO Toxicology in Vitro (1990), 4(1), 63-9
 CODEN: TIVIEQ; ISSN: 0887-2333
 DT Journal
 LA English
 AB Since fibroplasia has been reported in rats treated with SKF L-94901 (I),
 a novel thyromimetic drug, studies were undertaken to investigate the
 tropic effect of the agent in a number of in vitro proliferation assays and
 its ability to cause in vitro cell transformation. There was no effect in
 any of these assays when I was incubated directly with the cells, so
 consideration was given to the possibility that the chemical could be having
 an indirect mitogenic effect by stimulating the production of growth factors
 from other tissues such as the pituitary. However, the conditioned medium
 from pituitary superfusates also failed to show any evidence of a
 mitogenic effect, so the proliferative lesions do not appear to be associated
 with an over-production of growth factors by the pituitary. Thus, the in vivo
 growth-promoting activity of I is not caused by a direct mitogenic effect
 in the cells resulting in cell transformation or by stimulation of growth
 factors from the pituitary. The actions of I may require a nuclear pump
 or concentrating mechanism which does not operate in vitro, or they may be
 mediated by a metabolite of I.
 IT 105211-23-2
 RL: BIOL (Biological study)
 (fibroplastic lesions induction by, mechanism of)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-
 hydroxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 58 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1990:171639 CAPLUS
 DN 112:171639
 TI The disposition of SK & F L-94901, a selective thyromimetic in rat, dog and cynomolgus monkey
 AU Pue, M. A.; Ransley, J. A.; Writer, D. J.; Dean, A. J.; Franklin, E. R.; Beattie, I. G.; Ross, D. A.
 CS Dep. Drug Metab. Pharmacokinet., SK and F Res. Ltd., Welwyn, UK
 SO European Journal of Drug Metabolism and Pharmacokinetics (1989), 14(3), 209-19
 CODEN: EJDPD2; ISSN: 0398-7639
 DT Journal
 LA English
 AB SKFL L-94901(I) is a novel thyromimetic, structurally related to thyroxine. The absorption, distribution, excretion and metabolism of radiochem. labeled [14C]-SKF L-94901 were investigated in the rat, dog and cynomolgus monkey. Oral absorption from solution was low or moderate in all 3 species. The compound was widely distributed and rapidly excreted, although traces of radioactivity were still evident in some tissues at 7 days post-dose, particularly in the kidney where radioactivity was located in an area approximating to the corticomedullary junction. Elimination of [14C]-SKF L-94901 was both metabolic, mediated by liver, and renal. The major metabolic routes of elimination were via oxidative deamination to lactate and acetate derivs.
 IT 126463-67-0 126463-68-1
 RL: BIOL (Biological study)
 (as metabolite of SKF L-94901 in dog and rat and monkey)
 RN 126463-67-0 CAPLUS
 CN Benzenepropanoic acid, 3,5-dibromo-4-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenoxy]- α -hydroxy- (9CI) (CA INDEX NAME)



RN 126463-68-1 CAPLUS
 CN Benzenepropanoic acid, 3,5-dibromo-4-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)




IT 105211-23-2, SKF L-94901
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (metabolism and pharmacokinetics of, in rat and dog and cynomolgus monkey)

RN 105211-23-2 CAPLUS


CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 59 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1990:139812 CAPLUS
 DN 112:139812
 TI The synthesis of carbon-14-labeled SK&F L-9490. A novel thyromimetic
 AU Crowe, A. M.; Lawrie, K. W. M.; Saunders, D.
 CS Smith Kline and French Res. Ltd., Welwyn/Herfordshire, AL6 9AR, UK
 SO Synth. Appl. Isot. Labelled Cpd. 1988, Proc. Int. Symp. (1989), Meeting
 Date 1988, 431-5. Editor(s): Baillie, Thomas A.; Jones, John Richards.
 Publisher: Elsevier, Amsterdam, Neth.
 CODEN: 560XA8
 DT Conference
 LA English
 OS CASREACT 112:139812
 AB A symposium. The novel thyromimetic SK&F L-94901 (I) has been labeled
 with ¹⁴C for drug metabolism studies. A six stage synthesis from
 [β -¹⁴C]tyrosine is described. The overall radiochem. yield was
 13.7%.
 IT **118608-57-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, from labeled tyrosine)
 RN 118608-57-4 CAPLUS
 CN L-Tyrosine- β -¹⁴C, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




~~10~~

L4 ANSWER 60 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:614446 CAPLUS
 DN 111:214446
 TI Synthesis and chemistry of 4,5-dihydro-6-(2,4-dimethylphenyl)-3-(2H)-pyridazinone azine
 AU Nada, Afaf Aly; Haggag, Bahiga; Abd El Halim, Mohamed Said; Rifae, Zakia
 CS Natl. Res. Cent., Dokki/Cairo, Egypt
 SO Egyptian Journal of Chemistry (1987), Volume Date 1986, 29(4), 479-83
 CODEN: EGJCA3; ISSN: 0367-0422
 DT Journal
 LA English
 OS CASREACT 111:214446
 AB Acidic hydrolysis of the title compound gave $2,4\text{-Me}_2\text{C}_6\text{H}_3\text{COCH}_2\text{CH}_2\text{CO}_2\text{H}$ along with $\text{N}_2\text{H}_4\cdot\text{HCl}$. Condensation of the related thiienyl azine with aromatic aldehydes gave thiienylpyridazinones I ($\text{R} = \text{Ph}, 4\text{-MeOC}_6\text{H}_4, 4\text{-ClC}_6\text{H}_4$) in 31-42% yields. Chlorination of I ($\text{R} = 4\text{-MeOC}_6\text{H}_4$), followed by substitution with N_2H_4 and diazotization gave tetrazolo derivative II. II was also formed by chlorination and cyclocondensation with NaN_3 .
 IT 123716-48-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and N-methylation of, with di-Me sulfate)
 RN 123716-48-3 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-(2-thienyl)- (9CI) (CA INDEX NAME)





IT 123716-50-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 123716-50-7 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-methyl-6-(2-thienyl)- (9CI) (CA INDEX NAME)





L4 ANSWER 61 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:547224 CAPLUS
 DN 111:147224
 TI Studies on the mechanism of organ selective receptor occupation by the synthetic thyromimetic SK&F L-94901
 AU Pearce, Nigel James
 CS Counc. Natl. Acad. Awards, London, UK
 SO (1988) 273 pp. Avail.: Univ. Microfilms Int., Order No. BRDX84672
 From: Diss. Abstr. Int. B 1989, 49(12, Pt. 1), 5239
 DT Dissertation
 LA English
 AB Unavailable
 IT 105211-23-2, SKF L-94901
 RL: BIOL (Biological study)
 (as thyromimetic, organ-selective receptor occupation by)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 62 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:509416 CAPLUS
 DN 111:109416
 TI Rapid stimulation of hepatic oxygen consumption by 3,5-diiodo-L-thyronine
 AU Horst, Claus; Rokos, Hartmut; Seitz, Hans J.
 CS Inst. Physiol. Chem., Univ. Krankenhaus Eppendorf, Hamburg, D-2000/20,
 Fed. Rep. Ger.
 SO Biochemical Journal (1989), 261(3), 945-50
 CODEN: BIJOAK; ISSN: 0306-3275
 DT Journal
 LA English
 AB Triiodothyronine (T3) and thyroxine (T4) as well as 3,5-diiodothyronine (T2) stimulated O₂ consumption by isolated perfused livers from hypothyroid rats at a concentration as low as 1 pM by about 30% within 90 min. Application of T2 resulted in a faster stimulation than did application of T3 or T4. Inhibition of iodothyronine monodeiodinase by propylthiouracil, thereby blocking the degradation of T4 to T3 and of T3 to T2, demonstrated that only T2 is the active hormone for the rapid stimulation of hepatic O₂ consumption: T3 and T4 lost all of their stimulative activity, whereas T2 was a potent as in the absence of propylthiouracil. Perfusion expts. with thyroid-hormone analogs confirmed the specificity of the T2 effect. The nucleus is unlikely to contribute to the rapid T2 effect, as can be deduced from perfusion expts. with cycloheximide and lack of induction of malic enzyme by T2. In conclusion, a new scheme of regulation of mitochondrial activity is proposed: T2 acts rapidly and directly via a mitochondrial pathway, whereas T3 exerts its long-term action indirectly by induction of specific enzymes.
 IT 105211-23-2, L 94901
 RL: BIOL (Biological study)
 (oxygen consumption by liver cells stimulation by, structure in relation to)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 63 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:418101 CAPLUS
 DN 111:18101
 TI The thyroid hormone analog SKF L-94901: nuclear occupancy and serum binding studies
 AU Barlow, John W.; Raggatt, Lorna E.; Lim, Chen Fee; Munro, Sharon L.; Topliss, Duncan J.; Stockigt, Jan R.
 CS Ewen Downie Metab. Unit, Alfred Hosp., Melbourne, 3181, Australia
 SO Clinical Science (1989), 76(5), 495-501
 CODEN: CSCIAE; ISSN: 0143-5221
 DT Journal
 LA English
 AB A brominated thyroid hormone analog, SKF L-94901 (I), which has the potential to lower serum cholesterol without adverse cardiovascular effects, was studied. This compound was .apprx.50% as active as T3 in liver nuclear receptor binding in vivo, but was only 1% as active in vitro; it had nearly 200-fold more enzyme-inducing activity in liver than in heart. The interaction of SKF L-94901 with [¹²⁵I]T3 binding to the intact nuclei in whole cells, isolated nuclei, and nuclear exts. of human HeLa cells was examined and the binding of this compound to human serum was investigated. Relative to T4, the affinity of this compound for T4-binding globulin was 0.0035%, for transthyretin 1.66%, and for albumin 1.26%. Low affinity for serum proteins, giving a relatively high circulating free fraction, could explain why SKF L-949001 is more potent in vivo than in vitro. Human HeLa cell nuclei, isolated after whole-cell incubations, bound [¹²⁵I]T3 with high affinity (dissociation constant (K_d) = 78 pmol/L) which was displaceable
 by T3 analogs in the order Triac > T3 > T4 >> reverse T3. Similar high-affinity (K_d = 58 pmol/L) and identical specificity was observed in high-salt (0.4M KCl) nuclear exts. In nuclei of whole cells incubated with [¹²⁵I]T3 and SKF L-94901, the analog was 0.8% as potent as T3; in exts. with nuclear extract, the analog was 7.7% as potent as T3. Results from incubation of T3 with isolated nuclei were virtually identical to those obtained with nuclear exts. These results suggest an extranuclear component may be involved in restricting access of SKF L-94901 to the nucleus. Whether such mechanisms account for observed differences in its effects on different tissues, with reduced influence of SKF L-94901 on cardiac tissue, remains to be established. Thus, SKF L-94901 is weakly bound in serum and shows less potent competition for T3 nuclear binding after incubation of whole cells than after incubation with nuclear exts. or isolated nuclei. This compound may allow further anal. of intracellular mechanisms of thyroid hormone transport and action.
 IT 105211-23-2, SKF-L 94901
 RL: PROC (Process)
 (receptor and serum protein binding of, in human)
 RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L4 ANSWER 64 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:407319 CAPLUS
 DN 111:7319
 TI Synthesis of 6-aryl-4-(o-methoxyphenylmethyl)pyridazines and some derivatives
 AU Kandile, Nadia Garib; El-Oawi, Ahmed; Seliem, Violet Ragab; Ismail, Mohamed Fekry
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Acta Chimica Hungarica (1988), 125(4), 631-9
 CODEN: ACHUDC; ISSN: 0231-3146
 DT Journal
 LA English
 OS CASREACT 111:7319

AB 6-Aryl-4,5-dihydro-3(2H)pyridazinones undergo base-catalyzed condensation with 2-MeOC₆H₄CHO to give 6-aryl-4-(o-methoxyphenylmethyl)pyridazin-3(2H)-ones I (X = O; R = Ph, 4-MeC₆H₄; R₁ = H) in moderate yields. The reaction of these compds. with di-Me sulfate, formaldehyde, acrylonitrile and Mannich bases proceed at the 2-position to give compds. I (X = O, R = same, R₁ = Me, CH₂CH₂CN, CH₂OH, 1-piperidinomethyl, 4-morpholinomethyl). Arylchloro(methoxyphenylmethyl)pyridazines II (R = same, R₂ = Cl), prepared by the action of POCl₃ on I (X = O, R₁ = H), react with benzylamine or hydrazine to give II (R₂ = NHCH₂Ph, NHNH₂) resp., while their reactions with alc. thiourea yield I (X = S, R₁ = H). The reactions of these thiones with di-Me sulfate and acrylonitrile involve the mercaptopyridazine form II (R₂ = SH) to give II (R = Ph, R₂ = SMe, R = 4-MeC₆H₄, R₂ = SCH₂CH₂CN), resp.

IT 121137-81-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and alkaline hydrolysis of)
 RN 121137-81-3 CAPLUS
 CN 1(6H)-Pyridazinepropanenitrile, 5-[(2-methoxyphenyl)methyl]-6-oxo-3-phenyl- (9CI) (CA INDEX NAME)




IT 121137-72-2P 121137-73-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reactions of)
 RN 121137-72-2 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 121137-73-3 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-(4-methylphenyl)- (9CI)
(CA INDEX NAME)



IT 121137-74-4P 121137-75-5P 121137-76-6P


121137-77-7P 121137-78-8P 121137-79-9P

121137-80-2P 121137-82-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 121137-74-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-(hydroxymethyl)-4-[(2-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 121137-75-5 CAPLUS

CN 3(2H)-Pyridazinone, 2-(hydroxymethyl)-4-[(2-methoxyphenyl)methyl]-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 121137-76-6 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-phenyl-2-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 121137-77-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-(4-methylphenyl)-2-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 121137-78-8 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-2-(4-morpholinylmethyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 121137-79-9 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-6-(4-methylphenyl)-2-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 121137-80-2 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(2-methoxyphenyl)methyl]-2-methyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 121137-82-4 CAPLUS

CN 1(6H)-Pyridazinepropanoic acid, 5-[(2-methoxyphenyl)methyl]-6-oxo-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 65 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:173722 CAPLUS
 DN 110:173722
 TI Synthesis of thyroid hormone analogs. Part 3. Iodonium salt approaches to SK & F L-94901
 AU Hickey, Deirdre M. B.; Leeson, Paul D.; Novelli, Riccardo; Shah, Virendra P.; Burpitt, Brian E.; Crawford, Lynne P.; Davies, Bryan J.; Mitchell, Michael B.; Pancholi, Kirit D.; et al.
 CS Med. Chem. Dep., Smith Kline and French Res. Ltd., Welwyn/Hertfordshire, AL6 9AR, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1988), (12), 3103-11
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 110:173722
 AB The key step in the synthesis of the title compound L-I, a novel, selective, and potent thyromimetic, is the formation of the hindered diaryl ether moiety. This paper describes an investigation into the formation of the required diaryl ether by copper-catalyzed reaction both of sym. iodonium salts, e.g. R₂I+ O₂CCF₃, and mixed iodonium salts II (R₁ = H, R₂ = OMe; R₁ = R₂ = H, OMe) with protected dibromotyrosine 4,3,5-HO(Br)2C₆H₂CH₂CH(NHCOCF₃)CO₂Me. The importance of the counterion of the iodonium salt is discussed. This work is extended to a large-scale synthesis of SK & F L-94901 (I).

IT 120147-86-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and attempted coupling of, with dibromotyrosine derivative)
 RN 120147-86-6 CAPLUS
 CN Iodonium, bis[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 120147-85-5
 CMF C24 H22 I N4 O4



CM 2

CRN 14477-72-6
 CMF C2 F3 O2


IT **105190-13-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deblocking of, with hydrobromic acid)

RN 105190-13-4 CAPLUS

CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


IT **105211-23-2P 120129-88-6P 120129-95-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 105211-23-2 CAPLUS


CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 120129-88-6 CAPLUS

CN 3(2H)-Pyridazinone, 2-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-6-[(5-iodo-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 120129-95-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(5-iodo-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




IT 105190-08-7

RL: PROC (Process)


(sym. iodonium salt formation of, with iodine tris(trifluoroacetate))

RN 105190-08-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 66 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:173721 CAPLUS
 DN 110:173721
 TI Synthesis of thyroid hormone analogs. Part 2. Oxidative coupling approach to SK & F L-94901
 AU Hickey, Deirdre M. B.; Leeson, Paul D.; Carter, Steven D.; Goodyear, Michael D.; Jones, Sarah J.; Lewis, Norman J.; Morgan, Ian T.; Mullane, M. Valerie; Tricker, Jane Y.
 CS Med. Chem. Dep., Smith Kline and French Res. Ltd., Welwyn/Hertfordshire, AL6 9AR, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1988), (12), 3097-102
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 110:173721
 AB A synthesis of the title compound L-I, a novel, selective and potent thyromimetic, is described. The key step in this synthesis involves the formation of a hindered diaryl ether moiety. This paper describes an approach via oxidative coupling of the hindered phenols II and 4,3,5-HO(Br)2C6H2CH2CH(NHCOCF3)CO2Me. Some byproducts and impurities generated during the synthesis are discussed briefly.
 IT 105190-08-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and chlorodehydration of, with phosphorus oxychloride)
 RN 105190-08-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



IT 105190-17-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and de-tert-butylation-hydrolysis of, with hydrobromic acid)
 RN 105190-17-8 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-5-(1,1-dimethylethyl)-4-hydroxyphenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 105211-23-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 105211-23-2 CAPLUS

CN L-Tyrosine, 3,5-dibromo-0-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 67 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:173720 CAPLUS

DN 110:173720

TI Synthesis of thyroid hormone analogs. Part 1. Preparation of 3'-heteroarylmethyl-3,5-diido-L-thyronines via phenol-dinitrophenol condensation and relationships between structure and selective thyromimetic activity

AU Leeson, Paul D.; Emmett, John C.

CS Smith Kline and French Res. Ltd., Welwyn/Hertfordshire, AL6 9AR, UK

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1988), (12), 3085-96

CODEN: JCPRB4; ISSN: 0300-922X

DT Journal

LA English

OS CASREACT 110:173720

AB 3'-Heteroarylmethyl analogs, e.g. I (R = H, F), of the natural thyroid hormone 3,3',5-triiodo-L-thyronine (T3) were synthesized as potential selective (cardiac-sparing) thyromimetics. The di-Ph ether moiety was constructed by condensation of 3-substituted 4-methoxyphenols with a 3,5-dinitro-L-tyrosine derivative. Synthesis of the key phenols required the in situ preparation, at low temps., of novel metalated species, e.g. 2-lithio-5-methoxypyridine, and 2,6-difluoro-3-lithiopyridine, followed by reaction with 2,4-MeO(PhCH₂O)C₆H₃CHO. Structure-activity relationships indicate that selective thyromimetic activity is associated with 2-oxyheteroaren-5-ylmethyl 3'-substitution, as found in the pyridone I (R = H). The location of the oxy substituent in the heterocycle is critical for both hormonal activity and for binding to the T3 receptor.

IT 105170-23-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and deblocking of, (heteroarylmethyl)diiodothyronine from)

RN 105170-23-8 CAPLUS

CN L-Tyrosine, O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-3,5-diido-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 105170-22-7P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and sequential reduction, diazotization, and iodination of)

RN 105170-22-7 CAPLUS

CN L-Tyrosine, O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-3,5-dinitro-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 105170-21-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and substitution reaction of, with dinitrotyrosine derivative)

RN 105170-21-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(5-hydroxy-2-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 105170-16-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and thyromimetic activity of)

RN 105170-16-9 CAPLUS

CN L-Tyrosine, O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 68 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:115292 CAPLUS
 DN 110:115292
 TI Selective thyromimetics. Cardiac-sparing thyroid hormone analogs containing 3'-arylmethyl substituents
 AU Leeson, Paul D.; Emmett, John C.; Shah, Virendra P.; Showell, Graham A.; Novelli, Ricardo; Prain, H. Douglas; Benson, Martin G.; Ellis, David; Pearce, Nigel J.; Underwood, Anthony H.
 CS Smith Kline French Res. Ltd., Frythe/Welwyn, AL6 9AR, UK
 SO Journal of Medicinal Chemistry (1989), 32(2), 320-36
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 OS CASREACT 110:115292
 AB Introduction of specific arylmethyl groups at the 3'-position of the thyroid hormone 3,3',5'-triiodo-L-thyronine (T3), and its known hormonally active derivs., gives liver-selective, cardiac-sparing thyromimetics (e.g., I, X = O, S; R = aryl group), with potential utility as plasma cholesterol lowering agents. Correlations between in vivo and in vitro receptor binding affinities show that liver/heart selectivity does not depend on receptor recognition but on penetration or access to receptors in vivo. QSAR studies of the binding data of a series of 20 3'-arylmethyl T3 analogs show that electroneg. groups at the para position increase both receptor binding and selectivity in vivo. However, increasing 3'-arylmethyl hydrophobicity increases receptor binding but reduces selectivity. Substitution at ortho and meta positions reduces both binding and selectivity. Replacement of the 3,5-iodo groups by halogen or Me maintains selectivity, with 3,5-dibromo analogs in particular having increased potency combined with oral bioavailability. Di-Ph thioether derivs. also have improved potency but are less orally active. At the 1-position, the D enantiomer retains selectivity, but removal of the α -amino to give a propionic acid results in loss of selective thyromimetic activity.

IT 105170-16-9 105170-24-9 105211-23-2
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (thyromimetic activity of)


RN 105170-16-9 CAPLUS
 CN L-Tyrosine, O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105170-24-9 CAPLUS
 CN L-Tyrosine, 3,5-dichloro-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105211-23-2 CAPLUS


CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 69 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:58032 CAPLUS
DN 110:58032
TI The synthesis of [14C] and [3H2] SK&F L-94901. A novel thyromimetic
AU Crowe, A. M.; Lawrie, K. W. M.; Saunders, D.
CS Smith Kline and French Res. Ltd., Welwyn/Hertfordshire, AL6 9AR, UK
SO Journal of Labelled Compounds and Radiopharmaceuticals (1988), 25(7),
763-72
CODEN: JLCRD4; ISSN: 0362-4803
DT Journal
LA English
OS CASREACT 110:58032
AB Novel labeled thyromimetic SK&F L-94901, L-3,5-dibromo-3'-(6-oxo-1,6-dihydropyridazin-3-ylmethyl)thyronine, (I, R = 3H, *CH2 = 12CH2; R = H, *CH2 = 14CH2) were prepared for drug metabolism and nuclear binding studies. A six stage synthesis from [β -14C]tyrosine is described. The overall radiochem. yield was 13.7%. Syntheses of I (R = 3H, *CH2 = 12CH2) of specific activities 1.22 Ci mmol⁻¹ and 13.9 Ci mmol⁻¹ are described and the instability of these compds. noted.
IT 118584-65-9P 118608-57-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 118584-65-9 CAPLUS
CN L-Tyrosine-2,6-t2, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




10

RN 118608-57-4 CAPLUS
CN L-Tyrosine-β-14C, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 70 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:8598 CAPLUS
 DN 110:8598
 TI Synthesis and scale-up of SK & F L-94901 - a novel thyromimetic
 AU Lewis, Norman
 CS Org. Chem. Dep., Smith Kline and French Res. Ltd., Tonbridge/Kent, UK
 SO Chemistry & Industry (London, United Kingdom) (1988), (4), 109-13
 CODEN: CHINAG; ISSN: 0009-3068
 DT Journal
 LA English
 OS CASREACT 110:8598
 AB The preparation and scale-up of the title compound (I) by a variety of routes
 are given.
 IT 105190-08-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and chlorination of, with phosphorus oxychloride)
 RN 105190-08-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



IT 105190-13-4P 105190-17-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and deprotection of, with hydrogen bromide)
 RN 105190-13-4 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105190-17-8 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-5-



(1,1-dimethylethyl)-4-hydroxyphenyl]-N-(trifluoroacetyl)-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 71 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1987:131516 CAPLUS
 DN 106:131516
 TI A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity
 AU Underwood, A. H.; Emmett, J. C.; Ellis, D.; Flynn, S. B.; Leeson, P. D.; Benson, G. M.; Novelli, R.; Pearce, N. J.; Shah, V. P.
 CS Smith Kline and French Res. Ltd., Welwyn/Hertfordshire, AL6 9AR, UK
 SO Nature (London, United Kingdom) (1986), 324(6096), 425-9
 CODEN: NATUAS; ISSN: 0028-0836
 DT Journal
 LA English
 AB A new class of thyromimetics (agents that mimic the ability of the thyroid hormone T3 [6893-02-3] to decrease plasma cholesterol levels) is described. The most potent of these SKF L94901 (I) [105211-23-2] (as determined by the induction of mitochondrial cytochrome c 3-phosphoglycerate oxidoreductase [9001-49-4] in heart and liver of hypothyroid rats) was as active as T3 at reducing cholesterol levels and at stimulating liver function but had .apprx.0.1% the activity of T3 on heart function. In hypothyroid rats and rats with normal thyroid function, I was also shown to be a potent hypcholesterolemic agent with only a small effect on metabolic rate (determined by whole body O consumption). The affinities of the thyromimetics for the thyroid hormone receptor of isolated heart and liver nuclei were determined, and the relationship between receptor affinity and structure is discussed.
 IT 105170-16-9 105211-23-2
 RL: BIOL (Biological study)
 (as thyromimetic, hypcholesterolemic activity of and heart and liver functions response to, thyroid hormone receptor binding in relation to)
 RN 105170-16-9 CAPLUS
 CN L-Tyrosine, O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]-3,5-diodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 105211-23-2 CAPLUS
 CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.




L4 ANSWER 72 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1987:18467 CAPLUS
 DN 106:18467
 TI Synthesis and reactions of some β -aroyle- α -(indol-3-yl)propionic acids
 AU Sayed, G. H.; El-Kady, M. Y.; Abd-Elmawgoud, I.; Hamdy, M.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Journal of the Chemical Society of Pakistan (1985), 7(4), 263-72
 CODEN: JCSPDF; ISSN: 0253-5106
 DT Journal
 LA English
 OS CASREACT 106:18467
 AB The title acids I (R = CO₂H; R₁ = H, Me) were prepared by the reaction of 3,4-R₁ClC₆H₃COCH:CHCO₂H with indoles in dry benzene. Dehydration of I yielded the butenolides II (R₂ = 3-indolyl) which underwent ring opening by reaction with amines to give I (R = CONHCH₂Ph). Reaction of I with N₂H₄·H₂O or PhHNHNH₂ afforded the dihydropyridazinones III (R₃ = R₆ = H, Ph; R₄R₅ = O). III (R₃ = R₆ = H; R₄R₅ = O) reacted with POCl₃ and P₂S₅ and yielded the chloropyridazine III (R₅R₆ = bond; R₄ = Cl; R₃ = H) and thione III (R₃ = H; R₄R₅ = S). Reactions of pyridazinones III with 4-MeOC₆H₄CHO, Grignard reagents and Br-AcOH are described. The behavior of III (R₅R₆ = bond; R₄ = Cl; R₃ = H) towards N₂H₄·H₂O, NaN₃ and anthranilic acid IV was investigated. Thus, from IV V was obtained. Reaction of III (R₃ = R₆ = H; R₄R₅ = O, S) with PhMgBr gave III (R₃ = Ph; R₄R₅ = O, S; R₆ = H).
 IT 105398-36-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 105398-36-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-chlorophenyl)-4-(1H-indol-3-yl)-5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 73 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1986:626436 CAPLUS
 DN 105:226436
 TI Studies on some β -arooyl- α -(1,3-disubstituted
 5-oxo-2-pyrazolin-4-yl)propionic acids
 AU Sayed, G. H.; Ismail, A. A.; Hashem, Z.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Egyptian Journal of Chemistry (1985), Volume Date 1984, 27(6), 757-65
 CODEN: EGJCA3; ISSN: 0367-0422
 DT Journal
 LA English
 OS CASREACT 105:226436
 AB Addition of pyrazolinones I (R = Ph, R1 = Me, Ph) to aroylacrylic acids II
 (R2 = R3 = Cl; R2 = H, R3 = Br) gave adducts III. Cyclocondensation of
 III with R4NHNH2 (R4 = H, Ph) gave pyridazinones IV. In vitro
 antibacterial screening of III (R = R1 = Ph; R2 = R3 = Cl; R2 = H, R3 =
 Br) showed substantial activity against gram-pos. and gram-neg. bacteria.
 IT 94051-54-4P 94051-55-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 94051-54-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-bromophenyl)-4-(4,5-dihydro-3-methyl-5-oxo-1-
 phenyl-1H-pyrazol-4-yl)-5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX
 NAME)



RN 94051-55-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-bromophenyl)-4-(4,5-dihydro-5-oxo-1,3-diphenyl-1H-
 pyrazol-4-yl)-5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 74 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1986:609386 CAPLUS
 DN 105:209386
 TI Thyronines and thyronine analogs
 IN Leeson, Paul David; Emmett, John Colin; Underwood, Anthony Hubert; Ellis, David
 PA Smith Kline and French Laboratories Ltd., UK
 SO Eur. Pat. Appl., 59 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 188351	A2	19860723	EP 1986-300178	19860113
	EP 188351	A3	19890315		
	EP 188351	B1	19910313		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AU 8652219	A1	19860724	AU 1986-52219	19860113
	AU 577917	B2	19881006		
	AT 61581	E	19910315	AT 1986-300178	19860113
	CA 1319148	A1	19930615	CA 1986-499485	19860113
	US 4766121	A	19880823	US 1986-818626	19860114
	IL 77605	A1	19900209	IL 1986-77605	19860114
	DK 8600185	A	19860719	DK 1986-185	19860115
	DK 164592	B	19920720		
	DK 164592	C	19921207		
	ZA 8600319	A	19860827	ZA 1986-319	19860116
	FI 8600229	A	19860719	FI 1986-229	19860117
	NO 8600159	A	19860721	NO 1986-159	19860117
	HU 40401	A2	19861228	HU 1986-244	19860117
	HU 194807	B	19880328		
	ES 551005	A1	19871101	ES 1986-551005	19860117
	JP 61167643	A2	19860729	JP 1986-8800	19860118
	JP 07103070	B4	19951108		
	CN 86100894	A	19860903	CN 1986-100894	19860118
	CN 1010310	B	19901107		
	US 4826876	A	19890502	US 1987-136240	19871221
	US 4910305	A	19900320	US 1988-168780	19880316
	US 5061798	A	19911029	US 1989-428264	19891027
PRAI	GB 1985-1372	A	19850118		
	EP 1986-300178	A	19860113		
	US 1986-818626	A1	19860114		
	US 1988-168780	A3	19880316		

OS CASREACT 105:209386; MARPAT 105:209386


AB Acids and derivs. I [R1 = 2-amino-2-carboxyethyl, CO₂H, carbalkoxy, carbamoyl, carboxy-, carbalkoxy-, or carbamoylalkyl, etc.; R2 and R3 = H, halo, alkyl, NO₂, NH₂; Z1 = O, S, CH₂; R4 = OH, alkoxy, OCH₂Ph, etc.; R5 = H, alkyl; R6 = 4-HOC₆H₄, 5-hydroxy-2-pyridyl, 6-oxo-3(1H)-pyridyl, 6-oxo-3(1H)-pyridazinyl] were prepared, and they exhibited anticholesteremic activity in rats. A 3,5-dibromotyrosine derivative was etherified by a diaryliodonium perchlorate derivative to give, after deprotection, I [R1 = CH₂CH(NH₂)CO₂H, R2 = R3 = Br, Z1 = O, R4 = HO, R5 = H, R6 = 6-oxo-3(1H)-pyridyl].

IT 105170-55-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and condensation of, with glycine derivative)

RN 105170-55-6 CAPLUS

CN Benzaldehyde, 3,5-dibromo-4-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)




IT 105170-54-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion of, to benzaldehyde analog)

RN 105170-54-5 CAPLUS

CN Benzonitrile, 3,5-dibromo-4-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)



IT 105170-23-8P 105170-25-0P 105190-13-4P


105190-17-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deprotection of)

RN 105170-23-8 CAPLUS

CN L-Tyrosine, O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-3,5-diido-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105170-25-0 CAPLUS

CN L-Tyrosine, 3,5-dichloro-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105190-13-4 CAPLUS

CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105190-17-8 CAPLUS

CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-5-(1,1-dimethylethyl)-4-hydroxyphenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


IT **105170-53-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and etherification of, by iodobenzonitrile derivative)

RN 105170-53-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(5-hydroxy-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


IT **105190-08-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, with phosphoryl chloride)

RN 105190-08-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


IT **105170-21-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, with tyrosine derivative, thyronine derivative from)

RN 105170-21-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[(5-hydroxy-2-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 105170-22-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and successive reduction, diazotization and reaction of, with
potassium iodide-iodine)

RN 105170-22-7 CAPLUS

CN L-Tyrosine, O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-
methoxyphenyl]-3,5-dinitro-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




IT 105170-51-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 105170-51-2 CAPLUS

CN 2-Propenoic acid, 2-(acetylamino)-3-[3,5-dibromo-4-[3-[(1,6-dihydro-6-oxo-
3-pyridazinyl)methyl]-4-hydroxyphenoxy]phenyl]- (9CI) (CA INDEX NAME)




IT 105170-16-9P 105170-24-9P 105170-48-7P
 105170-49-8P 105170-50-1P 105190-23-6P
 105211-23-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as anticholesteremic)

RN 105170-16-9 CAPLUS

CN L-Tyrosine, O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105170-24-9 CAPLUS

CN L-Tyrosine, 3,5-dichloro-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105170-48-7 CAPLUS

CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 105170-49-8 CAPLUS


CN D-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 105170-50-1 CAPLUS

CN Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- α -methyl- (9CI) (CA INDEX NAME)



RN 105190-23-6 CAPLUS


CN Benzaldehyde, 3-bromo-4-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-methoxyphenoxy]-5-nitro- (9CI) (CA INDEX NAME)



RN 105211-23-2 CAPLUS

CN L-Tyrosine, 3,5-dibromo-O-[3-[(1,6-dihydro-6-oxo-3-pyridazinyl)methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 75 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1985:24542 CAPLUS

DN 102:24542

TI Synthesis of some new β -aroyle- α -[4-(1,3-disubstituted-2-pyrazolin-5-one)]propionic acids and 4-pyrazolinonylpyridazinones and the study of their antibacterial activities

AU Sayed, G. H.; Ismail, A. A.; Hashem, Z.

CS Fac. Sci., Ain Shams Univ., Cairo, Egypt

SO Journal of the Chemical Society of Pakistan (1984), 6(2), 95-101

CODEN: JCSPDF; ISSN: 0253-5106

DT Journal

LA English



AB $\text{RCOCH:CHCO}_2\text{H}$ ($\text{R} = 4\text{-BrC}_6\text{H}_4, 3,4\text{-Cl}_2\text{C}_6\text{H}_3$) react with 1,3-disubstituted-2-pyrazolin-5-ones in dry C_6H_6 to give β -aroyle- α -[4-(1,3-disubstituted-2-pyrazolin-5-one)]propionic acids (I, $\text{R}_1 = \text{Me, Ph}$). Esterification of I ($\text{R} = 3,4\text{-Cl}_2\text{C}_6\text{H}_3, \text{R}_1 = \text{Ph}$) with CH_2N_2 gives the corresponding Me ester. Reactions of I with N_2H_4 and PhNHNH_2 afford the 4-pyrazolinonylpyridazinones II ($\text{R}_2 = \text{H, Ph}$). Dehydration of I yielded the butenolides, which undergo ring opening reaction with amines to give the N-alkylamides of I. Reactions of II ($\text{R}_2 = \text{H}$) with $4\text{-MeOC}_6\text{H}_4\text{CHO}$, $\text{BrCH}_2\text{CO}_2\text{Et}$, Et_2SO_4 , and Grignard reagents have also been described. The in vitro antibacterial screening reveals substantial activities against Gram-pos. and Gram-neg. bacteria for I ($\text{R} = 4\text{-BrC}_6\text{H}_4, 3,4\text{-Cl}_2\text{C}_6\text{H}_3, \text{R}_1 = \text{Ph}$) while I ($\text{R}_1 = \text{Me}$) and II ($\text{R} = 3,4\text{-Cl}_2\text{C}_6\text{H}_3, \text{R}_2 = \text{Me, R}_2 = \text{H}$) are inactive.

IT 94051-54-4P 94051-55-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 94051-54-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-(4-bromophenyl)-4-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)-5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 94051-55-5 CAPLUS


CN 3(2H)-Pyridazinone, 6-(4-bromophenyl)-4-(4,5-dihydro-5-oxo-1,3-diphenyl-1H-pyrazol-4-yl)-5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 76 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1983:488135 CAPLUS
 DN 99:88135
 TI Some reactions with 4-(aryl methyl)-6-methylpyridazin-3(2H)-ones
 AU Ismail, M. F.; Shams, N. A.; El Sawy, O. M.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Egyptian Journal of Chemistry (1982), Volume Date 1981, 24(1-3), 223-6
 CODEN: EGJCA3; ISSN: 0367-0422
 DT Journal
 LA English
 OS CASREACT 99:88135
 AB I reacted with HCHO to give II (R = H, Me, MeO, Cl). Several derivs. of these, e.g., III, were prepared
 IT 86816-83-3P 86816-84-4P 86816-87-7P
 86816-89-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 86816-83-3 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(hydroxymethyl)-6-methyl-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 86816-84-4 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(hydroxymethyl)-4-[(4-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 86816-87-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-methyl-4-[(4-methylphenyl)methyl]-2-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 86816-89-9 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 5-[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 75256-52-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with formaldehyde or Et bromoacetate)
 RN 75256-52-9 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




IT 74819-18-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with formaldehyde or formaldehyde and morpholine)
 RN 74819-18-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-methyl-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 77 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1982:582331 CAPLUS
 DN 97:182331
 TI Synthesis of 6-(α -styryl)pyridazin-3(2H)-ones
 AU Ismail, M. Fekry; Shams, Nabil A.; Mostafa, Omnia E.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including
 Medicinal Chemistry (1982), 21B(4), 371-2
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 97:182331
 AB 6-(α -Styryl)pyridazin-3(2H)-ones (I) have been prepared by the action
 of SeO_2 on their 4,5-dihydro derivs. in EtOH. This method has also been
 applied successfully in the synthesis of 6-arylpypyridazin-3(2H)-ones.
 4-Substituted 6-(α -styryl)pyridazin-3(2H)-ones have been readily
 obtained by the base-catalyzed condensation of 4,5-dihydropypyridazinones
 with aromatic aldehydes. The reactions of I with Me_2SO_4 and $POCl_3$ are also
 described.
 IT 83516-79-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 83516-79-4 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-(2-phenylethenyl)- (9CI)
 (CA INDEX NAME)




L4 ANSWER 78 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1981:515437 CAPLUS
 DN 95:115437
 TI Nucleophilic addition of indoles to β -aroylerylic acids and some reactions with the adducts
 AU Sayed, G. H.; Abd Elhalim, M. S.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1981), 20B(5), 424-6
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 95:115437
 AB β -Aroylerylic acids react with indoles in dry benzene to give the corresponding β -aroyle-(indol-3-yl)propionic acids (I). Esterification of I with CH₂N₂ gives the corresponding Me β -aroyle-(indol-3-yl)propionates. Reactions of I with N₂H₄ and H₂NNHPh afford the corresponding pyridazinones. Reactions of 6-(3,4-dichlorophenyl)-4-(indol-3-yl)-2,3,4,5-tetrahydropyridazin-3-one with anisaldehyde, Et bromoacetate and POCl₃ are described. Behavior of 3-chloro-6-(3,4-dichlorophenyl)-4-(indol-3-yl)-4,5-dihydropyridazine towards N₂H₄, thiophenol, NaN₃ and anthranilic acid has also been investigated.
 IT 78860-98-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 78860-98-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dichlorophenyl)-4-(1H-indol-3-yl)-5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




X



L4 ANSWER 79 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1981:480869 CAPLUS
 DN 95:80869
 TI Synthesis and reactions of some 3(2H)-pyridazinethiones
 AU Jahine, H.; Zaher, H. A.; Sayed, A.; Saeda, M.
 CS Fac. Educ., Ain Shams Univ., Cairo, Egypt
 SO Pakistan Journal of Scientific Research (1980), 32(1-2), 91-5
 CODEN: PJSRAV; ISSN: 0552-9050
 DT Journal
 LA English
 OS CASREACT 95:80869
 AB Treating pyridazinethiones I (R = H, CH₂Ph; X = S), obtained by treating I (X = O) with P₂S₅, with EtI, PhCH₂Cl, and CH₂:CHCN gave II (R₁ = Et, PhCH₂, CH₂CH₂CN).
 IT 57999-76-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (sulfuration of)
 RN 57999-76-5 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX
 NAME)




L4 ANSWER 80 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1981:443017 CAPLUS
 DN 95:43017
 TI Reactivity of 4-arylmethyl-3-chloro-6-methylpyridazines towards some nucleophilic reagents
 AU Ismail, M. F.; Shams, N. A.; Soliman, E. A.; El-Sawy, O. M.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1981), 20B(1), 78-9
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 95:43017
 AB Treating pyridazines I (R = Ph, tolyl, 4-ClC₆H₄; R₁ = Cl) (II) with PhNH₂ and N₂H₄ gave I (R₁ = PhNH, NHNH₂) resp., whereas treating II with NaN₃ gave tetrazolopyridazines III.
 IT 74819-18-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 74819-18-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-methyl-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 81 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1981:407187 CAPLUS
 DN 95:7187
 TI Conversion of α -arylidene- γ -phenyl- $\Delta\beta,\gamma$ -butenolides into nitrogen heterocycles
 AU Khattab, Samir A.; Hosny, Mohammad M.
 CS Fac. Sci., Cairo Univ., Cairo, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1980), 19B(12), 1038-43
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 95:7187
 AB Treatment of butenolides I (R = H, OMe, NO₂, NMe₂) with strong nucleophiles brings about opening of the γ -lactone ring with the formation of 4-RC₆H₄CH:C(CH₂COPh)COR₁ (II, R₁ = NH₂, NHMe, NHCH₂Ph, NHNHPH, OH) which undergo facile condensation with carbonyl compds. to give II (R₁ = NH₂X, X = CHPh, CHC₆H₄R₂, CHCH:CHPh, cyclohexylidene; R₂ = 2-OH, 4-OMe, 4-NO₂, 4-NMe₂). Cyclization of II by various acidic and basic reagents affords pyridazinone and pyrrolinone heterocycles. Conversion of pyrrolinones into pyridazinones takes place via an isolable benzylidenehydrazone derivative of α -phenacylcinnamic acid. Structures assigned to the products are based on spectral and chemical evidence.
 IT 57999-76-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and aminomethylation of)
 RN 57999-76-5 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)




IT 77811-76-8P 77811-77-9P 77811-78-0P
 77811-80-4P 77811-81-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 77811-76-8 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-nitrophenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 77811-77-9 CAPLUS


CN 3(2H)-Pyridazinone, 4-[[4-(dimethylamino)phenyl]methyl]-6-phenyl- (9CI)
(CA INDEX NAME)




RN 77811-78-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2,4-dinitrophenyl)-4-[(4-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)





RN 77811-80-4 CAPLUS
CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2,6-diphenyl- (9CI) (CA INDEX NAME)




RN 77811-81-5 CAPLUS
CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-phenyl-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 82 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1980:586276 CAPLUS
 DN 93:186276
 TI Base-catalyzed condensation of aromatic aldehydes with
 4,5-dihydro-6-methylpyridazin-3(2H)-one
 AU Ismail, M. F.; El Khamry, A. A.; Shams, N. A.; El Sawy, O. M.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including
 Medicinal Chemistry (1980), 19B(3), 203-5
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 93:186276
 AB Condensing dihydropyridazinone I ($R = R1 = H$) with aromatic aldehydes
 $R2C6H4CHO$ (II, $R2 = H, 4\text{-Me}, 4\text{-MeO}, 4\text{-Cl}$) gave I ($R = H, R1 = R2C6H4CH2$)
 (III), which reacted in lactim form with $POCl_3$ to give IV, and reacted in
 lactam form with Me_2SO_4 to give I ($R = Me, R1 = R2C6H4CH2$). Treating III
 with $BrCH_2CO_2Et$ in the presence of $NaOEt$ gave the esters I ($R = CH_2CO_2Et, R1 = R2C6H4CH2$), which reacted with $PhCH_2NH_2$ and $NH_2NH_2 \cdot H_2O$ to give the
 corresponding N-benzylamides and hydrazides. The esters are readily
 hydrolyzed to the corresponding acids.
 IT 75256-54-1P 75256-55-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 75256-54-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2,6-dimethyl-4-[(4-methylphenyl)methyl]- (9CI) (CA
 INDEX NAME)




RN 75256-55-2 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2,6-dimethyl- (9CI) (CA
 INDEX NAME)




IT 74819-18-4P 75256-52-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation, chlorination, and methylation of)
 RN 74819-18-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-methyl-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX)

NAME)



RN 75256-52-9 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX
NAME)

L4 ANSWER 83 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1980:532435 CAPLUS
 DN 93:132435
 TI Synthesis of some 3-mercaptopypyridazine derivatives
 AU Ismail, M. Fekry; Shams, Nabil A.; El Sawy, Omar M.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Synthesis (1980), (5), 410-12
 CODEN: SYNTBF; ISSN: 0039-7881

DT Journal

LA English

OS CASREACT 93:132435


AB The thiols I (R = H, R1 = H, Me, Cl) were prepared by thiolating the corresponding chloropyridazines with thiourea or by thiolating the pyridazinones with P2S5. I (R = H) were alkylated to I (R = Me, Et). Reaction of I (R = H) with acrylonitrile gave I (R = CH₂CH₂CN) and no N-substitution product.

IT 74819-31-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and hydrolysis of)

RN 74819-31-1 CAPLUS

CN 1(6H)-Pyridazinepropanenitrile, 3-methyl-5-[(4-methylphenyl)methyl]-6-oxo-
 (9CI) (CA INDEX NAME)




IT 74819-32-2P 74819-33-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 74819-32-2 CAPLUS

CN 1(6H)-Pyridazinepropanenitrile, 5-[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-
 (9CI) (CA INDEX NAME)




RN 74819-33-3 CAPLUS



CN 1(6H)-Pyridazinepropanoic acid, 3-methyl-5-[(4-methylphenyl)methyl]-6-oxo-
 (9CI) (CA INDEX NAME)

IT **74819-18-4**RL: RCT (Reactant); RACT (Reactant or reagent)
(thiolation of)


RN 74819-18-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-methyl-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX
NAME)


L4 ANSWER 84 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1979:575281 CAPLUS
 DN 91:175281
 TI Synthesis and reactions of some 3(2H)-pyridazinethiones
 AU Jahine, H.; Zaher, H. A.; Sayed, A.; Seada, M.
 CS Fac. Educ., Ain Shams Univ., Cairo, Egypt
 SO Pakistan Journal of Science (1978), 30(1-6), 6-11
 CODEN: PAJSAS; ISSN: 0030-9877
 DT Journal
 LA English
 OS CASREACT 91:175281
 AB Pyridazines I (R = H, CH₂Ph; R₁ = Et, CH₂Bz, CH₂Ph, CH₂CH₂CO₂H, CH₂CH₂CN) were obtained from the thiones II (R₂ = H). II (R = R₂ = H) also formed Mannich bases II (R = H, R₂ = piperidinomethyl, morpholinomethyl). I (R = H, R₁ = Et) was oxidized to the sulfone. II were obtained by thiolating the corresponding oxo compds. or the 4,5-dihydro derivs.
 IT 57999-76-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (thiolation of)
 RN 57999-76-5 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 85 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1978:152531 CAPLUS
 DN 88:152531
 TI Reactions of 3-pyridazinones with aldehydes and Grignard reagents
 AU Kaddah, A. M.; Khalil, A. M.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including
 Medicinal Chemistry (1977), 15B(11), 1025-8
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 88:152531
 AB The pyridazinones I (R = p-MeOC₆H₄, p-ClC₆H₄, Ph, p-PhC₆H₄, p-MeC₆H₄) condensed with R₁CHO (R₁ = H, Ph, substituted Ph) to give II. I and II (R = p-MeOC₆H₄, R₁ = Ph; R = p-ClC₆H₄, R₁ = o-ClC₆H₄; R = p-PhC₆H₄, R₁ = H) were treated with piperidinediimide and HCHO to give the corresponding 2-(piperidinomethyl)-4,5-dihydro-3(2H)-pyridazinone derivs. The compound I (R = p-PhC₆H₄) and PhMgBr gave the pyridazine III. III (R = p-MeOC₆H₄, p-ClC₆H₄, p-PhC₆H₄, p-MeC₆H₄) were prepared from the corresponding 2-(piperidinomethyl)-4,3-dihydro-3(2H)-pyridazinone and PhMgBr.
 IT **66122-33-6P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and methylation of)
 RN 66122-33-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)



IT **57999-76-5P 66122-37-0P 66122-42-7P**
66122-45-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 57999-76-5 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 66122-37-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-chlorophenyl)-4-[(4-methoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 66122-42-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[1,1'-biphenyl]-4-yl-4-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 66122-45-0 CAPLUS


CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 86 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1977:601445 CAPLUS
 DN 87:201445
 TI Reactions with 3-chloro- and 3-hydrazino-4-benzyl-6-phenylpyridazines
 AU Jahine, H.; Zaher, H. A.; Sayed, A.; Seada, M.
 CS Fac. Educ., Ain Shams Univ., Cairo, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1977), 15B(4), 352-5
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 87:201445
 AB 4-Benzyl-6-phenyl-3(2H)-pyridazinone (I) reacted with $\text{PCl}_5\text{-POCl}_3$ to give 4-benzyl-3-chloro-6-phenylpyridazine (II), which on reaction with NH_2NH_2 at $150-70^\circ$ gave 4-benzyl-3-hydrazino-6-phenylpyridazine (III). III reacted with 1-cyanoacetyl-3,5-dimethylpyrazole to give 4-benzyl-3-cyanoacetylhydrazino-6-phenylpyridazine. Condensation of which with acetylacetone gave $\text{N}-(3-(4\text{-benzyl-6-phenylpyridazinyl})\text{amino})\text{-3-cyano-4,6-dimethyl-2-pyridone}$, whereas condensation of III with benzoylacetone gave $1-[3-(4\text{-benzyl-6-phenylpyridazinyl})\text{-3-methyl-5-phenylpyrazole}$. 8-Benzyl-6-phenyltetrazolo[1,5-b]pyridazine was obtained by the reaction of II with NaN_3 or by the reaction of III with nitrous acid. Reaction of II with anthranilic acid gave 4-benzyl-2-phenylpyridazino[3,2-b]quinazolin-10(H)-one and $\text{o}-(3-(4\text{-benzyl-6-phenylpyridazinyl})\text{amino})\text{benzoic acid}$. Reaction of I or 4-(p-anisyl)-6-phenyl-3(2H)-pyridazinone with alkyl halides or halo esters gave the N-alkylated derivs.
 IT 57999-76-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of)
 RN 57999-76-5 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)




IT 64657-96-1P 64657-98-3P 64658-00-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 64657-96-1 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-2-methyl-6-phenyl- (9CI) (CA INDEX NAME)



RN 64657-98-3 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-phenyl-2-(phenylmethyl)-
 (9CI) (CA INDEX NAME)





RN 64658-00-0 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 5-[(4-methoxyphenyl)methyl]-6-oxo-3-phenyl-,
 ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 87 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1976:577470 CAPLUS
 DN 85:177470
 TI Pyridazine derivatives
 IN Garland, Ian P.; Hatton, Leslie R.; Leeds, William G.; Parnell, Edgar W.
 PA May and Baker Ltd., UK
 SO Ger. Offen., 98 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2557956	A1	19760701	DE 1975-2557956	19751222
	BE 836965	A1	19760622	BE 1975-163028	19751222
	DK 7505867	A	19760624	DK 1975-5867	19751222
	SE 7514559	A	19760624	SE 1975-14559	19751222
	NL 7514945	A	19760625	NL 1975-14945	19751222
	FR 2295953	A1	19760723	FR 1975-40375	19751222
	JP 51088633	A2	19760803	JP 1975-153215	19751222
	BR 7508495	A	19760824	BR 1975-8495	19751222
	ZA 7507945	A	19761229	ZA 1975-7945	19751222
	DD 125317	C	19770413	DD 1975-190453	19751222
	AU 7587754	A1	19770630	AU 1975-87754	19751222
	GB 1481990	A	19770803	GB 1974-55473	19751222
	ES 443752	A1	19771001	ES 1975-443752	19751222
PRAI	GB 1974-55473	A	19741223		
	GB 1975-36743	A	19750905		
AB	Pyridazines I [Rn = H, Me, Me2, Me3, halo, Cl2, 2-Et, MeS, MeO, ClMe; R1 = H; R2 = H, Me, Et, OH, MeO, EtO, R1R2 = O, NOH; (±) when R1 = H, R2 ≠ H] (69 compds.), useful as herbicides at 0.25-8.0 kg/ha, were prepared by 12 methods. Thus, 2-MeC6H4CH2Br, Me 2-furoate, and FeCl3 in CCl4 refluxed 18 hr gave furoate II (R3 = 2-MeC6H4CH2, R4 = CO2Me), which was saponified with KOH in aqueous MeOH, the resultant acid II (R3 = 2-MeC6H4CH2, R4 = CO2H) decarboxylated with CuO in 4 hr at 200°, the product furan II (R3 = 2-MeC6H4CH2, R4 = H) alkoxylated in MeOH and Na2CO3 and the formed dihydrofuran III cyclized with N2H4 in refluxing PhOH 70 hr to give I (Rn = 2-Me, R1 = R2 = H).				
IT	60906-68-5P 60906-69-6P 60932-69-6P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation and chlorination of)				
RN	60906-68-5 CAPLUS				
CN	3(2H)-Pyridazinone, 6-[(2,6-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)				




RN 60906-69-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[(2,6-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 60932-69-6 CAPLUS


CN 3(2H)-Pyridazinone, 6-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 88 OF 88 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1976:43568 CAPLUS
 DN 84:43568
 TI Preparation and reactions of some acyl azides
 AU Awad, W. I.; Hashem, A. I.; El-Badry, K.
 CS Univ. Coll. Women, Ain Shams Univ., Cairo, Egypt
 SO Indian Journal of Chemistry (1975), 13(11), 1139-41
 CODEN: IJOCAP; ISSN: 0019-5103
 DT Journal
 LA English
 AB Reaction of the butenolides I (R = H, Me, MeO, Cl) with N₂H₄ gave p-RC₆H₄CH:C(CH₂COPh)CONHNH₂, which on treatment with NaNO₂-HCl underwent ring closure to the 3(2H)-pyridazinones II (no azide formation). Treatment of I with aqueous NaOH followed by SOCl₂ and NaN₃ gave p-RC₆H₄CH:C(CH₂COPh)CON₃ (III). III on refluxing in EtOH, thermolysis in dry benzene, or pyrolysis gave, resp., urethane derivs., isocyanates, or oxazine derivs. IV.
 IT 57999-75-4P 57999-76-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 57999-75-4 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methylphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 57999-76-5 CAPLUS
 CN 3(2H)-Pyridazinone, 4-[(4-methoxyphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)



10/807,993

=> => d his

(FILE 'HOME' ENTERED AT 07:39:07 ON 12 JUN 2006)

FILE 'REGISTRY' ENTERED AT 07:39:12 ON 12 JUN 2006

L1 STRUCTURE UPLOADED
L2 30 S L1 SSS SAM
L3 543 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 07:43:59 ON 12 JUN 2006

L4 88 S L3

FILE 'CAOLD' ENTERED AT 07:45:11 ON 12 JUN 2006

=> s 13
L5 0 L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	619.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-65.25

STN INTERNATIONAL LOGOFF AT 07:45:22 ON 12 JUN 2006

Application Number **SEARCH**

IDS Flag Clearance for Application

IDS
Information

Content	Mailroom Date	Entry Number	IDS Review	Reviewer
M844	06-23-2004	14	<input checked="" type="checkbox"/>	06-12-2006 10:24:46 drao
M844	08-26-2004	17	<input checked="" type="checkbox"/>	06-12-2006 10:25:48 drao

UPDATE